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INTRODUCCIÓN 
 Aún no se tiene un pleno conocimiento de la patogénesis del síndrome de distrés 
respiratorio agudo (ARDS) y su forma menos severa, el daño pulmonar agudo (ALI) 
(2). Sin embargo, actualmente se piensa que estos síndromes comienzan con una 
respuesta inflamatoria que puede ser inducida por daños extra-pulmonares (sepsis, 
trauma severo, pancreatitis aguda, etc.) o por alteraciones directas en el pulmón 
(neumonía, contusión pulmonar, aspiración de ácidos gástricos, etc.) (3). Dicha 
respuesta inflamatoria puede conllevar alteraciones en la permeabilidad de la barrera 
alveolo-capilar, provocando edema intra-alveolar (3, 4). Ante este escenario, la 
alteración del surfactante pulmonar complica aún más la situación (5). 
 El surfactante pulmonar es un complejo macromolecular  esencial para mantener 
el alveolo abierto y por consiguiente, permitir un adecuado intercambio gaseoso. Sin 
surfactante, el alveolo colapsaría al no disminuir la tensión superficial de la interfase 
aire-líquido durante la espiración (1, 6). Por tanto, una de las principales funciones del 
surfactante pulmonar es establecer una monocapa en la interfase aire-líquido que 
excluye las moléculas de agua de la interfase y por tanto disminuye la tensión 
superficial a 1 mN/m en la espiración (1). Para llevar a cabo su función 
correctamente, el surfactante pulmonar está formado por lípidos (principalmente 
fosfolípidos) y apolipoproteínas específicas del surfactante, denominadas SP-A, SP-B 
y SP-C.  
 El surfactante pulmonar es secretado por los neumocitos tipo II al fluido alveolar 
en forma de agregados grandes (LA), que generan rápidamente una monocapa estable 
en la interfase aire-líquido (1). Este proceso se denomina adsorción interfacial del 
surfactante pulmonar. Después de la adsorción, la monocapa de surfactante está 
sometida periódicamente a procesos de compresión durante la exhalación y de 
expansión durante la inhalación. Los procesos de compresión producen cambios en la 
tensión superficial (γ) de ~23 mN/m a ~1 mN/m para prevenir el colapso alveolar  
mientras que la inspiración produce la expansión de la monocapa, produciéndose un 
incremento de γ hasta 20–25 mN/m para mantener la estabilidad alveolar. Como 
consecuencia de estos ciclos reiterados de compresión/expansión se van generando 
vesículas no funcionales del surfactante pulmonar, denominadas agregados pequeños 
(SA). Estas vesículas son capturadas continuamente por los neumocitos tipo II o los 
macrófagos alveolares. 
  
10 Resumen/Summary 
 La alteración o déficit del surfactante pulmonar conlleva edema intra-alveolar, 
alteración en la compliance pulmonar, desajuste de la ventilación-perfusión e 
hipoxemia (1, 5, 6). 
 La presencia de una acusada hipoxemia precisa de soporte ventilatorio, cuya 
utilización ha requerido estudiar los posibles efectos adversos de la ventilación 
mecánica per se, conocido como daño pulmonar agudo inducido por ventilación 
mecánica (VILI) (7). Actualmente se considera que VILI se genera como 
consecuencia de volutrauma (distensión pulmonar cuando se somete a presión 
alveolar alta) y/o atelectrauma (causado por la apertura y el cierre cíclicas del espacio 
aéreo) (7). Estas alteraciones pueden estimular la respuesta inflamatoria (denominado 
biotrauma), resultando en daño pulmonar progresivo e inflamación sistémica (7). 
 Actualmente, el soporte ventilatorio para pacientes con ALI o ARDS consiste en 
ventilar con bajo volumen corriente (para disminuir el volutrauma) y aplicar una 
presión positiva al final de la expiración (PEEP) y/o un ratio de FiO2/PEEP adecuados 
(para reducir el atelectrauma) (8). El PEEP aumenta la presión del espacio aéreo al 
final de la espiración. Sin embargo, debido a que las presiones de apertura del espacio 
aéreo pueden variar notablemente entre pacientes e incluso dependiendo del estado de 
un mismo paciente, la aplicación de PEEP para revertir o limitar atelectasis dorsal-
caudal, casi siempre sucederá a costa de un exceso de distensión de las regiones 
pulmonares ventrales u otras áreas que tienen presiones inferiores de apertura (9).  
 Dada la importancia de un correcto manejo de los parámetros ventilatorios para 
mantener a los pacientes con ARDS y ALI (7, 8),  se ha comenzado a estudiar el 
efecto de la ventilación mecánica en pulmones sanos. Para ello, la utilización de 
modelos animales expuestos a estrategias ventilatorias convencionales o dañinas es 
indispensable para conocer mejor los mecanismos que inducen VILI. 
En esta tesis, ratas sanas han sido expuestas a las siguientes estrategias ventilatorias 
(10): 
 Ventilación mecánica perjudicial (HV) durante 2.5 h caracterizada por alto  
volumen corriente (VT = 25 ml/kg) y ausencia de PEEP ya que nuestro objetivo 
era provocar alteraciones alveolares causadas por volutrauma, atelectrauma y/o 
biotrauma.  
 Ventilación mecánica convencional (LV) durante 2.5 h caracterizada por volumen 
corriente moderado (VT = 9 ml/kg) y aplicación de PEEP (PEEP = 5 cm H2O), con 
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el objetivo de simular la estrategia ventilatoria utilizada habitualmente en la 
unidad de cuidados intensivos.  
 Ventilación mecánica convencional prolongada (VT = 9 ml/kg, y PEEP = 5 cm 
H2O). 
 Ventilación mecánica convencional prolongada (VT = 9 ml/kg, y PEEP = 5 cm 
H2O) después de 2.5 h de exposición a una estrategia ventilatoria dañina (VT = 25 
ml/kg, y PEEP = 0). Este modelo simula situaciones clínicas en las que los 
pacientes con alteraciones pulmonares son ventilados con estrategias ventilatorias 
convencionales.  
 
OBJECTIVOS 
 El objetivo principal de esta tesis fue estudiar los cambios morfológicos y 
funcionales en pulmones ventilados con estrategias ventilatorias dañinas o 
convencionales, así como identificar la relación entre la ventilación mecánica 
agresiva, la inflamación, el edema y la disfunción del surfactante para poder entender 
los mecanismos implicados en el daño pulmonar agudo inducido por ventilación 
mecánica (VILI).  
 En este estudio contestaremos dos preguntas que actualmente están siendo 
debatidas (9): si los cambios en la composición y funcionalidad del surfactante 
preceden al comienzo de VILI y si VILI ocurre sólo en aquellos animales que tienen 
inactivado el surfactante pulmonar. 
 Esta tesis se compone de tres capítulos los cuales evalúan:  
 El impacto de estrategias ventilatorias dañinas en el espacio alveolar y 
concretamente sus efectos sobre la composición, estructura y funcionalidad del 
surfactante pulmonar. Además se determinaron las causas de la inactivación del 
surfactante tras la ventilación  mecánica lesiva. (Chapter 1). 
 Los factores implicados en la resistencia al daño inducido por ventilación 
mecánica debido a que dichos factores pueden contribuir a desarrollar terapias 
profilácticas o intervenciones previas a la ventilación. (Chapter 2). 
 Las consecuencias de una ventilación mecánica convencional prolongada, con 
o sin previa exposición a estrategias ventilatorias perjudiciales. Este estudio 
permitiría determinar si la inflamación en el pulmón esta relacionada con la 
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duración a la exposición de estrategias ventilatorias convencionales así como 
dilucidar si dicha estrategia ventilatoria convencional tiene efectos beneficiosos 
o perjudiciales en aquellos animales previamente expuestos a ventilación 
mecánica lesiva. (Chapter 3). 
 
RESULTADOS Y CONCLUSIONES 
 
Capítulo 1 
El objetivo de este capítulo fue caracterizar los cambios producidos en el 
espacio alveolar debido a estrategias ventilatorias dañinas. La mayoría de los animales 
expuestos a ventilación mecánica lesiva desarrollaron daño agudo (VILI) 
caracterizado por: 1) presión parcial de oxígeno arterial/porcentaje de oxígeno 
inspirado (PaO2/FiO2) < 300 mmHg; 2) evidencias de alteración tisular; 3) aumento 
de marcadores inflamatorios tales como TNF-α y la actividad de la esfingomielinasa 
ácida en BAL; 4) contaminación de proteínas plasmáticas en los alvéolos y aumento 
de los niveles de la proteína carbonilada en BAL, e 5) inactivación del surfactante 
pulmonar. 
Aunque la ventilación con alto volumen corriente estimuló la secreción de 
surfactante por parte de los neumocitos tipo II, éste fue rápidamente inactivado. La 
inactivación del surfactante pulmonar puede deberse a la oxidación tanto de sus 
componentes lipídicos como proteicos debido al estrés oxidativo, a la degradación de 
los mismos por parte de fosfolipasas y proteasas y a la presencia de inhibidores de las 
membranas del surfactante que provengan del torrente sanguíneo o bien sean 
secretados por las células alveolares. En concreto, hemos observado una disminución 
significativa en los niveles de las proteínas específicas del surfactante SP-A, SP-B y 
SP-C, así como una disminución en sus niveles de expresión en el tejido pulmonar. 
Además, hemos encontrado un aumento significativo de lípidos peroxidados en las 
membranas del surfactante junto con un aumento significativo de la proteína C 
reactiva (CRP), un inhibidor del surfactante que se inserta en sus membranas 
alterando sus propiedades biofísicas (1). 
 
  
13 Resumen/Summary 
Conclusiones del C.1: Este estudio indica que estrategias ventilatorias lesivas 
producen daño directo en el pulmón, promoviendo la inflamación, el estrés oxidativo 
y la liberación de diversos factores, que todos juntos están implicados en la 
inactivación del surfactante. Dicha inactivación conlleva atelectasis manifestada por 
alteraciones en el intercambio gaseoso y disminución de la complianza dinámica. 
 
Capítulo 2 
Durante la realización del anterior estudio, observamos que un pequeño 
número de animales expuestos a estrategias ventilatorias lesivas no mostraban 
evidencias de disfunción pulmonar. Por consiguiente, el objetivo de este capítulo fue 
identificar los factores involucrados en la resistencia al daño pulmonar agudo 
inducido por ventilación mecánica. Para este propósito, el grupo ventilado con alto 
volumen corriente  y ausencia de PEEP fue dividido en dos grupos según sus valores 
de presión arterial media (MAP) que se registraba continuamente: 1) animales 
susceptibles a la ventilación mecánica lesiva (sHV), caracterizados por valores de 
MAP inferiores a 50 mmHg y una acusada disminución de PaO2 tras 60 minutos de 
ventilación: y 2) animales resistentes a la ventilación mecánica lesiva (rHV) los cuales 
no tenían cambios sustanciales en MAP y PaO2 tras 60 minutos de ventilación.  
El grupo sHV se caracterizó por: 1) PaO2/FiO2<200 mmHg; 2) alteraciones 
histológicas incluyendo presencia de membranas hialinas; 3) Una disminución 
acusada de macrófagos alveolares; 4) Edema intraalveolar; 5) Aumento de 
marcadores inflamatorios en BAL (TNF-α, MIP-2, MCP-1, y actividad 
esfingomielinasa ácida) y en plasma (MIP-2), y 6) Marcadas alteraciones en la 
composición y funcionalidad del surfactante pulmonar tal y como se describen en el 
Capítulo 1.  
Por el contrario, el grupo rHV presentó una respuesta inflamatoria atenuada en 
el pulmón, representada por un aumento de los niveles de IL-6 en BAL acompañada 
de una disminución de TNF-α, MCP-1 y MIP-2, junto con ausencia de actividad 
esfingomielinasa ácida. La ventilación mecánica estimuló la secreción de surfactante, 
aislándose surfactante sin alteraciones en su composición ni presencia de 
peroxidación lipídica. A diferencia del grupo sHV, el surfactante pulmonar de los 
animales aislados del grupo rHV era capaz de: i) adsorberse y establecer una 
monocapa estable en la interfase aire-líquido, ii) disminuir la tensión superficiales 1 
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mN/m durante la compresión, y iii) re-extenderse durante la expansión. Aunque los 
animales resistentes a las estrategias ventilatorias lesivas mostraron algunas 
evidencias de daño tisular, disminución de células alveolares y liberación de 
citoquinas proinflamatorias en BAL, estos animales no presentaron edema intra-
alveolar y una relación PaO2/FiO2 normal (450 mm Hg) tras 2.5 h de ventilación. 
 
Conclusiones del C.2: Estos resultados indican que VILI se genera solo en aquellos 
animales donde el surfactante pulmonar se encuentra inactivado y que hay una clara 
relación entre una pronunciada respuesta pro-inflamatoria y la inactivación del 
surfactante pulmonar. Además, estos resultados muestran que una respuesta 
inflamatoria atenuada junto con un aumento de la secreción endógena de surfactante 
activo protegen del desarrollo de edema intra-alveolar e hipoxia, sucesos típicos de 
animales ventilados con estrategias ventilatorias lesivas. 
 
Capítulo 3 
El objetivo de este capítulo fue dilucidar el efecto de estrategias ventilatorias 
convencionales prolongadas en animales previamente expuestos o no a estrategias 
ventilatorias lesivas. 
Se determinó que los individuos expuestos por un periodo de tiempo 
prolongado a una ventilación mecánica convencional mostraban un aumento de 
infiltración neutrofílica y de liberación de citoquinas proinflamatorias en el espacio 
alveolar (IL-6 yMIP-2 pero no TNF-α) y en plasma (IL-6). Sin embargo, la respuesta 
inflamatoria no fue lo suficientemente dañina como para producir daños histológicos, 
alteraciones en el surfactante y disfunción pulmonar. 
Por otro lado, se observó que la ventilación convencional prolongada  tras 
ventilar los animales con una estrategía ventilatoria lesiva tiene efectos nocivos en 
aquellos animales que sobreviven a dicha estrategia ventilatoria r(HV+LV). Los 
animales mostraron edema intra-alveolar, infiltración de neutrófilos, aumento de MIP-
2 en BAL y en plasma así como ligeras alteraciones en el intercambio gaseoso 
mientras que el surfactante pulmonar no mostraba alteraciones. Estos datos indican 
que las alteraciones en el espacio alveolar pueden sucederse sin alteraciones en el 
surfactante pulmonar. Además, estos datos apoyan nuestra conclusión de que VILI se 
presenta sólo en aquellos animales cuyo surfactante se encuentra inactivado, puesto 
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que estos animales no desarrollan VILI. Es más, un pequeño número de animales no 
sobrevivió a todo el proceso ventilatorio s(HV+LV) y presentó una respuesta 
inflamatoria exacerbada, edema intra-alveolar, evidencias de alteraciones histológicas, 
alteración en la composición y funcionalidad del surfactante y por consiguiente una 
disminución significativa de la oxigenación arterial (PaO2/FiO2< 200 mmHg). 
 
Conclusiones del C.3: Estos resultados indican que: 1) la inflamación en el pulmón 
está directamente relacionada con la duración de la estrategia ventilatoria 
convencional; 2) Que una adecuado funcionamiento del surfactante pulmonar es 
esencial para la supervivencia de aquellas ratas expuestas a estrategias ventilatorias 
lesivas y/o ventilación mecánica prolongada bajo estrategias no dañinas; y 3) Los 
cambios en la composición y funcionalidad del surfactante pulmonar no preceden al 
inicio del daño pulmonar agudo inducido por ventilación mecánica (VILI). 
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INTRODUCTION 
 The pathogenesis of acute respiratory distress syndrome (ARDS) and the less 
severe condition known as acute lung injury (ALI) (2) is still not fully understood. 
However, it is currently thought to begin with an inflammatory response induced by 
extrapulmonary injury (sepsis, severe trauma, acute pancreatitis, etc.) or direct 
pulmonary injury (pneumonia, aspiration of gastric contents, pulmonary contusion, 
etc.) (3). The inflammatory response increases alveolar epithelial and pulmonary 
vascular endothelial permeability, causing alveolar filling (3, 4). The alteration of the 
pulmonary surfactant system complicates the clinical picture (5).  
 Surfactant is necessary to keep the alveolus open, thereby allowing gas exchange. 
Without surfactant the alveoli collapse since the surface tension at the air–water 
interface exerts a collapsing pressure (1, 6). Thus, one of the main lung surfactant 
functions is to form a stable lipid monolayer at the air–liquid interface that excludes 
water molecules from the interface and effectively lowers surface tension to 1mN/m 
on expiration (1). To fulfill this function, the surfactant extracellular membranes are 
composed of lipids (mainly phospholipids) and three surfactant apolipoproteins (SP-
A, SP-B, and SP-C). After surfactant secretion by epithelial type II cells, the secreted, 
tightly packed surfactant membranes (known as large surfactant aggregates [LA]) 
rapidly transfer surface-active material to the air-liquid interface, forming the 
surfactant monolayer (1). This process is known as interfacial adsorption of 
surfactant. After adsorption, the surfactant film is periodically compressed during 
exhalation and expanded during inhalation. Compression involves changes in surface 
tension (γ) from~23 mN/m to ~1 mN/m to prevent alveolar collapse, whereas film 
expansion increases γ to a maximum of 20–25 mN/m to maintain alveolar stability. 
With repetitive surface compression and expansion cycles, small surfactant vesicles 
with poor surface activity (known as small surfactant aggregates [SA]) are generated. 
They are taken up continuously by alveolar macrophages and epithelial cells. Deficit 
or alteration of lung surfactant leads to intraalveolar edema, impaired lung 
compliance, ventilation-perfusion mismatch (including shunt flow due to altered gas 
flow distribution), and hypoxemia (1, 5, 6). 
 Critical hypoxemia results in the need for mechanical ventilation, thereby 
providing the context in which ventilator-induced lung injury (VILI) can develop (7). 
It is thought that VILI is generated as a result of volutrauma (intensified tissue 
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tensions at the junctions of closed and open alveolar units when subjected to high 
alveolar pressure) and/or atelectrauma (caused by the cyclical airspace opening and 
closing) (7). These stresses might further stimulate the inflammatory response (termed 
biotrauma) resulting in progressive lung injury and systemic inflammation (7). 
 The current respiratory support in ALI or ARDS consists of low tidal volume (to 
reduce volutrauma) and appropriate positive end-expiratory pressure (PEEP) and/or 
FiO2/PEEP ratio (to reduce atectrauma) (8).  
 The application of PEEP is thought to be useful in counteracting increased 
surface tension (thereby reversing the resulting atelectasis). PEEP increases end-
expiratory airspace pressure, but since airspace opening pressures can vary markedly 
between and within patients, applying PEEP to reverse or limit dorsal-caudal 
atelectasis will almost always come at the expense of over-distending ventral lung 
regions and other areas having lower opening pressures (9). 
 Given the importance of ventilatory management for acute respiratory syndrome 
(ARDS or ALI) (7, 8), investigators have started to explore the effects of ventilation 
in healthy lungs. Animal models exposed to conventional and injurious ventilator 
strategies are being used to understand the mechanisms of lung injury induced by 
mechanical ventilation. 
 In this thesis, healthy rats have been exposed to the following ventilator strategies 
(10): 
 Injurious high-stretch ventilation (HV) during 2.5 h, with high tidal volumes (VT 
= 25 ml/kg) and without PEEP application since our aim was to provoke alveolar 
alterations caused by volutrauma, atelectrauma, and/or biotrauma.  
 Conventional low-stretch ventilation (LV) during 2.5 h, with moderated tidal 
volume (VT = 9 ml/kg) and application of positive end-expiratory pressure (PEEP 
= 5 cm H2O), to emulate a ventilator strategy widely used in critical care units. 
 Prolonged conventional low-stretch ventilation (VT = 9 ml/kg, and PEEP = 5 cm 
H2O). 
 Prolonged low-stretch ventilation (VT = 9 ml/kg, and PEEP = 5 cm H2O) after 2.5 
h exposition to high-stretch ventilation (VT = 25 ml/kg, and PEEP = 0). This 
condition simulates clinical situations in which patients with pulmonary 
alterations are subjected to conventional mechanical ventilation. 
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OBJECTIVE 
 The main objective of this thesis was to study morphological and functional 
changes in the lungs after exposition to injurious or conventional mechanical 
ventilation and to identify the relationship among high-stretch ventilation, 
inflammation, edema, and surfactant dysfunction in order to understand the 
mechanisms involved in ventilator-induced lung injury (VILI). Two important 
questions, currently under debate (9), will be answered in this study: whether changes 
in surfactant composition and in surface tension precede the onset of VILI, and 
whether VILI occurs only in animal models when lung surfactant is inactivated. 
The thesis is composed of three chapters, which evaluate: 
 The impact of high-stretch ventilation in the alveolar space and in particular its 
effects on the composition, structure, and functional activity of lung surfactant. 
The causes of surfactant inactivation after high-stretch ventilation were 
assessed (Chapter 1). 
 Factors involved in resistance to ventilator-induced lung injury, since 
identification of such factors may help to develop prophylactic therapies or 
early interventions prior to exposition to mechanical ventilation (Chapter 2). 
 Consequences of prolonged conventional low-stretch ventilation, with or 
without previous exposition to injurious high-stretch ventilation. This would 
allow determination of whether inflammation in the lung was directly related to 
the duration of conventional low-stretch ventilation and whether prolonged 
conventional low-stretch ventilation has beneficial or damaging effects in 
surviving rats exposed to injurious high-stretch ventilation (Chapter 3). 
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RESULTS & CONCLUSIONS 
 
Chapter 1 
 The aim of this chapter was to characterize changes produced in the alveolar 
compartment due to injurious high-stretch mechanical ventilation. Most of the 
animals exposed to injurious high-stretch ventilation developed lung injury (VILI), 
which was characterized by 1) arterial oxygen tension/inspiratory oxygen fraction 
(PaO2/FiO2) < 300 mmHg; 2) histological evidence of tissue injury; 3) increase of 
inflammatory markers such as TNF- and acidic sphingomyelinase activity in BAL; 
4) leakage of plasma proteins into the alveoli and increased levels of protein 
carbonyls in BAL, and 5) loss of surfactant biophysical function. 
Even though high-stretch ventilation stimulated surfactant secretion by type II 
cells, surfactant is rapidly inactivated. Surfactant inactivation can rise from protein 
and lipid oxidation as a consequence of oxidative stress, degradation of surfactant 
lipids and proteins by phospholipases and proteases, and incorporation of inhibitors in 
surfactant membranes leaked from capillaries or secreted by alveolar cells. 
Specifically, we found a marked decrease in levels of surfactant apolipoproteins (SP-
A, SP-B, and SP-C) and reduced expression of these proteins by lung tissue, increased 
levels of lipid peroxides in surfactant membranes, and increased levels of surfactant 
inhibitors such as C reactive protein (CRP) that insert into surfactant membranes and 
critically affect surfactant physical properties (1).  
Ch.1 conclusions: This study indicates that injurious high-stretch ventilation 
produces direct damage tothe lung, promoting inflammation, oxidative stress, and 
release of factors that together inactivate lung surfactant. Surfactant impairment leads 
to atelectasis as manifested by impaired gas exchange and decrease in dynamic 
compliance. 
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Chapter 2 
During the previous study we realized that a number of animals subjected to 
high-stretch ventilation did not show evidence of physiological lung dysfunction. 
Hence, the aim of this chapter was to identify factors involved in the resistance to 
ventilator-induced lung injury. To this end, the high-stretch ventilated group (HV) 
was subdivided in two groups according to the mean arterial pressure (MAP) value, 
which was continuously monitored: 1) animals susceptible to high-stretch 
ventilation (sHV), showing MAP values lower than 50 mmHg and a substantial PaO2 
reduction at 60 min of ventilation; and 2) animals resistant to high-stretch 
ventilation (rHV), with insignificant MAP and PaO2 changes at 60 min. Lung tissue, 
plasma, bronchoalveolar fluid (BAL), and lung surfactant were analyzed. 
The sHV group was characterized by: 1) PaO2/FiO2<200 mmHg; 2) histological 
evidence of tissue injury with hyaline membrane formation; 3) prominent decrease of 
alveolar macrophages; 4) intraalveolar edema; 5) increase of inflammatory markers in 
BAL (TNF-α, MIP-2, MCP-1, and acidic sphingomyelinase activity) and in plasma 
(MIP-2); and 6) pronounced changes in the composition and function of lung 
surfactant as reported in Chapter 1. In contrast, the rHV group was distinguished by 
an attenuated lung inflammatory response, evidenced by increased levels of IL-6 in 
BAL but reduced levels of TNF-α, MCP-1, and MIP-2 and absence of acidic 
sphingomyelinase activity. High-stretch ventilation stimulated surfactant secretion, 
and high amounts of fully active surfactant with normal protein and lipid composition 
and absence of lipid peroxides were isolated from the lungs. Contrary to surfactant 
isolated from lungs of the sHV group, surfactant from the rHV group was able to: i) 
adsorb onto an air/water interface, ii) lower surface tension to values near 1mN/m 
upon compression, and iii) re-spread during expansion. Even though animals resistant 
to high-stretch ventilation showed evidence of some tissue injury, decrease in alveolar 
macrophages, and release of proinflammatory cytokines in the alveolar fluid, these 
animals did not exhibit plasma protein leakage into the alveolar space and showed 
normal PaO2/FiO2 (450 mm Hg) after 2.5 h of ventilation.  
Ch.2 conclusions:  These results clearly indicated that VILI occurred only in animal 
models when surfactant was inactivated and that there is a direct link between 
pronounced proinflammatory response and surfactant inactivation. In addition, these 
  
22 Resumen/Summary 
results show that an attenuated inflammatory response together with increasing 
endogenous, fully active, surfactant pools protect against the hypoxia and protein 
leakage that usually occur when ventilating animals with large VT and no PEEP. 
 
Chapter 3 
The aim of this chapter was to elucidate the effect of prolonged conventional 
low-stretch ventilation, with or without previous exposition to injurious high-stretch 
ventilation. We found that animals subjected to prolonged conventional mechanical 
ventilation showed neutrophils infiltration and increase of proinflammatory cytokines 
in the alveolar space (IL-6 and MIP-2 but not TNF-α) and plasma (IL-6). However, 
the inflammatory response was not damaging enough to show histological evidence of 
tissue injury, pulmonary surfactant alteration, and evidence of physiological lung 
dysfunction. 
On the other hand, we found that prolonged conventional low-stretch ventilation 
has damaging effects in surviving rats previously exposed to injurious high-stretch 
ventilation (rHV+LV). Animals showed intra-alveolar edema together with 
neutrophils infiltration, increase of MIP-2 in BAL and plasma, and slight alterations 
in gas exchange, whereas pulmonary surfactant showed no evidence of impairment. 
These studies indicate that alveolar damage can occur without parallel surfactant 
damage. These animals were resistant to VILI and confirm our previous conclusion 
that VILI occurred only in animal models when surfactant was inactivated. 
Moreover, few animals did not survive the whole mechanical ventilation process 
s(HV+LV) and exhibited exacerbated inflammatory response, edema, histological 
evidence of tissue injury, alterations in the composition and function of pulmonary 
surfactant, and consequently, significant decrease of arterial oxygenation (PaO2/FiO2< 
200 mmHg). 
Ch.3 conclusions: These results indicated that: 1) inflammation in the lung was 
directly related to the duration of conventional low-stretch ventilation; 2) proper 
functioning of pulmonary surfactant is essential for survival of rats exposed to 
injurious and/or prolonged non-injurious mechanical ventilation, and 3) changes in 
surfactant composition and function do not precede the onset of acute lung injury 
induced by mechanical ventilation. 
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1. Respiratory system 
Respiration defines the process by which gas exchange occurs between and 
organism and its surrounding environment.  
Specifically, the respiratory system supplies the body with adequate oxygen for 
aerobic metabolism and removes its major waste product, carbon dioxide. To 
accomplish these features, the respiratory system must provide two physiological 
functions: (I) ventilation, the process by which ambient air is delivered to the alveoli 
which are closely related to blood, and (II) gases exchange diffusion, defined as the 
movement of oxygen and carbon dioxide in opposite directions across the alveoli and 
capillary walls (11). 
The respiratory system is divided into two sections according to these functions: 
Upper Respiratory Tract and the Lower Respiratory Tract.  
 
 
Figure 1. Respiratory System diagram. 
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Upper Respiratory Tract included the Nasal cavity, Pharynx, and the Larynx. Its 
primary function is to receive the air from the external environment and filter, warm, 
and humidify it before it reaches the alveoli where gas exchange will occur (12). 
The Lower Respiratory Tract is conformed by the tracheo-bronchial tree and the 
lungs, both residing in the thoracic cavity. The airway is divided 23 times from the 
trachea to the alveoli sacs, conforming an airway ramification comprised by the 
bronchi and the smaller airways called bronchioles (13). Each bronchiole ends in an 
elongated space enclosed by many air sacs called alveoli, which are surrounded by 
blood capillaries. Therefore, the branching anatomic structure is ideal for maximizing 
surface area to allow optimal gas diffusion or movement of gases across the alveoli. 
In fact, there are 300 million of alveoli in a human (12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Tracheo-bronchial tree diagram. Schematic representation of human 
airways that depicts branching generations (G) beginning at the trachea (0) and 
ending at the alveolar sacs (23). (Modified from reference [13]). 
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2. Alveolar-capillary unit 
The alveolar-capillary unit is highly specialized to maximize diffusion between 
the blood and air gases. This alveolar-capillary structure is the most extensive in the 
body. Specifically, the internal surface area of the adult lung is 70 to 80 m
2
, of which 
90% covers the pulmonary capillaries; thus the air-blood surface available for gas 
exchange is 60 to 70 m
2 
(14). 
The alveolar-capillary unit is comprised of three major constituents: pulmonary 
capillary endothelium, a mixture of cellular and extracellular interstitial components 
and the epithelial lining of the alveolus composed by epithelial lining cells and a thin 
layer of liquid covering the epithelial cells containing alveolar macrophages and 
covered by pulmonary surfactant (15). 
 
 
 
 
 
Figure 3. Schematic representation of the main parts comprising the alveolar-
capillary unit. (Modified from reference (1)). 
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2.1. Pulmonary endothelium 
The lung microvascular bed is the major collection of endothelial cells in the 
human body (13). Alveolar capillary endothelial cells are large attenuated cells 
adapted to facilitate efficient was exchange (13, 15), joined by tight junctions forming 
a continuous, non-fenestratred, monolayer. Their luminal surface is in contact with 
blood whereas their the abluminal surface rests on the endothelial basement 
membrane containing type IV collagen in the lamina densa providing strength to 
withstand rise in capillary pressure with exercise (15). 
Ultrastructurally, endothelial cells had their nuclei usually oriented in the 
direction of blood flow, lesser presence of intracellular organelles than other cell 
types but a large number of plasmalemmal transport vesicles probably due to its role 
in the transport of macromolecules (16).  
In addition to its structural role as part of the alveolar-capillary membrane, 
maintaining its integrity (17), pulmonary endothelium cells participate in the 
regulation of blood flow, coagulation and fibrinolysis (18, 19). In fact, these cells 
contribute to the regulation of pulmonary vascular tone by secretion of lipid mediators 
or maintaining nitric oxide homeostasis (20). Furthermore, endothelium cells 
participate in inflammatory reactions by its activation, facilitating leukocyte migration 
from the blood into the alveolar airspace (21). Endothelial cells activation includes 
changes in chemokine production and an increased of adhesion molecules expression 
on the luminal surface of these cells in response to stimuli such as injury or infection, 
leading to a dramatic increased of leukocytes migration (19). 
Therefore, pulmonary endothelium possesses metabolic, structural, and 
immunological functions that might be deregulated during injury. 
 
 
 
 
 
 
 
 
  
29 Introduction 
2.2. Pulmonary interstitium 
The thinness and hydration state of the interstitial layer between the alveolus and 
the endothelial cells is critical for a proper gas exchange. The pulmonary interstitium 
comprises the extracellular matrix (ECM) and mesenchymal and immune cells such 
as fibroblasts or interstitial macrophages. ECM is conformed by the interstitial 
connective tissue and the basement membranes (BM) (22). 
Alveolar interstitial connective tissue is mainly comprised by types I collagen, 
type III collagen and fibronectin (22, 23). 
On the other hand, basement membranes are condensed sheet-like structures 
separating endothelial and epithelial cells from interstitial connective tissue.  
In both rat and human lungs, the alveolar epithelial BM and alveolar capillary 
BM have been shown to consist of highly cross-linked type IV collagen, laminin and 
fibronectin (22, 23). This composition is thought to play a significant role in 
preserving normal alveolar structure and function. Specifically, fibronectin is believed 
to be involved in epithelial cell regeneration (24). Furthermore, a comparison of the 
level and distribution of fibronectin expression in normal and fibrotic lungs supports 
the hypothesis that fibronectin plays an important role in alveolar epithelial cell repair 
(25). 
Interestingly, the rat lung had two different interstitium morphologies according 
to the thickness between the epithelium and the endothelium, suggesting a modulator 
role of alveolar epithelial cell phenotype (26, 27). Specifically, it exist a thing area 
where capillary endothelium and alveolar epithelium are separated by only a single 
fused alveolar and capillary basement membrane, and thick areas, where endothelium 
and epithelium are separated by their respective basement membranes and connective 
tissue of the interstitial space (28).  
Also, interstitial macrophages are quite prominent in the lung, constituting 
approximately 40% of total macrophages in tissue (29). Due to their direct contact 
with matrix and other pulmonary connective-tissue components, it is thought that the 
release of mediators or enzymes by interstitial macrophages may have greater effects 
than those released by macrophages in the alveolar compartment (30). 
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2.3. Pulmonary epithelium 
The alveolar epithelium is comprised of two morphologically distinct epithelial 
cell types, the alveolar type I (ATI) and type II cells (ATII) (31), that are continuously 
lined among terminal air spaces forming a barrier that is anatomically 1-cell thick 
(32). Consequently, ATI and ATII cells form a tight barrier, which effectively 
separates the alveolar air space from the vascular and interstitial spaces. However, 
alveolar epithelium is an order of magnitude less permeable to small solutes than the 
capillary endothelium (33). Thus, injury to the pulmonary epithelium increases 
susceptibility to alveolar flooding (34).  
Interestingly, morphometric studies have demonstrated that the distribution and 
morphology of these cell types is remarkably analogous among mammalian species 
including rat and human (35). 
2.3.1. Alveolar epithelial type I (ATI) cells 
ATI cells comprise only ~8-9% of the parenchymal cell population within the 
lung, but cover ~95% of the alveolar surface (35, 36). 
Morphologically, ATI cells are large squamous epithelial cells with widely 
spread cytoplasmic extensions, small nucleus, few small mitochondria and 
inconspicuous endoplasmic reticulum (ER) and Golgi apparatus (37). This 
morphological adaptation provides a short diffusion path for gas exchange (36). ATI 
cells are not metabolically active and are considered to be “inert” cells, mainly 
providing a barrier function. However, there is accumulating evidence that ATI cells 
contribute in active ion transport as well as are critical in maintaining alveolar fluid 
balance and resolving air space edema (38). 
2.3.2. Alveolar epithelial type II (ATII) cells 
ATII cells comprise ~15% of lung parenchymal cells, but cover only ~3-5% of 
the alveolar surface (35, 36). Typically located in the corners of alveoli, ATII cells are 
cuboidal in shape, with apical microvilli and characteristic surfactant-containing 
organelles known as lamellar bodies (35, 39). Known functions of ATII cells include 
the synthesis, secretion and recycling of pulmonary surfactant (40), regulation of 
alveolar fluid and electrolyte balance (41), host defense and immunomodulation (40). 
In addition to their synthetic and secretory capacities, ATII cells function as the stem 
cell of the alveolar epithelium and have a central role in alveolar epithelial repair (42).  
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2.4. Pulmonary surfactant 
As previously described, the alveolar epithelial cell surface is lined with a thin 
fluid layer, denominated the alveolar lining layer, which is covered by a film of 
pulmonary surfactant (PS) (15). 
PS is a surface-active lipoprotein complex. The main function of PS film is to 
stabilize the alveoli by the reduction of surface tension at the air-liquid interface, 
preventing the alveolar collapse during end-exhalation (43). In addition, PS possesses 
non-surface tension related functions such as host defense and pathogen barrier 
functions, which makes PS physiologically essential (6). 
Deficiency or dysfunction of PS causes severe respiratory diseases (6). 
Specifically, the first pathology associated with PS alterations was the Neonatal 
Respiratory Distress Syndrome (RDS) in the late 50s (44). This syndrome is 
originated by an immaturity of the epithelium to synthesize and secrete a sufficient 
amount of PS due to prematurity (45). Conversely, accumulation of PS in the alveolar 
airspaces, as in pulmonary alveolar proteinosis, can be deleterious leading to gas 
exchange impairment (46). 
  In addition, qualitative alterations of PS have been also involved in other 
pathologies such as Acute lung injury (ALI) and its severe form, Acute Respiratory 
Distress Syndrome (ARDS) (6, 46). These pathologies displays symptoms similar to 
RDS but they can affect patients from any age, having mortality rates of ~30-40% (3, 
47). 
Therefore, research in PS biology in the past three decades leaded to open new 
lines of study focused on the development of potential surfactant replacement 
therapies (46). Hence, the study of PS has both physiological and clinical relevance. 
2.4.1. Composition 
Comparative biological studies suggest that PS exist in all air-breathing 
vertebrates but with slightly composition differences (6, 48). However, PS 
composition in mammals is outstandingly similar among species, i.e., approximately 
90% lipids and 10% proteins by weight (wt.) (6, 49). 
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2.4.1.1. Lipid composition 
The lipids consist mainly of phospholipids (PL, ~90–95% wt.) with asmall 
amount of neutral lipids (~5–10% wt.), primarily cholesterol (6, 50). 
Interestingly, the most prevalent class of PL in PS is phosphatidylcholine (PC), 
which accounts for ~80% of the total PL from most mammalian species. PC may have 
either saturated or unsaturated acyl chains, whose length and saturation have an 
impact on the fluidity of the lipid (51). 
Although notable exceptions exist (52), in most cases ~40% of the PC is 
dipalmitoylphosphatidyl choline (DPPC) (16:0/16:0 PC) (6). DPPC is a long-chained, 
disaturated and zwitterionic (i.e. carry no net electrical charge) PL, mainly 
responsible for reducing surface tension (γ) values to near-zero values upon film 
compression. Despite its high capacity to reduce surface tension, DPPC does not 
adsorb or re-spread to the surface quickly enough in vivo. At 37ºC, DPPC typically 
exists in a gel phase, i.e., with its acyl chains in a rigid close-packed arrangement 
Figure 4. Pulmonary Surfactant composition diagram. PL: phospholipids; PC: 
phosphatidylcholine; PG: phosphatidylglycerol; DPPC: 
dipalmitoylphosphatidylcholine; SP-A, SP-B, SP-C and SP-D: pulmonary surfactant 
protein (SP) -A, -B, -C, -D. 
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allowing to form a condensed monolayer upon compression and resisting high surface 
pressures (50). 
In contrast, unsaturated lipids at 37ºC exist in a liquid crystalline phase and 
cannot form a condensed monolayer in a highly compressed state. These lipids are 
more fluid-like because of the double bond. Therefore, the presence of unsaturated 
lipids in PS helps in fluidizing and re-spreading DPPC and other saturated lipids (51). 
Other PL classes that are also present in lung surfactants but in minor proportion, 
include phosphatidylethanolamine (PE), phosphatidylglycerol (PG), 
phosphatidylinositol (PI), phosphatidylserine (PS) and sphingomyeline (SM). These 
lipids also help in the adsorption and re-spreading of DPPC. At physiological pH, PC 
PE or SM are zwitterionic, while PG, PI and PS are anionic or negatively charged (6). 
Anionic PL as a group accounts for ~15%of the total PL and have been shown to 
interact with the cationic surfactant protein B and C, being critical for the proper 
functioning of PS at the air/alveolar liquid interface (53).  
Finally, neutral lipids constitute 10% wt. of the PS with cholesterol accounting 
for approximately 80-90% wt. Its main function resides in its ability to maintain the 
balance between fluidic and rigid lipid phases in PS (51). 
 
2.4.1.2. Protein composition 
Besides the aforementioned lipidic components, four surfactant proteins (SPs) are 
also present in PS. They are named pulmonary surfactant protein (SP)-A, -B, -C and -
D, based on the nomenclature proposed by Possmayer (54). 
Interestingly, SPs can be separated in two groups according to their role 
accomplished in the PS system as active inhibitors of a broad spectrum of foreign 
pathogens or as regulators of the interfacial surface tension (55).  
Hence, the first group are large hydrophilic SPs, SP-A and -D, are members of a 
family of collagenous carbohydrate binding proteins, known as collectins, or calcium-
dependent (C-type) lectins. Collectins consist of oligomers of trimeric subunits, which 
are able to recognize, inhibit and inactivate a wide range of foreign pathogens (55). 
Conversely, the small molecular weight hydrophobic SPs, SP-B and-C, are tightly 
associated with PS film at the air–liquid interface contributing to regulate the 
structure, integrity and composition of the surface lipid film (6, 55-57). 
  
34 Introduction 
Among these PS-associated proteins, SP-A is the most abundant by mass (but not 
by molar ratio), accounting for ~5% wt. of PS, with SP-D, accounting for ~0.5% and 
SP-B and SP-C constituting together approximately~1-1.5% (58). 
 
Collectins 
SP-A 
 SP-A (630 kDa) is a large multimerichydrophilic glycoprotein consisting of 18 
subunits, each weighing 28-36 kDa conformed by four structural domains (59):  
(I) N-terminal segment involved in intermolecular disulfide bond formed by 7–10 
amino acids. 
(II) Collagen-like domain formed by 79 residues characterized by 23 Gly-X-Y 
repeats with an interruption near the midpoint of the domain of Pro-Cys-Pro 
sequence that is responsible for the formation of SP-A characteristic supra-
quaternary structure (59, 60). The collagen-like domain of mammalian SP-A 
functions as scaffolding that amplifies the ligand binding activities of globular 
domains. Moreover, collagen-like domain is responsible for the binding of SP-
A to some receptors on the surface of alveolar macrophages and epithelial 
cells (61). 
(III) Neck region located between the collagen and the globular domain conformed 
by a 35 amino acid segment with high -helical propensity. 
(IV) C-terminal globular domain composed by 115 residues, including four 
conserved cysteins that form two intra-molecular disulfide loops and 18 highly 
conserved amino acid residues common to C-type leptines. The basic structure 
of the globular domain consists of a structural core conformed of –helical 
and –strands (59). This conformational shift enhances lipid binding and 
allows Ca
2+
-dependent binding of oligosaccharides, protein self-association 
and SP-A-mediated lipid aggregation (59, 61, 62).  
 The human SP-A locus consists of two similar but non-identical genes, SP-A1 
and SP-A2, each approximately 5 kb in length and a truncated and nonfunctional 
pseudogene that shares 85% similarity with the SP-A 3´ untranslated region (63); 
however in other mammals such as rats (64) there is a single-copy gene.  
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The human SP-A locus has been assigned to chromosome 10q22-q23 near the 
loci for SP-D and MBP, suggesting that this area of chromosome 10 is involved in the 
evolution of collagenous C-type lectins (63). Recently, it has been found that SP-A1 
and SP-A2 are in linkage disequilibrium, indicating close physical association. In fact, 
it has been detected opposite transcriptional orientation suggesting that both genes 
might share cis-acting regulatory elements (65). Indeed, it is thought that both gene 
products are expressed in a 2:1 ratio (SP-A1:SP-A2) and associated through their 
collagenous domains to form heterotrimers (66).  
SP-A is modified after translation in the ER and Golgi (cleavage of the signal 
peptide, proline hydroxylation, and N-linked glycosylation) and assembled into a 
complex oligomeric structure that resembles a flower bouquet (59, 61, 62). SP-A 
assembly is an intracellular process that can be conceptualized in two parts: the 
folding of monomeric subunits into trimers (Figure 5a) and the association of six 
trimers into an octadecamer (59) (Figure 5b). Interestingly, mammalian SP-A is not 
only assembled in supratrimeric oligomers but also forms multimers by self-
association of the protein in the presence of Ca
2+
. 
Supratrimeric oligomerization and multimerization of mammalian SP-A seems to 
be needed for many of its functions, such as host defense and immunosuppressive SP-
A high-affinity binding capabilities (to lipids, carbohydrate-bearing surfaces, and 
proteins ) (59). 
Figure 5. Models of trimeric (a) and oligomeric (b) forms of SP-A. All human SP-A 
structural domains are depicted: I) NH2-terminal segment; II) collagen-like domain with a 
sequence irregularity, which divides the collagen-like domain in two parts; III) neck 
region; and IV) COOH-terminal globular domain. (Figure modified from reference [55]) 
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SP-A participates in alveolar innate immune defense, together with SP-D and 
other proteins and peptides, by direct killing of microorganisms or by indirect killing 
through enhancing the uptake of pathogens by phagocytes (55). 
SP-A can bind to some micro-organisms such as Gram negative bacteria (67), 
that may lead to either bacterial killing and/or bacterial aggregation. Bacterial 
aggregation facilitates phagocytosis mediated by the collagen tails of SP-A, initiating 
a proinflammatory response (61). As well, SP-A contributes to phagocytosis of some 
virus like respiratory syncytial virus, influenza virus A or herpes simplex virus type 1 
(68-70). 
Also, SP-A binding to receptors results in an antiinflammatory response (71, 72) 
and prevents the persistence of inflammation, which is detrimental to the lung. For 
example, SP-A regulates signaling pathways in macrophages in response to microbial 
recognition that controls inflammation like toll-like receptor-2 (TLR-2) signaling 
pathway (73). As well, SP-A binds to various receptors of ATII cells including P63 
(74) and SPAR (75), to activate the phosphatidylinositol 3-kinase (PI3K) pathway 
triggering in last term the expression of pro-inflammatory genes (75). 
 Finally, SP-A is mainly associated with PS and has some properties related to 
its ability to bind and aggregate PS membranes: 
(I) Together with SP-B, contributes to the formation of tubular myelin. 
(II) Improves the rate of surfactant adsorption to an air–liquid interface. 
(III) Protects PS membranes against inactivation by transudated serum proteins 
(59, 62).  
 
SP-D 
As SP-A, SP-D (520 kDa) is also a member of the family commonly known as 
collectins that are involved in the first line of defense against fungal, bacterial, and 
viral infections (76).  
SP-D as other collectins is assembled as oligomers of trimeric subunits, 
specifically formed a cruciform structure in which four homotrimeric subunits self-
associate at their N-termini to form highly ordered SP-D dodecamers (Figure 6b).  
Each subunit (43 kDa) consists of four regions (Figure 6a): (I) a short N-terminal 
non-collagen sequence; (II) a very long collagen domain of 59 Gly-X-Y repeats; (III) 
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ashort linking domain, the „neck‟ region that connects the collagen domain to the 
fourth region; and (IV) C-terminal carbohydrate recognition domain (CRD) (55). 
Some studies suggested that folding of the CRD, trimerization of monomers, 
triple helix formation, the amino-terminal association of trimeric subunits and the 
formation of inter-chain disulfide cross-links occur in the rough ER whereas 
oligosaccharide maturation occurs in the Golgi immediately prior to secretion (77). 
As previously described, SP-D gene have been localized in the region of 
10q22.2–23.1 close to SP-A (63, 76). Conversely, a single gene encodes human SP-D. 
However, protein, cDNA, and genomic sequencing together suggest the existence of a 
number of SP-D alleles, some of which are characterized by amino-acid substitutions 
in the coding region. Therefore, the SP-D gene encodes at least one, and probably 
two, untranslatedexons at the5´-end of the gene, similar to SP-A (76). 
SP-D plays complex role in innate immunity in the alveolus by decreasing 
inflammation and promoting clearance of pathogens from the respiratory tract without 
stimulating a secondary immune response. The functions of SP-D have been 
investigated at different levels according to the interaction between effector cells and 
pathogens. 
Figure 6. Models of trimeric (a) and oligomeric (b) forms of SP-D. All structural 
domains of SP-D are represented: I) NH2-terminal segment; II) collagen-like domain; III) 
neck region; and IV) COOH-terminal globular domain.  
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First, SP-D binds to carbohydrate structures of several pathogens such as 
influenza A virus, a variety of gram-negative bacteria including Klebsiella 
pneumoniae, Pseudomonas aeruginosa, Hemophilus influenzae, and Escherichia coli 
or opportunistic fungal pathogens such as C. neoformans, Aspergillus fumigatus 
conidia and Candida albicans, leading to their inhibition (76-79). 
Second, SP-D binds to leukocytes such as alveolar macrophages and dendritic 
cells modifying their activities by: (I) opsonization or other effects mediated by the 
specific interactions of the leukocyte with SP-D-coated organisms; (II) direct effects 
of SP-D on phagocyte function; and (III) SP-D-mediated alterations in particle 
presentation secondary to aggregation (77).  
However, all these mechanisms may be operative, alone or in combination, in 
specific microbial-phagocyte interactions. 
Also SP-D−/− knockout mice show that they have impaired host defense upon 
injury or infection instead of an exaggerated inflammatory response, heightened 
susceptibility to inflammatory stimuli, infections or allergic sensitization (55). 
Furthermore, immune cells in the lung of SP-D−/−mice display multiple 
abnormalities including altered morphology and constitutive release of pro-
inflammatory mediators (55).  
 
Hydrophobic peptides 
SP-B 
Though SP-B comprises only~10% (w/w) of SPs, its absence or dysfunction due 
to mutations results in respiratory failure and death shortly after birth (80).  
Human SP-B mRNA is produced from a single gene located on chromosome 2 at 
a site syntenic with the murine SP-B gene located on chromosome 6 (81, 82). The SP-
B gene is first transcribed/translated into a significantly larger monomeric pre-pro-
protein of approximately 42 kDa,which is processed to a smaller, lipid-associated 
peptide in the distal secretory pathway within the type II cells (46, 83). 
The monomeric pre-pro-protein is first N-glycosylated on regions flanking the 
mature SP-B sequence (83). These flanking arms are cleaved at several steps among 
trans-golgi, multi-vesicular bodies (MVB) and proximal lamellar bodies (LB) where 
proteases such as napsin A, cathepsin H and pepsinogen C are involved (46, 83).  
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Once finishing the protein processing, the mature form of SP-B results in a 79 
amino acid homodimer of approximately 18 kDa (84), contained in the LB of the 
secretory pathway of ATII. 
Analysis of the sequence of SP-B reveals that this protein belongs to the family 
of the saposin-likeproteins. Each SP-B monomer (9kDa) possess small folds of 
around 80 amino acids containing amphipathic alpha-helices and three intramolecular 
disulfide bridges that link Cys-8–77, Cys-11–71, and Cys-35–46 (85, 86). The 
remaining cysteine at position 48 establishes the intermolecular bond responsible for 
dimerization of SP-B that does not take place until the cleavage of the flanking arms 
is completed. This bond is a disulfide linkage that presumably constrains the protein‟s 
flexibility and contributes to the remarkable thermal stability of the secondary 
structure (87) and the unusual resistance to both acid and proteolytic degradation. 
Although it still lacks a three-dimensional model of the structure and disposition 
of SP-B in surfactant membranes, it has been proposed that SP-B interacts 
superficially with the surface of bilayers and monolayers, through amphipathic helical 
motifs (88). 
 
Figure 7. Models of the homodimer of SP-B (a) and its models of interaction with 
lipid monolayers (b) and bilayers (c). 
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In fact, all saposin-likeproteins have activities related to interacting with and 
inserting todifferent extents into PL membranes (85), but SP-B is the only member of 
the family that is permanently membrane-associated, partially due to its high 
hydrophobicity (56). Also the net positive charge of SP-B likely promotes a certain 
selective interaction of SP-B with the anionic PL fraction of surfactant, and 
particularly with PG (89) though there is a certain controversy due to whether SP-B 
prefers PG-enriched or PC-enriched membrane regions (90). Conversely, it has been 
established that SP-B is distributed specially in disordered regions of membranes and 
interfacial films (56). 
Therefore, SP-B facilitates organization of PS membranes in the lamellar body, 
likely through its ability to promote membrane-membrane contacts, perturbation of 
lipid packing, and membrane fusion (46). Furthermore, SP-B promotes a rapid and 
efficient adsorption of surfactant PL into the air–liquid interface and modulates the 
stability and dynamic behavior of interfacial surfactant films subjected to continuous 
compression–expansion cycling (45). 
On the other hand, SP-B deficiency, arising from mutations in the human gene 
(SFTPB) or disruption of the mouse locus (Sftpb), results in vesiculated LB with few 
or no bilayer membranes and electron dense inclusions (46). Most importantly, severe 
SP-B deficiency (i.e., ~75% reduction in SP-B content in the airspaces) results in fatal 
RDS (91). Indeed, SP-B expression is altered in several acute and chronic lung 
diseases contributing to their pathogenesis (80). 
 
SP-C 
SP-C (4 kDa) is a non-homologous protein considered the most specific protein 
in terms of biophysical activity of PS and tightly linked with lung differentiation in 
mammals (56). Surprisingly, animals lacking expression of a functional SP-C are able 
to breath and therefore survive (92), suggesting that the action of SP-C is not as 
critical as SP-Bs. However, deficiencies in SP-C are irretrievably associated with 
severe respiratory pathologies (80). 
Human SP-C gene is organized into six exons and is localized in the short arm of 
chromosome 8 (93). Differential splicing of the primary transcript, localize primary at 
5´and 3´of exon 5, leads to several SP-C RNAs, but the SP-C RNA of ~0.9 kb 
encodes a pro-protein of 197 amino acid in human or 194 amino acids in rat (93-95).  
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Like SP-B, SP-C is first synthesized as a pro-protein. During its biosynthesis, the 
transmembrane segment of proSP-C, which will be afterwards the main part of the 
mature protein, is oriented with its N-terminal end exposed to the cytosol and the C-
terminal side to the lumen of the ER (95).  
The cytosolic domain encodes information required for intracellular trafficking of 
SP-C to the MVB/LB compartments (96). Here, assembly of SP-C into PS 
membranes is coupled with proteolytic processing of proSP-C precursor, to liberate 
N-terminal and C-terminal propeptides (46). Specifically, the generation of the 35-
amino acid mature peptide involves a removal of 23-25 residues of N-terminal pro-
peptide and 133-139 residues from the C-terminus of the pro-protein (94). Also, SP-C 
is post-translationally modified by addition of palmitoyl groups via thioester bonds to 
Cys-5 and Cys-6 (97). Interestingly, it is suggested that the processing machinery of 
SP-C maturation might be shared with SP-B as cathepsin H seems to be implicated 
(96). 
Subsequently, fusion of the MVB with a LB leads to SP-B-mediated 
incorporation of SP-C-containing luminal vesicles into existing PS membranes that 
are eventually secreted into the airspaces. Thus the highly hydrophobic mature SP-C 
maintains its transmembrane orientation throughout biosynthesis (46). 
As a result, mature SP-C is a small hydrophobic lipopeptide of 35 amino acids, 
containing palmitoylated cysteines, which is co-purified with SP-B and PL in 
chloroformic extractions of PS (98). Its three-dimensional structure consisted in a 
rigid α-helix covering approximately two thirds of the sequence and an unstructured 
N-terminal segment containing palmitoylated cysteines (97) (Figure 8a). In 
membranes, the helical segment of SP-C adopts a transmembrane orientation, adapted 
to traverse the DPPC bilayer in a fluid state(46) (Figure 8b and c). 
SP-C, with lower activity that SP-B, is also able topromote adsorption and 
transfer of PL into the air–liquid interface (99). 
Also, it has been suggested that SP-C could contribute to the remodeling of 
composition and structure of the interfacial films due to its exclusion of the 
monolayer during compression together with its intrinsic ability to interact and disrupt 
PL membranes with both α-helical segment, and N-terminal regions (100-102). 
Furthermore, it has been detected that SP-C promotes the formation of multilamellar 
structures associated with interfacial films during compression of surfactant films 
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(103). For that purpose, the presence of palmitic acid chains esterifying the cysteines 
in the N-terminal segment of the SP-C molecule seems to be critical to maintain this 
association (104). 
On the other hand, increasing evidence indicate that SP-C is also involved in 
immunomodulation that is critical for the stability and host defense of the airways 
(80). Interestingly, SP-C-deficient mice were found to be susceptible to bacterial and 
viral infections showing excessive inflammation (105, 106) and more vulnerable to 
develop severe outcomes in bleomycin-induced fibrosis (107).  
A well, several studies observed that the amino-terminal segment of SP-C binds 
LPS suppressing inflammation (108-110) and SP-C-containing surfactant vesicles 
bind and interfere with toll-like receptors mediating the inflammatory responses in 
macrophages (105). 
 
 
Figure 8. Model of the monomer of SP-C (a) and its models of interaction with 
lipid monolayers (b) and bilayers (c).  Nt: Amino-terminal region; palmitoyl groups 
bonded to Cysteine (Cys) 5 and 6 are indicated with black arrows. Ct: Carboxyl-
terminal region. 
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2.4.2. Metabolism 
ATII cells are mainly responsible of the synthesis, storage, secretion, and even 
recycling of almost all components comprising PS. Here we divided the metabolism 
of PS in three sections: Synthesis and processing; Secretion; and Recycling and 
turnover. 
 
2.4.2.1. Synthesis and storage 
The PL and proteins of PS are synthesized in ATII cells, assembled in lamellar 
bodies and extruded into the alveolar lumen by exocytosis. 
Phospholipids synthesis 
As SPs synthesis and processing has been mentioned in the last section, here we 
briefly summarize the synthesis of main important lipids of PS. 
Figure 9. Diagram of the metabolism of pulmonary surfactant. ATI: alveolar type I 
cells; ATII: alveolar type II cells; E.R.: endoplasmic reticulum; MVB: multi-vesicular 
bodies; LB: lamellar bodies.  
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Phospholipids are composed of a glycerol backbond, two fatty acids and a polar 
phosphorylated moiety. This composition conferred to the PL amphipathic properties. 
The fatty acids required for PS lipid synthesis might be recruited from circulation as 
free fatty acids or triacylglycerols in lipoproteins but also might be synthesized de 
novo by ATII cells from several precursors such as glucose, lactate or acetate (111). 
All diacylglycerol phospholipids are synthesized in the ER through a chain of 
biochemical events beginning with the formation of phosphatidic acid, which is 
hydrolyzed to diacylglicerol. Subsequently, specific enzymes transform this product 
generating compounds with several polar heads, like PC, PG or PI (112). 
Interestingly, as previously mentioned, half of the PC in PS is DPPC, accounting for 
~40% of total surfactant PL (6). Two pathways contribute to the production of DPPC, 
de novo synthesis andremodeling via lysoPC. However, the latter pathway accounts 
for up to 75% of DPPC in ATII cells and involves deacylation of unsaturated PC at 
the sn-2 position by a Ca
2+
-dependent phospholipase A2 (14, 46). 
The regulation of PL synthesis in the lung is influenced by developmental and 
hormonal factors affecting several rate-limiting metabolic steps. Corticosteroids and 
thyroid hormones enhance the activity of several enzymes within the PL synthetic 
pathway whereas insulin, epithermal growth factor (EGF) or transforming growth 
factor  (TGF-) influence PS production (112, 113). Interestingly, some of these 
factors e.g. glucocorticoids, are directly involved in the control of AMPc production, 
which in last term regulate SP levels (114, 115). 
Storage 
Pulmonary surfactant complexes are assembled in ATII cells and stored in form 
of tightly packed membranes in the LBs (e.g. the characteristic storage granules of PS 
in ATII cells) (Figure 10) (116). They consist of a limiting membrane surrounding 
about 20-70 tightly packed PL bilayers, or lamellae, arranged in a hemisphere (117, 
118). These organelles belong to the endosomal–lysosomal pathway and their 
maturation requires proper trafficking of proteins and lipids along the regulated 
exocytic pathway (119). 
As previously mentioned, it has been postulated that SP-B and SP-C are 
synthesized in the ER and processed through the Golgi and MVBs reaching LBs 
(120). Conversely, though SP-A is also synthesized and processed in ER and Golgi, 
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now it is widely accepted that it is secreted into the extracellular media by a different 
pathway and probably interacts with PS membranes once in the alveolar space (121).  
As well, the major surfactant PLs are synthesized in the ER. Three pathways of 
intracellular lipids transport has been postulated: vesicular transport, non-vesicular 
transport, and diffusion at membrane contact sites (122). 
 
 
Vesicular transport plays an important role in trafficking newly synthesized SPs 
andis also important for recycling of PS proteins and lipids via the endocytic pathway. 
However, though there are some evidences of PS lipids vesicular transport from the 
ER to the LB (123) a separate study found that inhibition ofvesicular transport did not 
inhibitincorporation of newly synthesized lipid intothe LB (124). 
The non-vesicular transport pathway can answer these results due to the 
localization of the ABC transporter (ABCA3) to the limiting membrane of the LB 
(125, 126). Indeed, as ABC transporters typically move substrateout of the cytosol, 
Figure 10. Ultrastructural appearance of alveolar epithelial type II cells by electron 
microscopy (bar=0.2m). Lamellar bodies (LB), nuclei (N), mitochondria (M), alveolar 
lumen (AL), capillary (CA). (Image from Fehrenbach et al. Respiratory Research 2005.) 
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being liable that ABCA3 would be an essential transporter of PL into the LB. In fact, 
disruption of the Abca3 locus results in neonatal lethal RDS associated with loss of 
LBs (127, 128). 
Another postulated mechanism for PL transfer from ER to LBs is via diffusion or 
facilitated exchange at membrane contact sites that would require the participation of 
accessory proteins to ensure the formation of transient contact sites between the 
appropriate donor (ER) and acceptor (LB) organelles (122). However, these pathways 
remain as an important and unresolved question. 
There are several classes of LBs according to their packaging statement from 
round–concentric-like membranes to very tightly packed piles of membranes (56). 
These types areusually linked with the proximity with the alveolar surface. Thus, 
when LB acquired the final packed state, they are found near the alveolar surface to 
be extruded into the alveolar lumen by exocytosis. 
 
 
2.4.2.2. Secretion 
PS secretion requires the transportation ofLB to the apical membrane of ATII 
cells. According to several stimuli such as cholinergic and -sympathomimetic 
agents, Ca
2+ 
ionophores, purine agonists and the most important, alveolar stretching, 
the limiting LB membrane is merged with the plasma membrane of ATII cell, 
extruding the LB into the hypophase (e.g. thin aqueous layer covering the ATII cell 
surface) by exocytosis (Figure 11a) (129, 130). 
In the hypophase, the tightly packed surfactant membranes comprising the LBs 
tend to reorganize to form a loose network of interconnected membranes named 
tubular myeline (TM) (Figure 11b). It is not clear how the structural transformation of 
surfactant membranes is triggered, but potential effectors include changes in the 
hydration of surfactant complexes, pH, presence of surfactant apoproteins or calcium 
concentration (50–52).  
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TM is composed of large square elongated tubes, constituted primarily of  PL 
(DPPC and PG), proteins SP-A and SP-B, and Ca
2+ 
(6), ranging in size from 
nanometers to microns (53,54). Membranes in TM arrange in an ordered pattern, 
whose dimensions are related with the molecular size of SP-A macromolecule, 
suggesting that SP-A is the main determinant for TM organization. Though the 
mechanisms of TM are still under discussion, it is likely that TM formation requires: 
(I) close contacts between opposing DPPC-rich membranes mediated by SP-A; (II) 
SP-A self-association mediated by Ca
2+
, and (III) membranes fusion mediated by SP-
B (59). As SP-A is mainly implicated in innate defense (59), current thinking assumes 
that TM structure plays also some role in optimizing clearance of pathogens. 
Subsequently, PS components of TM are transferred to form a surface-active film 
at the air–water interface of alveoli by rapid adsorption. In this case, SP-B and SP-C 
are thought to facilitate PL transfer (specifically DPPC) from TM to the surface film 
(56, 58).  
 
Figure 11. Electron micrographs sections (bar=0.1 m). a) A lamellar body in the 
process of exocytosis from a type II cell. (Figure from reference [122]). b) Lamellar bodies 
(LB) are seen forming tubular myelin (TM). Inset: detail of tubular myelin showing small 
projections in the corners, thought to represent SP-A (Image from reference [34]). 
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Traditionally, the PS film has been considered to be a monolayer (131, 132). 
However, several studies using different techniques (133-136) conclude that at least 
part of the PS film is thicker than a single monolayer. Specifically, plus the surface 
monolayer, there are at least one lipid bilayer closely and apparently functionally 
associated with the interfacial monolayer (Figure 12). These multilayers structures 
could provide additional stability to PS monolayers, thereby allowing the attainment 
of very low surface tension (6).  
Therefore, upon compression of the PS film during expiration, SPs induce the 
formation of unsaturated phospholipids-rich multilayers that remain associated with a 
monolayer enriched in saturated PL species. After inspiration, some of the lipids in 
the reservoirs are re-adsorbed into the surface film, helped by the hydrophobic 
peptides in order to avoid significant loss of material (57). 
 
 
 
 
 
 
 
Figure 12. Diagram of a multilayer interfacial surfactant film structure. 
It depicted the possible interaction between pulmonary surfactant-associated proteins 
with the monolayer in the air-liquid interface and the bilayers associated.  
Yellow: SP-C; Red: SP-B; and Green: SP-A. 
  
49 Introduction 
2.4.2.3. Recycling and turnover 
Compression-expansion cycling during respiration leads to progressive 
conversion of the surface-active fractions of PS into lesser active lipid/protein 
complexes (46). The inactivation of PS may result from detachment of small PS 
particles from the air-liquid interface, changes in lipid/protein association, and 
oxidation of lipid and protein species of PS without rejecting the possibility of 
inactivation byincorporation of materials inhaledfrom the upper airways (6, 137). 
Maintenance of a fully functional surfactant film therefore requires continual film 
refinement through efficient removal of spent PS and incorporation of newly secreted 
complexes (46). 
These lesser active PS complexes are small vesicular forms named small 
aggregates (SA) that represent used PS destined for clearance and re-uptake. These 
aggregates can be separated by centrifugation of lung lavage fluid from the fraction of 
heavy, large aggregates (LA) forms containing more surface active material i.e. 
tubular myelin, lamellar bodies and proteins (138). Measurement of aggregate 
conversion is used experimentally to estimate PS inactivation, being correlated the 
increment of SA with lung injury (139, 140).  
SA is continuously taken up by ATII cells for recycling or, toa lesser extent (5-10 
% of total), cleared by alveolar macrophages (141) (Figure 13). However, it has been 
demonstrated that alveolar macrophages depletion significantly affects PS metabolism 
(142). 
The surfactant lipids that are recycled back into the ATII cells can either be 
catabolized for the novo lipogenesis in lysosomes or reutilized intact in the LB were 
the biosynthetic and endocytic pathways converge. The estimated turnover period of 
PS range from 4 to 11h (143). 
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2.4.3. Functions 
The main functions of PS system are: (I) reduce the surface tension in the 
alveolar air-liquid interface; (II) Alveolar-capillary fluid homeostasis maintenance; 
and (III) Host defense against pathogens and inflammation. These functions can be 
accomplished by the whole PS system or specifically by one of its components.  
 
2.4.3.1. Surface tension reduction in the alveolar air-liquid 
interface 
Molecules at an interface between two phases, like the alveolar air-liquid 
interface, are subjected to specialized conditions that generate associated forces 
manifested as surface tension (144). 
Specifically, because liquid molecules at the interface have strong attraction 
toward the bulk of the liquid (i.e. water is a strongly polar substance with a significant 
intramolecular attractive forces) with no equivalent forces above the surface because 
air molecules are dilute, this imbalance leads to minimize surface area of the alveoli, 
raising the surface tension (144). 
Figure 13. Diagram of recycling and turnover of pulmonary surfactant LA: large 
aggregates or functional fraction of pulmonary surfactant; SA: small aggregates or 
inactive fraction of pulmonary surfactant; LB: lamellar bodies.  
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PS is a surface-active lipoprotein complex which has energetic preference to the 
interface due to its amphipathic condition. As a result, PS film ubication at the 
alveolar air-liquid interface decrease the net unbalanced attractive forces between 
interfacial region and bulk liquid molecules, lowering surface tension (51). 
The resulting PS surface film is compressed and expanded during breathing and 
lowers and variances surface tension in a dynamic way. As alveolar size decreases 
during exhalation, PS film is compressed and surface tension reaches very low values 
(<1 mN/m compare with 70 mN/m for pure water at 37ºC). Conversely, when 
alveolar size increases with inspiration, the PS films is expanded, and surface tension 
proportionaly increases (~23 mN/m at 37ºC). This dynamic variation of surface 
tension with area allows alveoli of different sizes to coexist stably at fixed pressure 
during respiration (51).  
Therefore, idealicing the alveoli shape as spherical cavities, it can be applied the 
Laplace-Young law which enounces that the pressure () inside the alveoli is directly 
proportional tosurface tension () and inversely proportional to alveolar radius (r). 
As a result, small alveoli resist collapse at end expiration because their surface 
tension is low, and alveolar inflation is better distributed during inhalation because the 
ratio of surface tension to area is more uniform in different-sized alveoli (Figure 14) 
(51).  
Moreover, by reducing surface tension throughout the lungs, PS decreases the 
pressures (work) needed fot pulmonary inflation. Interestingly, there is a direct 
conection between the surface activity of PS and pulmonary pressure-volume 
mechanics. The physologic consecuences of PS deficiency or dysfunction includes 
atelectasis, uneven inflation and severe ventilation/perfusion alterations present in the 
lungs of preterm infants with RDS (144). 
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2.4.3.2. Alveolar-capillary fluid homeostasis  
PS also plays a role in homeostasis maintenance of the alveolar fluid, thereby 
preventing edema formation. Edema is defined as an abnormal accumulation of fluid 
in the interstitium followed by fluid compilation in the alveolar space. 
The net flow fluid (Q) across the alveolar-capillary membrane is generally 
expressed using the Starling equation: 
Q=Kf ([Pc-Pi]-R[c-i]) 
Therefore the net fluid movement between compartments is determined by six 
factors: 
1) The filtration coefficient (Kf): is the constant of fluid permeability of the capillary 
wall. Therefore, a low value indicates a low capillary permeability whereas a high 
value indicates a highly water permeable capillary typical of several damages like 
ARDS.  
2) The hydrostatic pressure difference across the capillary, which is determined by the 
difference between the capillary hydrostatic pressure (Pc) and the interstitial 
hydrostatic pressure (Pi, which is negative). 
Figure 14. Surface tension in the alveolar air-liquid interface. a) Law of Laplace-
Young illustrated. The small alveoli tend to empty into the large one in order to balance 
the pressure difference between them. b) Alveoli with presence (normal state) and absence 
(collapse state) of pulmonary surfactant. pressuresurface-tension; r: ratio. 
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3) The reflection coefficient (R) is used to correct the magnitude of the oncotic 
pressure gradient taking into account the efficiency of the capillary wall to prevent 
protein leakage. It can have a value from 0 to 1, being 0 total protein leakage and 1 
absence of protein flow. 
4) The oncotic pressure difference across the capillary, which is assessed by the 
positive difference between plasma colloid oncotic pressure (c) and interstitial 
colloid oncotic pressure i). 
Therefore, under normal conditions, the balance of Starling forces across the 
alveolar-capillary membrane favors a net flow of fluid out of the microvascular space 
into the interstitium (145, 146). 
The resulting small net filtration is balanced by lymphatic drainage of the 
interstitium, which also contributes to the subatmospheric pressure in the interstitial 
spaces, favoring fluidfiltration. However, an excess of fluid accumulation in the 
interstitium leads to fills progressively the alveoli (145). 
 
Figure 15. Diagram of the forces implicated in the net flow of fluid from the 
capillary to the interstitium. Pc: capillary hydrostatic pressure; Pi: interstitial 
hydrostatic pressure; c plasma colloid oncotic pressure;i: interstitial colloid 
oncotic pressure. 
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PS contributes to maintain constant the negative levels of Pi by keeping intra-
alveolar pressures due to its action of decreasing surface tension and alveoli area 
proportionally during expiration. Consequently, PS inactivation results in a surface 
tensionincrement causing a reduction in the negative value of Pi, altering the 
hydrostatic pressure difference and consequently increasing the net fluid movement to 
the interstitium and subsequently to the alveolar space (147). Interestingly, intra-
alveolar edema promotes PS inactivation triggering ALI, leading to a damaging 
feedback. 
 
2.4.3.3. Innate host defense 
PS is involved at several levels in host defense mechanisms: 
Physical barrier: The alveolar epithelium is a potential pathogens gateway as it is the 
greater surface contact of the organism with the environment. Consequently, the 
inhaled pathogens that manage to evade the defense mechanisms of the upper 
airwaysface PS. Thus, PS is the first defensive barrier at the alveolar space hindering 
the adhesion of the incoming particles to the alveolar epithelium and facilitating their 
removal through mucocilliary transport (148). 
Inhaled particles interaction: PS-collectins SP-A and SP-D mainly accomplish this 
function (see section 2.4.1.2). Both collectins are able to bind a wide range of ligands 
including allergens, LPS and other surface molecules of bacteria, virus or fungi (148). 
As a result, the complex pathogen-collectin can be eliminated either directly by 
enhancing the membrane permeability (149) or indirectly by improving the 
aggregation, opsonization and clearance of these pathogens via leukocytes (55, 148). 
Immunomodulatory interaction with leukocytes: Almost all components of PS are 
able to accomplish immunomodulatory activities. 
Recent studies have illuminated a potentially important roleof surfactant PL in 
altering the immune response. PL, specifically anionic lipids appear to act as 
immunosuppressive mediators by inhibiting responses such asrelease of reactive 
oxygen species and proinflammatory cytokines (80, 148). Specifically, phosphatidil 
glycerol (POPG) attenuates or even blocks TLR-2 and TLR-4-dependent 
inflammatory processes and prevent infection of some virus (150, 151). Also, 
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dipalmitoylphosphatidyl glycerol (DPPG) inhibit viral infection by blocking 
attachment of the virions to host cells (152). On the other hand, DPPC, the major PS 
phospholipid, blocks epithelial cell expressed TLR4 activation by limiting 
translocation of TLR-4 to membrane lipid raft micro domains (153) and induced 
expression of several macrophage innate immune receptors (154). 
As well, some studies suggested that the hydrophobic peptides SP-B and SP-C 
have an inmunomodulatory role (148) (see section 2.4.1.2). SP-B-deficiency is 
suggested to impair the ability of the lung to counteract LPS-induced inflammation 
and promotes an inflammatory status mediated by alveolar macrophages and ATII 
cells (155, 156). On the other hand, SP-C may be involved in host defense as it 
interacts with both LPS and the pattern recognition molecule CD14 found on 
phagocytes to reduce it response (88, 110, 157). 
Additionally, collectins can also modulate the host inflammatory response 
independent of activities against microbial agents. Specifically, SP-A and SP-D play a 
major role regulating inflammation by hastening the clearance of apoptotic cells and 
impeding the release of cytokines and other proinflammatory products. Moreover, 
some experiments depicted that SPA or SP-D knockout mice, have increased the 
presence of proinflammatory cytokines and inflammatory response resulting due to 
infection (55). 
 
2.5. Pulmonary immune system 
The lung is constantly exposed to environmental pathogens, allergens and 
toxicants. Therefore, this system had developed robust defenses to protect itself 
against the deleterious effects of such challenges (158). The mechanisms of 
pulmonary defense can be divided into non-specific defenseandspecific defense 
accomplished by the innate immune system.  
Non-specific defenses are mechanisms of physical removal such as cough and 
expectoration, lymphatic flow from the alveolus to the lymph nodes, and mucociliary 
clearance (158). The innate immune system includes soluble factors like proteins that 
bind to microbial products and leukocytes that ingest particulates and kill 
microorganisms (159). 
The soluble constituents of airway and alveolar fluids have acritical role in the 
innate immune defense in the lungs. There are a wide range of soluble factors in the 
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alveolar and airway aqueous fluids accomplishing this role suchlysozyme, which is 
lytic to many bacterial membranes; lactoferrin, which excludes iron from bacterial 
metabolism; IgA and IgG, being IgG the most abundant immunoglobulin in alveolar 
fluids (160); defensins, which are antimicrobial peptides released from leukocytes and 
respiratory epithelial cells (161); LPS-binding protein (LBP) and soluble CD14 
(sCD14), which are key molecules in the recognition of LPS by alveolar macrophages 
and other cells in the alveolar environment (162, 163); and complement proteins and 
surfactant-associated proteins (SP-A and SP-D) that serve as additional microbial 
opsonins (see sections 2.4.1.2 and 2.4.3.3).  
Cellular innate immune mechanisms include inflammatory cells such as alveolar 
macrophages, neutrophils, monocytes, lymphocytes, and eosinophils. Alveolar 
macrophages account for approximately ~95% of airspace leukocytes, with ~1 to 4% 
lymphocytesand only ~1% neutrophils (160). 
Alveolar macrophages represent the most important defense system both for non-
specific phagocytic defense and for antigen triggered immunity via activation of T-
lymphocytes and neutrophils recruitment (164-166).  
Morphologic studies have shown that alveolar macrophages are large, mature 
cells, with an increased cytoplasm/nucleus ratio, which resembles other tissue 
macrophages. These cells reside within the alveolus and are often seen protruding 
from the alveolar epithelial walls into the lumen of the lungs (30). 
Macrophages are highly heterogeneous cells that can change their function in 
response to local signals in their environment. They are commonly divided into 
subpopulations based on their functional phenotype. However, rather than being 
separated subpopulations, macrophages represent a spectrum of phenotypes, and they 
can switch from one phenotype to another in response to signals present in the 
environment. 
The two commonly known sub-populations are named classically activated 
macrophages, and alternatively activated macrophages. Exposure to interferon-
(IFN-) stimulates the first classic pathway of activation that yields M1 
macrophages with efficient capacitiesfor phagocytosis, antigen presentation and 
production of Th1 cytokines, including IL-1, IL-6, IL-12, and tumor necrosis factor-
 (TNF-, that are all important for clearance of intracellular and bacterial 
pathogens. Conversely, the alternatively activation take place when macrophages 
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gather with IL-4 and IL-13, involving Th2 responses and antiinflammatory functions 
(165, 166). 
Interestingly, though alveolar macrophages are critical for the normal function of 
the innate and adaptive immune responses during host defense, they might be also 
implicated in the abnormal function of these same systems when they drive 
inflammatory diseases.  
As alveolar macrophages are the primary sentinel cells which sensed pathogens 
and elaborated a cytokine response, neutrophils are key effector cells of the innate 
immune system recruited by macrophages (164). These cells are recruited through the 
pulmonary capillaries and into the air spaces, being initiated by the upregulation of 
adhesion molecules on pulmonary endothelial cells (167). Intravasated neutrophils 
phagocytose microbes, which are killed by reactive oxygen species, antimicrobial 
proteins, and degradative enzymes. Neutrophils also produce proinflammatory 
cytokines that recruit and activate other cells of the innate and adaptive immune 
system. Thus, alterations in neutrophil functions predispose the lung to respiratory 
infections and may exacerbate inflammation (164).  
Figure 16. Ultrastructural appearance of an alveolar macrophage by electron 
microscopy. Alveolar macrophage (AM); alveolar type I cell (ATI); nuclei (N). (Image 
from © 2005, Angeline Warner, D. V. M., D. Sc.) 
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3. Acute lung injury 
Acute lung injury (ALI) results from a dysregulated inflammatory response, and 
can progress to severe respiratory failure termed the acute respiratory distress 
syndrome (ARDS). 
The first description of ARDS was published in 1967, when Ashbaugh and 
colleagues described patients in intensive care units with an onset of respiratory 
failure characterized by hypoxemia refractory to oxygen therapy, decreased lung 
compliance, and diffuse alveolar infiltrates on chest radiograph, preceded either by 
severe trauma, viral infection, or acute pancreatitis (168). 
Thereafter, Murray and colleagues proposed a 4-point lung-injury scoring system 
based on the statement that severity of lung injury determines survival. This 4-point 
score was assessed by measurements of lung function, lung compliance, and degree of 
pulmonary edema (169). However, the clinical usefulness of this score was limited 
because it could not be used to predict outcome in the first 24 to 72 h after the onset 
of ARDS. 
In 1994, the American-European Consensus Conference Committee on ARDS 
proposed the currently widely accepted defining clinical criteria to distinguished ALI 
and ARDS based on the extent of hypoxemia (defined by a ratio of the partial 
pressure of arterial oxygen [PaO2] to the fraction of inspired oxygen [FiO2]) (Table 
1). In addition, acute onset, presence of bilateral infiltrates seen on lateral chest 
radiograph and a pulmonary artery wedge pressure (PAWP) <18 mmHg or no clinical 
evidence of left atrial hypertension are the other defining features of ALI/ARDS (2).  
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3.1. Epidemiology 
 
3.1.1. Incidence 
ALI/ARDS mortality rates have declined over the last 2 decades. In the 1980s, 
mortality rates were approximately 60–70% (170-172). However, these rates must be 
interpreted with caution, as accurate estimations were difficult to assess due to the 
lack of uniform definitions and diagnosis criteria until the 1994 consensus definitions 
together with the presence of etiologic variations, geographical variation and 
inadequate documentation (173). 
In 2003, Goss and colleagues (174) used the NIH-funded ARDS network 
database to prospectively identify ALI patients from 1996–1999, estimating an 
incidence of 64.2 cases per 100,000 person-years. More recently, Rubenfeld and 
colleagues (175) estimated that there are 200.000 cases of ALI each year in the United 
States, associated with 74.500 deaths, estimating a 39% mortality that accords with 
mortality rates of 40-60% previously assessed in other studies (3). 
 
 
 ONSET OXYGENATION 
CHEST 
RADIOGRAPH 
PAWP 
ALI Acute 
PaO2/FiO2<300 
mm Hg 
Bilateral 
infiltrates 
<18 mmHg/ no 
left atrial 
hypertension 
ARDS Acute 
PaO2/FiO2<200 
mmHg 
Bilateral 
infiltrates 
<18 mmHg/ no 
left atrial 
hypertension 
Table 1. Definition of Acute Lung Injury (ALI) & Acute Respiratory 
Distress Syndrome (ARDS) from the American-European Consensus 
Conference 1994 [163]. 
 
PaO2: partial pressure of arterial oxygen; FiO2: fraction of inspired oxygen. 
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3.1.2. Risk factors 
  The American-European Consensus Conference in 1994 defined several clinical 
disorders capable of triggering ALI divided according to the mechanism through 
which they cause lung damage (2). Thus, the first group of the disorders causes direct 
injury to the lung whereas the second group induces lung damage indirectly (Table 2). 
For example, pneumonia and aspiration of gastric contents belong to the most 
common causes of direct ALI whereas the most common causes of indirect ALI are 
sepsis and severe trauma with shock and multiple transfusions. Specifically, sepsis 
has a higher mortality rate than major trauma (43 vs. 11%) whereas pneumonia and 
aspiration have intermediate mortality rates (36 and 37%, respectively) (176).  
Other factors that influence mortality appear to be age and race. Rubenfeld and 
colleagues (175) found that mortality was significantly lower in patients 15–19 years 
of age (24%) compared to patients 85 years of age or older (60%). On the other hand, 
racial inequalities also occur, e.g. African-Americans and Hispanics have a higher 60-
day mortality rate (33%) compared to Caucasians (27%) (177). Finally, patients with 
multiple comorbidities, chronic alcohol abuse, or chronic lung disease, have an 
increased risk for ALI development (3). 
 
 
 
DIRECT INJURY INDIRECT INJURY 
Diffuse pulmonary infection (e.g. 
Pneumonia) 
Aspiration 
Lung contusion 
Near drowning 
Toxic inhalation 
Sepsis 
Transfusion-related 
Pancreatitis 
Sever non-thoracic trauma 
Cardiopulmonary bypass 
Table 2. Clinical disorders associated with development of ALI & ARDS, as 
identified by the American-European Consensus Conference Committee 1994 
(2). 
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3.1.3. Outcomes 
Patients who survive ALI have been shown to have a reduced health-related 
quality of life (178) and persistent functional limitation largely as a result of muscle 
wasting and weakness. In fact, mild lung function alterations such as gas-exchange 
deficit with exercise and residual impairment of pulmonary mechanics persist after 
the resolution of the syndrome, but these abnormalities seem to be asymptomatics 
(179) and in most patients, pulmonary function returns to normal within 6-12 months 
(180). 
 
3.2. Pathogenesis 
Acute lung injury is a disorder of acute inflammation that causes disruption of the 
lung endothelial and epithelial barriers. Cellular characteristics of ALI include loss of 
alveolar–capillary membrane integrity, excessive transepithelial neutrophil migration, 
and release of proinflammatory, cytotoxic mediators (173). 
In humans, the intrapulmonary inflammatory response begins before the onset of 
clinically defined ALI and is most intense in the first 3 days after the onset of 
ALI/ARDS (181, 182). This acute phase is characterized by the leakage of protein-
rich edema fluid and inflammatory cells into the alveolar space together with the 
formation of characteristic hyaline membranes. This ALI stage, also named exudative 
phase, rises as a consequence of both endothelial and epithelial cell injury with 
increased permeability of the alveolar-capillary barrier (3, 183, 184) (Figure 17).  
The subsequent histopathological stage of ALI (after ~1-2 weeks), known as the 
proliferative phase, is characterized by the proliferation of ATII cells along alveolar 
septa and the onset of epithelial regeneration (184). Under normal conditions, the 
denuded basement membrane is re-epithelialised with restoration of normal alveolar 
architecture and epithelial fluid transport capacity and rapid re-absorption of alveolar 
edema. However, in some patients alveolar edema persists, mesenchymal cells fill the 
alveolar spaces leading to a fibrotic stage (3). 
 
3.2.1. Endothelial and epithelial injury 
Disruption of the alveolar-capillary barrier is a well-established mechanism 
responsible for the influx of protein-rich edema fluid into the air spaces during the 
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initial phase of ALI (183). Therefore, the alteration of any of the components 
comprising the alveolar-capillary barrier may lead to the development of pulmonary 
edema that entails physiological events including hypoxemia and reduced lung 
compliance in ALI/ARDS patients (185). 
During ALI, microvascular endothelium is injured by proinflammatory cytokines, 
activated immune cells and reactive species leading to an increased of capillary 
permeability. This alteration allows the efflux of protein-rich fluid into the 
interstitium, ultimately crossing the epithelial barrier into the distal airspaces of the 
lung (183). Several studies have documented increased release of von Willebrand 
factor (186-188) and upregulation of intracellular adhesion molecule-1 (ICAM-1) 
(189, 190) following endothelial injury. Also, endothelial damage contributes to 
leukocyte recruitment, coagulation disorders and vascular leakage. 
On the other hand, the loss of epithelial integrity contributes importantly to 
edema formation for several reasons. Normally, ATI and ATII cells form tight 
junctions with each other, selectively regulating the epithelial barrier. Their alteration 
leads to disruption of normal fluid transport via down-regulated epithelial Na 
channels and Na
+
/K
+
ATPase pumps, impairing the resolution of alveolar flooding (3, 
183).  
As a result, increased permeability of this membrane during the acute phase of 
ALI leads to the influx of protein-rich edema fluid into alveolar space. Also, epithelial 
injury alters PS production by ATII cells (191), predisposes the lung to fibrosis during 
the later phases of ALI (192) and what is more, it allows the development of sepsis in 
those patients with pneumonia due to the entrance of  bacteria into circulation (193). 
 
3.2.2. Inflammation 
Aberrant activation of the immune system (i.e., increase in neutrophils and 
cytokines) contributes to pulmonary edema in ALI and ARDS (194). Normally, >90% 
of the alveolar cells in the alveolar fluid are alveolar macrophages and >2% are 
neutrophils. However, in ALI this ratio is reversed and neutrophils comprised >90% 
of the alveolar fluid cells (195). 
Macrophages contribute to ALI by regulating inflammatory and immune 
responses through the release of several mediators including cytokines, chemokines, 
metalloproteases or reactive oxygen species (ROS) (195). As well, endothelial and 
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ATII cells can also produce several cytokines and chemokines under numerousALI 
stimuli (196-199). Furthermore, some of the ALI mediators can up-regulate various 
surface molecules on the endothelial and epithelial surface allowing leukocytes, 
primary neutrophils, to adhere and migrate across the alveolar-capillary barrier (200-
202). 
In fact, a marked neutrophil accumulation is characteristic of the acute phase of 
ALI, suggesting that these cells play an important role in the pathogenesis of lung 
injury as they are considered primary perpetrators of inflammation (203-205).  
Excessive and/or prolonged activation of neutrophils contribute to basement 
membrane destruction and increased permeability of the alveolar–capillary barrier 
(205, 206). Specifically, elastase, a widely studied neutrophil mediator, seems to 
degrade epithelial junctional proteins and possess pro-apoptotic and direct cytotoxic 
effects on the epithelium (207, 208). Furthermore, ARDS patients with increased 
levels of granulocyte-colony stimulating factor (a neutrophil anti-apoptotic factor) in 
the lung lining fluid, have poorer outcomes (209). 
On the other hand, a complex balance of pro- and anti-inflammatory cytokines 
appears to initiate and regulate the inflammatory response in ALI (3, 182). Cytokines 
are low-molecular weight soluble proteins that transmit signals between cellsinvolved 
in the inflammatory response (210). 
IL-1β and TNF-α are unrelated early response cytokines as they are found in the 
early stages of ALI and are able to initiate further inflammatory responses. Several 
human studies determined that both cytokines play a role in mediate ALI as well as 
maintaining the inflammatory response (211). Besides, they are able to induce 
additional cytokine production including IL-6 and IL-8 (212). IL-6 is a pleiotropic 
cytokine with multiple functions such as stimulation of acute phase proteins, T-cells 
activation or even inhibits IL-1β and TNF-α production (213). IL-8 belongs to the 
CXC chemokine family that has significant neutrophilchemotactic activity (214). 
In patients with ALI/ARDS, those proinflammatory cytokines are persistently 
elevated in plasma and are strongly predicative of mortality (215-217). As well, IL-
1β, TNF-α and IL-8 are elevated in the alveolar fluid of ARDS patients (211, 215, 
218). Thus, systemic and local production of proinflammatory cytokines initiates and 
amplifies the inflammatory response and the subsequent injury in ALI and ARDS. 
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However, the presence of several specific inhibitors of proinflammatory 
cytokines including IL-1-receptor antagonist (IL-1ra), soluble TNF receptor (sTNF-R) 
and auto-antibodies against IL-8 and non-specific antiinflammatory cytokines like IL-
10 and IL-11 has been described to modulate inflammatory lung injury. Nonetheless, 
their low presence in the alveolar fluid of ARDS patients is associated with increased 
mortality rates (3, 182). Therefore, a balance between pro- and antiinflammatory 
mediators may lead to a solving proliferative phase or a proliferative phase leading to 
fibrotic processes. 
 
 
 
 
 
Figure 17. Pathophysiology of the acute phase of acute lung injury. Left side 
represents a normal alveolus; Right side represents an injured alveolus characterized by an 
edematous and an inflammatory state in the acute phase of lung injury. Alveolar Type I 
cell (ATI); Alveolar Type II cell (ATII); Interleukin (IL)-1-6-8-10; TNF-Tumoral 
necrosis factor ROS: Reactive Oxygen Species. 
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3.3. Treatment 
Currently, treatment of ALI is based in both ventilatory and non-ventilatory 
strategies. However, for many years, treatment of ALI was limited to the supportive 
treatment of organ failure and treatment of the underlying cause of lung injury. 
Improvements in this supportive treatment, rather than the success of a particular 
therapeutic intervention, are thought to account for the recently observed decline in 
mortality from (60-70% to ~30-40% (3)).  
The best evidence for the value of a lung protective strategy in patients with ALI 
is a study by the ARDS Network (ARDSNet) comparing conventional mechanical 
ventilation with a lung protective strategy of ventilation. This study reported a 22% 
reduction in mortality in patients ventilated using protective ventilation together with 
more ventilator free and non-pulmonary organ failure-free days (219). Moreover, 
clinical risk factors including sepsis, aspiration, pneumonia, and trauma did not affect 
the efficacy of the protective strategy of ventilation (176).  
Despite significant advances in the understanding of the pathogenesis of ALI, 
specific pharmacological interventions, including surfactant therapy, inhaled nitric 
oxide, glucocorticoids and other antiinflammatory agents, have shown little benefit al 
phase III trials (173, 220). 
There has been considerable preclinical data supporting the potential value of -2 
agonist therapy for the treatment of ALI as it has been suggested that they able to 
decrease inflammation and upregulate alveolar salt and water transport, hastening the 
resolution of alveolar edema (221-223). However, only a randomized trial in the UK 
recently demonstrated that intravenous salbutamol significantly lowered extravascular 
lung water (224). 
Currently lines of investigation are focused on the potencial benefits of enteral 
feeding (225), the use of statins, which are normally used for the prevention or 
treatment of cardiovascular diseases and also have significant antiinflammatory, 
immunomodulatory, and antioxidant effects (226-228), and treatment with bone 
marrow-derived mesenchymal stem cells (MSCs) as they possess the ability to 
differentiate into many types of cells and also are able to secrete paracrine factors that 
reduce the severity of ALI (e.g. growth factors, factors that regulate barrier 
permeability and antiinflammatory cytokines) (229, 230). 
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3.4. Animal models 
Modeling human disease in animals has contributed significantly to our 
understanding of lung physiology in health and in disease (231).  
As human studies provide important descriptive information about the onset and 
evolution of the physiological and inflammatory changes leading to formulate 
hypothesis about the mechanisms of injury, animal models provide a bridge between 
patients and the laboratory bench to test these hypothesis (232). 
The hypotheses formulated in human studies are difficult to test in 
humansbecause of the many clinical variables that are difficult to control in critically 
ill patients. Therefore, these hypotheses can be tested directly in animal models 
together with the results of in vitro studies in order to assess their relevance in intact 
living systems. Without animal models there would be no way to test clinical 
hypotheses generated in patients using intact biological systems, and there would be 
no way to validate the importance of fundamental laboratory findings without going 
directly to human experimentation (232). 
Ideally, animal models of ALI should reproduce one or more features of human 
ALI, including rapid onset (hours) after an inciting stimulus, evidence of pulmonary 
physiological dysfunction (e.g., abnormalities of gas exchange, decreased lung 
compliance), histological evidence of injury to the lung parenchyma (endothelium, 
interstitium, epithelium), and evidence of increased permeability of the alveolar-
capillary membrane. As well, the evolution of the injury and repair should also be 
reproduced, as the responses of the lungs to injury change with time. Ideally, the 
injury should evolve over time if the animals are supported for prolonged periods or 
even if specific studies focus on a narrow time frame (4, 232). However, no single 
animal model reproduces all of the characteristics of ALI/ARDS in humans, and most 
of the existing animal models are relevant for only limited aspects of human 
ALI/ARDS (4, 232). 
There are many anatomical and physiological differences between animals and 
humans that influence the response of the lung to an acute injurious stimulus and 
affect the evaluation of lung injury (233): 
(I) Respiratory rate: in humans an adult respiratory rate of ~12–16 bpm whereas in 
mice rise to ~250–300 bpm, rendering absolute respiratory rate inadequate as a 
parameter of ALI in mice (4, 5).  
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(II) Gross and microscopic anatomy: mice and rats have different lobar anatomy, 
fewer branches of the conducting airways proximal to the terminal bronchioles. 
As well, both, alveoli and thickness of the blood–gas barrier are smaller in the 
lungs of mice and rats compared with humans. 
(III) Inflammation: rodents have fewer circulating neutrophils (~10–25%) than 
humans (~50–70%) and do not express defensins. The neutrophil collection of 
CXC chemokines differs between rodents and humans (keratinocyte-derived 
chemokine KC [CXCL1] and macrophage inflammatory protein [MIP-2] in 
rodents and IL-8 in humans) (232, 234). 
(IV) ALI settings: murine lungs rarely demonstrate hyaline membranes under 
enhance permeability situations.  
(V) ALI development: in humans, ALI is developed in patients affected by the 
mechanisms involved in a primary illness (e.g., sepsis) and/or therapeutic 
modalities used for supportive care (e.g., mechanical ventilation) whereas 
animal studies frequently use young mice with no comorbidities (232). 
For all of these reasons, the responses of animal and human lungs to an injurious 
stimulus cannot be expected to be identical or perhaps even similar. 
To address this problem in 2010, an Official Committee was established in 
American Thoracic Society (ATS) Workshop (4) to determine the main features that 
characterize ALI in animal models and to identify the most relevant methods to assess 
these features. They concluded that the main features of experimental ALI include 
histological evidence of tissue injury, alteration of the alveolar capillary barrier, 
presence of an inflammatory response, and evidence of physiological dysfunction; 
they recommended that, to determine if ALI has occurred, at least three of these four 
main features of ALI should be present. However, the Committee emphasized that the 
list of ALI features is intended as a guide for investigators in which they might choose 
according to the experimental questions addressed and the specific aspects of each 
experimental design chosen. 
Commonly used animal models are based on clinical disorders that are associated 
with ALI/ARDS in humans. Investigators have tried to reproduce each of these risk 
factors in a variety of animals, and the frequency with which each model has been 
reported is shown in Table 3 (232). Each model has their own characteristics, 
advantages and similarities with ALI human models. However, animal models of 
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ventilator-induced lung injury are the more frequently studied because is the only 
model that has affected clinical practice and improved survival in humans (232). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Ventilator-induced lung injury  
Mechanical ventilation (MV) is routinely used for decades to provide respiratory 
support in critically ill patients. However, its safety for the treatment of ARDS 
patients has been a matter of concern ever since its introduction into medical practice 
(235). Yet already in 1974, Webb and Tierney demonstrated for the first time that MV 
could generate lung lesions in intact animals (236). Since then, several experimental 
and clinical studies have been performed to clarify the potential drawbacks of MV 
and its subsequent outcomes according to the strategy applied.  
Currently, we should take into account two different concepts related to MV 
alterations, ventilator-associated lung injury (VALI) and ventilator-induced lung 
injury (VILI). VALI is referred to the additional injury imposed on a previously 
injured lung by MV in either clinical settings or in experimental studies (also termed 
as two-hit experimental models (237)). Conversely, the term VILI is regarded as a 
sole method to generate lung injury, which is the direct application of an injurious 
ANIMAL MODELS OF ACUTE LUNG INJURY  % 
Mechanical Ventilation 
LPS 
Live bacteria 
Hyperoxia 
Bleomycin 
Oleic acid 
Cecal ligation and puncture 
Acid Aspiration 
30 
19 
16 
12 
10 
5 
4 
3 
Table 3. Percentage of the different animal models used to 
study Acute Lung Injury. 
Table modified from reference (226). 
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MV strategy (238). Here, we are going to focus mainly on VILI and its pathogenesis.  
 
4.1. Determinants of VILI 
 
4.1.1. Mechanical determinants  
Barotrauma vs. Volutrauma 
The term barotrauma is used to describe the lung damage attributable to MV 
with high peak pressures (239). However, a study performed by Dreyfuss and co-
workers (240) suggested that lung distension was more important to cause lung injury 
than airway pressure per se, coining the term volutrauma. In order to elucidate this, 
they ventilated rats with identical peak pressures using high or low tidal volumes 
(VT). As a result, they observed that rats subjected to high VT-high pressure 
ventilation developed pulmonary edema whereas those subjected to low VT-high 
pressure ventilation did not. Subsequently, other groups confirmed and replicated 
these findings in other experimental models (235, 241, 242). 
Therefore, the important fact is trans-pulmonary pressure (i.e. the pressure across 
the lung: airway pressure [alveolar pressure] – pleural pressure) and not the airway 
pressure itself (243). 
Atelectrauma 
It is important to highlight that ARDS patients had their lungs heterogeneously 
injured leading to their alveoli to pass thought one of three following conditions: (I) 
fluid-filled or collapsed, and thus closed and not inflated; (II) collapsed or filled with 
fluid at end-exhalation, but opened and air-filled at end-inspiration; or (III) expanded 
and aerated throughout the respiratory cycle (244). 
As the collapse of an alveolus causes shear stress not only on its own walls but 
also on those of adjacent alveoli, heterogeneously MV lungs are susceptible to cyclic 
damage by shear stress resulting from repetitive alveolar collapse and overdistension 
(or recruitment-derecruitment), termed atelectrauma (239). 
Thus, the application of positive end-expiratory pressure (PEEP) effectively 
opens the distal airways, maintaining recruitment throughout the ventilatory cycle 
(243). 
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The application of PEEP during VILI development has been associated with a 
preservation of the integrity of the alveolar epithelium besides few alterations 
including endothelial blebbing and interstitial edema (240). However, the influence of 
PEEP in VILI mustbe studied with caution according to the VT used. 
 
Protective ventilatory strategies: Low VT and PEEP 
The bases of lung protective strategies reside in: (I) prevention alveolar 
overdistention by limiting VT/ airway pressures; and (II) to maintain alveolar 
recruitment throughout the respiratory cycle through the addition of PEEP. 
Webb and Tierney (236) showed that edema was lessened by PEEP application 
during MV with high peak airway pressures and they attributed the beneficial effect to 
the preservation of PS activity.  
Later studies demonstrated that VT reduction, maintaining the same level of 
PEEP, significantly reduced both endothelial and epithelial injury and this was 
associated with lower histological lung injury severity scores (245). Furthermore, 
clinical trials reported significant decreases in the levels of both pulmonaryand 
systemic inflammatory mediators in patients ventilated using lung protective 
strategies (246). Moreover, the ARDSnet trial determined a reduction of 22% in the 
mortality rates of those patients MV with lower VT (6 ml/kg) compared to those 
ventilated with traditional VT (12 ml/kg) (219). Besides, the protective effect of PEEP 
was highlighted by Amato and colleagues, which demonstrated that the use of high 
levels of PEEP to alveolar recruitment resulted in improved 28 day-mortality (247). 
 
4.1.2. Biotrauma 
Barotrauma/Volutrauma and atelectrauma has been considered the principal 
causes of VILI until the biotrauma hypothesis emerged (248).  
Biotrauma relies on the hypothesis that lung tissue stretching might result in lung 
injury through the release of inflammatory mediators and leukocyte recruitment (249, 
250). This inflammatory reaction may not be exclusively of lungs, it may also involve 
systemic circulation, altering distal end-organs and therefore providing an explanation 
to the observation that most patients with ARDS die from multiple organ failure 
rather than hypoxemia (7, 251). 
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This hypothesis is supported by several clinical trials that observed that ARDS 
patients ventilated with a protective strategies exhibited lower bronchoalveolarlavage 
fluid and/or plasma concentrations of inflammatory mediators than patients ventilated 
with control strategies (252-254). Intriguingly, one of these studies observed an 
increased of most of antiinflammatory cytokines rather than proinflammatory (254), 
emphasizing that it remains unclear whether mechanical ventilation affects the 
balance of cytokines toward pro- or anti-inflammation (255). 
Accordingly, experimental studies also suggested that MVcould influence the 
proinflammatory/antiinflammatory balance in the lungs. Specifically, Tremblay et al. 
(250) showed in unperfused rat lungs that high VT ventilation with zero PEEP 
resulted in a dramatic increased of proinflammatory cytokines levels (TNF-, IL-1 
and macrophage inflammatory protein [MIP-2]) in lung lavage compared with 
controls. However, using the same model of unperfused rat lungs, others found only 
slightly higher IL-1 and MIP-2 bronchoalveolar lavage fluid concentration in 
injuriously MV rats compared with control ones, together with no changes in TNF- 
lung lavage levels among groups (256, 257). The authors concluded that injurious 
MV strategies do not necessarily result in primary production of proinflammatory 
cytokines in the lungs (257).  
 As a result, the concepts barotrauma/volutrauma, atelectrauma and biotrauma 
are currently considered as interrelated and not exclusive in the induction of stress 
failure since the mechanical determinants seem to induce biotrauma. Thus, ventilation 
with high VT or pressures can cause release of proinflammatory mediators by a 
number of different mechanisms, all of which appear to be clinically relevant (248): 
 Injurious MV can cause stress failure of the plasma membrane and epithelial and 
endothelial barriersleading tonecrosisand subsequent liberation of inflammatory 
mediators that will stimulate other intact cells to produce such mediators.  
 Stress failure of the barriers causes loss of compartmentalization with the 
consequent spreading of inflammatory mediators throughout the body. 
 MV with increasing positive pressures raises the pressure in the pulmonary 
circulation and thus vascular shear stress, stimulating endothelial cells. 
 Less injurious ventilation strategies that do not cause tissue destruction can elicit 
release of mediators by more specific mechanisms, presumably through 
activation of stretch-activated signaling cascades, termed as 
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mechanotransduction. As the sensing mechanism of these physical forces and 
the translation into cellular signals is largely unknown, several experimental 
studies in vitro and in vivo observed that mechanical stretch induce distinct 
patterns of gene expression including genes involved in immunity and 
inflammation, stress response, metabolism and transcription processes (258, 259). 
 
4.2. Pathogenesis 
 
4.2.1. Microscopic pathology 
 
Animal lungs injured by MV present a pattern of atelectasis, severe congestion 
and enlargement due to edema, which is associated with severe endothelial and 
epithelial abnormalities, the structural counterpart of permeability alterations (235, 
236, 240, 260, 261). 
Tsuno and coworkers (262) microscopic examination revealed that baby pig 
lung‟s subjected to high-pressure MV during 22h presented severe diffuse alveolar 
damage,with hyaline membranes, alveolar hemorrhage, and neutrophil infiltration. 
Also, small animals experimental studies depicted that under high peak pressures 
there were wide spread alterations of endothelial and epithelial barriers observed by 
electron microscopy (240, 260, 261, 263) together with edema presence. Specifically, 
they observed ATI cells discontinuities with some areas completely destructed 
leaving a denuded basement membrane, hyaline membranes filling the alveolar spaces 
and endothelial cells alterations including their detachment from their basement 
membrane resulting in the formation of intracapillary blebs or even endothelial cell 
breaks, allowing direct contact between neutrophils and the basement membrane 
(240, 261).  
However, there is an obvious relationship between the duration and severity of 
the mechanical injury and the overall appearance of the lung. Also, the animal model 
used entails different outcomes. Thus, edema is developed so rapidly in small animals 
that the lack of time prevents neutrophil infiltration. In contrast, larger animals need 
several hours to produce patent edema, time enough for activation, adherence, and 
significant migration of neutrophils into airspaces (262, 264). 
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4.2.2. Alveolar edema 
As previously described, VILI may produce breaks in the alveolar-capillary 
barrier leading to alveolar hemorrhage (240, 260, 261). Thus, this disruption can be 
also promoted by non-uniform mechanical lung inflation altering microvascular 
pressure, termed shear stress (235). However, alveolar edema presence could be 
alsoproduced due to alterations in the alveolar-capillary barrier permeability.  
Experimental studies have implicated epithelial and endothelial permeability 
changes in the presence of high content-protein edema in the alveolar space (243). 
Increase of epithelial permeability to small hydrophilic solutes occurs as lung 
volume increases, being this a physiologic phenomenon. The clearance of aerosolized 
99m
Tc-DTPA increased when the functional residual capacity was increased by 
applying PEEP during MV (265), or during spontaneous ventilation (266) in sheep. 
The same observation has been made in humans (267, 268). 
However, only major increasesin lung volume alter epithelial permeability to 
largemolecules during static inflation (235). Hence, some studies depicted that 
increased static inflation of fluid filled lung lobes in sheep led to the passage of larger 
solutes across the epithelium, a finding observed inother models (269, 270). 
Moreover, the redistribution of 
125
I-labelled albumin intothe extravascular space in 
MV rats demonstrated the presence of increased microvascular permeability (261). 
Furthermore, similar experimental studies in other species confirmed the alteration of 
endothelial permeability to solutes of both small and large molecular weight (271, 
272).  
In contrast to the clear evidence for increased permeability, relatively little is 
known about the contribution of hydrostatic pressures to the development of 
pulmonary edema in MV (243). 
 
 
4.2.3. Inflammation 
The role of the innate immune response and inflammation in the pathogenesis of 
VILI has been widely studied in recent years. Researchers have used a variety of 
experimental models to determine the effects of MV or mechanical strain on the 
expression of biological markers of inflammation or injury, including animal models, 
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ex vivo lung preparations and isolatedalveolar epithelial cells (238). 
 
The role of inflammatory cells 
Although many resident lung cells can produce inflammatory mediators, alveolar 
macrophages have a large capacity for cytokine and chemokine production, as well as 
nitric oxide and reactive nitrogen species elaboration (273). Specifically, several 
studies depicted a possible role of alveolar macrophages in the initial pathogenesis of 
VILI. 
Mechanical deformation of human alveolar macrophages in vitro, has been 
shown to increase the expression of IL-8 and matrix-metalloproteinase-9 (MMP-9) 
together with an increase in nuclear translocation of the transcription factor nuclear 
factor kappa-B (NFκB) after 30 min of cyclic strain (274). 
Frank and colleagues work also suggests that macrophage activation is an early 
and critical event in the initiation of VILI. They demonstrated that addition of 
bronchoalveolar lavage from rats exposed to injurious MV during 20 minutes induced 
the activation of naïve primary alveolar macrophages in culture. Furthermore, they 
observed that macrophage depletion decreased ventilator-induced endothelial and 
epithelial injury (273), supported by Eyal and co-workers (275). 
In addition to macrophages, neutrophils have been un-equivocally implicated in 
the pathogenesis of ALI and ARDS (276) and seem to be the major effector cells in 
the generation of the tissue injury characteristic of VILI (277). 
One of the first studies proposing that MV could lead to an inflammatory 
response used a model of neutrophil depletion by nitrogen mustard. Kawano et al. 
(264) demonstrated that the neutrophil-depleted animals had markedly improved 
oxygenation and decreased pathologic evidence of injury after MV versus a control 
group treated with the lavage and ventilatory protocol alone.  
Further evidence for the central role of the neutrophil in VILI has been provided 
by the work of Zhang and colleagues. In this study, alveolar lavage fluid obtained 
from ventilated patients with ARDS was incubated with neutrophils from normal 
volunteers. As a result, markers of neutrophil activation were significantly higher in 
those ventilated conventionally compared to those ventilated with a lung protective 
strategy (278). Interestingly, alveolar recruitment of neutrophils by instilling a 
chemmoatractant does not result in lung injury (279), indicating that other mediator 
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possibly cytokines, are necessary to activate leukocytes. 
 
The role of inflammatory mediators 
It is widely accepted that increased production of cytokines in the lung plays a 
key role in VILI. To examine the mechanisms of cytokine generation during MV, in 
vitro, ex vivo and in vivo models have been conducted (256).  
Upon stretch, cultured alveolar cells produce inflammatory mediators such as 
TNF- IL-1, IL-6, IL-8, IL-10 (274, 280). There are several reports of MV increased 
cytokines and chemokines in whole-animal models. Specifically, MV with high VT 
results in increased levels of the proinflammatory cytokines in lavage fluid, including 
TNF-and MIP-2 (281-283). However, other models under injurious MV detected no 
significant changes of TNF- in the alveolar lavage though other proinflammatory 
levels were augmented (284).   
Also, the use of isolated lung models allowed determining changes in the levels 
of many inflammatory mediators in VILI. The work of Tremblay and co-workers 
(250) previously mentioned, demonstrated that high VT, zero PEEP MV induced a 
greater increase in airspace of TNF- IL-1, IL-6, IL-10, MIP-2, and interferon- 
than low VT with or without PEEP application. Furthermore, similar to the study of 
Tremblay et al (250), Veldhuizen and colleagues (285) found that in isolated mouse 
lungs, ventilation with a tidal volume of 20 mL/kg without PEEP resulted in 
significant increased in BAL levels of TNF- and IL-6.  
On the other hand, clinical studies seem to support the concept that injurious MV 
promotes a pulmonary inflammatory response and cytokine decompartmentalisation. 
Ranieri and colleagues (246) reported significant decreases in bronchoalveolar fluid 
and plasma concentrations of many inflammatory mediators (TNF-, IL-6 and IL-8) 
in patients MV with a lung protective strategy. Moreover, the ARDSnet trial depicted 
that patients ventilated with a lung protective strategy had a greater decrease in levels 
of plasma IL-6 (219). 
Despite the fact that low VT MV ameliorates the inflammatory response, some 
studies confirmed that subjects subjected to MV may develop a proinflammatory state 
(286, 287). In fact, it is not yet established the ventilatory strategy that is the most 
effective in limiting inflammation. 
Other mediators implicated in VILI include coagulation factors, such as 
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plasminogen activator inhibitor-1, hormones, such as angiotensin-II and lipid derived 
mediators, such as cyclooxygenase and lipoxygenase (288). As well, some studies 
observed the implication of metalloproteases in the early stages of VILI (289) and 
ROS production in response to elevated mechanical stress (290-292). 
 
 
4.2.4. Pulmonary surfactant alterations 
PS plays a role in VILI in two related ways. Firstly, PS dysfunction or deficiency 
seems to amplify the injurious effects of MV and, secondly, MV itself can impair PS 
function thereby exacerbating the existing damage (243). 
It is widely accepted that mechanical stretch of ATII cells in vitro stimulates 
surfactant release (293). As well some animal models observed that total PS increased 
(294, 295). However, injurious MV strategies of high VT and zero PEEP lead to 
alterations in functional PS and a decreased LA/SA ratio (285, 294, 296-298).  
PS biophysical function impairment may contribute to VILI in several ways 
(243): (I) Alveoli and airways tend to collapse with generation of shear stress as they 
are reopened; (II) The irregular expansion of lung units increases regional stress 
forces through interdependence; (III) The transvascular filtration pressure is 
increased, promoting edema formation (299). 
In addition, PS system is thought to have important immunoregulatory functions 
(148), which may become impaired through MV. 
Therefore, improving the presence of an increased pool of functioning PS might 
lessen lung injury by MV as some studies suggested that surfactant therapy 
contributes to reduce mortality in the neonatal respiratory distress syndrome and may 
decrease lung injury (300). 
 
 
 
4.2.5. Consequences following VILI 
Abnormal or dysregulated repair processes are associated with increased 
morbidity and mortality following ALI/ARDS (301). However, the factors leading 
either to the fibrotic phase or resolution are incompletely understood. Nevertheless, 
some studies suggest that some transcriptional responses in ALI genes involved in 
inflammation and repair are differentially expressed simultaneously very early in the 
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course of injury (302), and many mediators are common to both processes. This is 
further supported by evidence that patients with well known chronic fibrotic lung 
disorders have persistently elevated levels of ALI related cytokines and chemokines 
in alveolar lavage samples (303, 304). 
Regarding to VILI, few studies have been conducted in order to characterize the 
potential mechanisms that occurs during resolution and repair following injurious MV 
(305-307). These studies observed that MV induced severe injury in the lungs 
characterized by histologic injury and edema, but they were able to repair 
spontaneously in the absence of further ventilation. Furthermore, Curley and co-
workers (306) studied the evolution of several inflammatory and fibroproliferative 
markers throughout two-weeks, detecting that proinflammatory cytokines returned to 
baseline within 24h, while anti-inflammatory remained increased for48 h. Moreover, 
VILI generated a marked but transient fibroproliferative response, which restored 
normal lung architecture represented as absence of evidence of fibrosis at 7 and 14 
days. 
Also, González-López et al (308) studied the mechanisms of repair after VILI 
using a model of injurious MV followed by a protective MV strategy during 4 hours. 
They also observed that surviving animals were recovered from the injury 
characterized by increased cell proliferation, lower levelsof collagen, and higher 
levels of MIP-2 and MMP-2. 
Therefore, these data suggest that VILI may be potentially reversible, and that the 
repair process depends on both an adequate inflammatory response and extracellular 
matrix remodeling. However, further investigation must be done in order to elucidate 
the precise roles of the factors involved in the resolution and repair processes 
following VILI. 
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The lung is a delicate organ that can develop significant dysfunction in response to 
minor injury. The pathophysiology of acute respiratory distress syndrome (ARDS) or 
the less severe condition known as acute lung injury (ALI) (2) is currently thought to 
begin with an inflammatory response induced by extrapulmonary injury (sepsis, severe 
trauma, acute pancretitis, etc.) or direct pulmonary injury (pneumonia, aspiration of 
gastric contents, pulmonary contusion, etc.) (3). The inflammatory response increases 
alveolar epithelial and pulmonary vascular endothelial permeability, causing alveolar 
filling (3, 4). The alteration of the pulmonary surfactant system complicates the clinical 
picture (5).  
Lung surfactant serves to stabilize the alveoli and distal airways at low lung 
volumes (1), and deficit or alteration of this macromolecular complex strengthens 
intraalveolar edema, impairs lung compliance, andresults in ventilation-perfusion 
mismatch (including shunt flow due to altered gas flow distribution) and hypoxemia (1, 
5, 6). Critical hypoxemia results in the need for mechanical ventilation, thereby 
providing the context in which ventilator-induced lung injury (VILI) can develop (7). It 
is thought that VILI is generated as a result of volutrauma (intensified tissue tensions at 
the junctions of closed and open alveolar units when subjected to high alveolar 
pressure) and/or atelectrauma (caused from the cyclical airspaceopening and closing) 
(7). These stresses might further stimulate the inflammatory response (termed 
biotrauma) resulting in progressive lunginjury and systemic inflammation (7). 
The current respiratory support in ALI or ARDS consists of low tidal volume (to 
reduce volutrauma) and appropriate positive end-expiratory pressure (PEEP) and/or 
FiO2/PEEP ratio (to reduce atectrauma) (8). The application of PEEP is thought to be 
useful in counteracting increased surface tension (thereby reversing the resulting 
atelectasis). PEEP increases end-expiratory airspace pressure, but since airspace 
opening pressures can vary markedly between and within patients, applying PEEP to 
reverse or limit dorsal-caudal atelectasis will almost always come at the expense of 
over-distending ventral lung regions and other areas having lower opening pressures 
(9). 
Given the importance of ventilatory management for acute respiratory syndrome 
(ARDS or ALI) (7, 8), investigators have started to explore the effects of ventilation in 
healthy lungs. Animal models exposed to conventional and injury ventilator strategies 
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have being used to understand the mechanisms of lung injury induced by mechanical 
ventilation. 
In this thesis, healthy rats have been exposed to two different ventilator strategies 
(10): 
 Injurious high-stretch ventilation (HV) with high tidal volumes (VT = 25 ml/kg) 
and without PEEP application (ZEEP = 0 PEEP).  
 Conventional low-stretch ventilation (LV) with moderated tidal volume (VT = 9 
ml/kg) and application of positive end-expiratory pressure (PEEP=5 cm H2O and 
FiO2/PEEP ratio of 0.3/5). 
The main objective of this thesis was to study morphological and functional 
changes in the lungs after exposition to injurious or conventional mechanical ventilation 
and to identify the relationship among high-stretch ventilation, inflammation, edema, 
and surfactant dysfunction to understand the mechanisms involved in ventilator-induced 
lung injury (VILI). Two important questions, currently under debate (9), will be 
answered in this study: whether changes in surfactant composition and in surface 
tension precede the onset of VILI, and whether VILI occurs only in animal models 
when lung surfactant is inactivated. 
The thesis is composed of three chapters which evaluate:  
1. Lung injury after high-stretch ventilation with a complete analysis of the 
composition, structure, and functional activity of lung surfactant as well as 
the causes of its inactivation after high-stretch ventilation (Chapter 1). 
2. Factors involved in the resistance to ventilator-induced lung injury, since 
identification of such factors may help to develop prophylactic therapies or 
early interventions, prior to exposition to mechanical ventilation (Chapter 2). 
3. Consequences of prolonged conventional low-stretch ventilation, with or 
without a previous short exposition to injurious high-stretch ventilation. This 
would allow determination of whether inflammation in the lung was directly 
related to the duration of conventional low-stretch ventilation (with 
FiO2/PEEP ratio of 0.3/5) and whether prolonged conventional low-stretch 
ventilation has beneficial or damaging effects in surviving rats exposed to 
injurious high-stretch ventilation. 
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1. Animals and experimental model. 
Male Sprague-Dawley (SD) rats (Harlan Iberica, Spain), weighing 325-375 g were 
acclimated to day/night cycles of 12 hours and fed with purina fodder (Nestlé S.A. 
Vevey, Switzerland). The animals were anesthetized with ketamine (90 mg/kg) and 
diazepan (5 mg/kg) by intaperitoneal route and the anesthesia was maintained during the 
intervention by a continuous perfusion of ketamine (50mg/kg/h) and midazolam 
(8mg/kg/h) through the femoral vein (infusion rate 10 mL/kg/h). The administration of 
these drugs was made under sterile conditions. 
Once anesthetized, a surgical tracheotomy was performed and a 14-gaugecannula 
was secured in place and connected to a mechanical ventilator (Babylog 8000 Plus 
Dräger, Germany). In addition, a 20-gauche catheter was inserted into the left carotid 
artery for monitoring arterial blood pressure (Hewlett Packard, Model 66S, Geneva, 
Switzerland). The surgical process was performed under sterility conditions. Body 
temperature was maintained constant during the experimental procedure using a self-
regulated heat source (Challomer Ltd. Marketing, England). 
Experiments were carried out following the Principles of Laboratory Animal Care 
(EU 609/86 CEE, Real Decreto 1201/05 BOE 252, Spain) and the guidelines for the 
care and use of experimental animals of University Hospital of Getafe (UHG). UHG 
Institutional Review Board approved the protocol.  
We established two mechanical ventilation strategies according to often settings 
applied in clinic and experimental studies (10): 
 Low-stretch group, ventilated with conventional parameters: Tidal Volume [VT] = 9 
ml/kg, positive end-expiratory pressure [PEEP] 5 cmH2O. 
 High-stretch group, ventilated with injurious parameters: VT = 25 mL/kg, zero 
PEEP.  
In both groups, respiratory rate was 70 bpm, inspiratory time 0.35 sec., expiratory 
time 0.56 sec. and FiO2 0.35.  
The animals were ventilated for an equilibration period of 30 min using the low 
VT ventilation parameters. Then, the assigned ventilator strategy was administered 
randomly starting at t=0 min. Dead-space ventilation (the volume of air inhaled that 
does not take part in the gas exchange) was increased in animals ventilated with high VT 
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(by increasing the length of the ventilatory circuit) to attain comparable values of 
PaCO2 (30-40 mmHg) during the ventilation period. The animals were ventilated with 
the parameters assigned during the time established in each experimental design 
(detailed in each chapter). 
 
2. Registration of hemodynamic and ventilatory parameters.  
At the beginning and end of each ventilator strategy (according to the experimental 
design) were registered the following parameters: mean arterial pressure (MAP) and 
mechanical ventilator parameters including peak inspiratory pressure (PIP), peak airway 
pressure (PAW) and dynamic respiratory system compliance (CRS). 
 
3. Biological sampling. 
At the end of the ventilatory period animals were sacrificed by exsanguination and 
subsequently we proceed to sampling (Figure 1). 
 
 
 
Figure 1: Sampling diagram. 
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Plasma: Blood samples were drawn at end times (according to the experimental 
protocol) to determine arterial blood gases and perform biochemical analysis.Also, 2 ml 
of blood were centrifuged at 3500 rpm during 10 min at 4ºC and the resulting plasma 
was store at -80ºC until its utilization for damage markers determination (Figure 2). 
 
Cell-free bronchoalveolar lavage: bronchoalveolar lavage was performed instilling 4 
times 10 ml of saline (NaCl 0.9%) at 4ºC. The bronchoalveolar lavage acquired was 
centrifuged at 400g for 10 min at 4ºC to obtain the pellet of alveolar fluid cells. Total 
bronchoalveolar lavage cell-free (BAL) volume was recorded and stored at -80ºC in 
order to isolate pulmonary surfactant (PS). An aliquot was separated to perform 
biochemical analysis (Figure 3). 
 
Lung tissue: cardiopulmonary block was extractedonce lungs were washed. The left 
lung was expanded by intratracheal instillation of 10 ml formaldehyde with 20 cm H2O 
pressure for histological analysis. On the other hand, the lower lobe of the right lung 
was divided in 3 pieces and stored at -80ºC avoiding tissue deformation to perform gene 
expression analysis (Figure 4). 
 
Figure 2: Plasma collection procedure. 
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Figure 3: Bronchoalveolar lavage free of cells (BAL) processing and isolation of 
Pulmonary Surfactant fractions. 
 
Figure 4: Lung tissue collection process: sampling to accomplish gene 
expression and histological analysis.  
 
 
Bronchoalveolar
lavage
BAL
0,9 % NaCl
10 ml x 4
BAL
Pellet
400 g 
10 min, 4˚C
Nº alveolar cells
% Alveolar macrophages
Total and oxidized protein
Acid sphingomyelinase activity
CRP TNF-α IL-6 
MCP-1 MIP-2
Small 
aggregates
(SA)
Large 
aggregates
(LA)
Total proteins
Total phospholipids
Cholesterol
Total proteins
Specific pulmonary 
surfactant proteins 
Total phospholipids
Lipid peroxidation
Cholesterol
Interfacial adsorption
48000 g 
1 h, 4˚C
-80˚C
-80˚C-80˚C
  
Material and Methods 89 
4. Arterial blood samples analysis.  
 Determination of arterial blood gases was accomplished using a blood gas analyzer 
(Gem Premier 3000, IL Instrumentation Laboratory). Levels of lactate, glucose, 
creatinine, lactate aminotrasferase (LDH) and creatinine kinase (CK) in arterial blood 
were assessed using a chemical analyzer (Integra 700, Roche Diagnostics). 
 
5. Alveolar fluid cells analysis  
Cellular pellet obtained from bronchoalveola rlavage centrifugation was 
resuspended in 1 ml of a solution 1:1, PBS: Streck Cell Preservative (Streck, Omaha, 
USA). Total number of BAL cells was determined assessing cell viability with trypan 
blue dye exclusion by counting in a Neubauer chamber (Marienfeld, Germany) using 15 
l of cell suspension. 
 
Flow cytometric analysis of BAL cells 
Cells were washed with PBS, centrifuged at 1500 rpm during 10 min at 4ºC and 
resuspended in a final volume of 2 ml of PBS. This cell suspension was used to assess 
alveolar macrophages and neutrophils proportion in alveolar fluid cells using a 
Fluorescence Flow Cytometer (FACScalibur, BD Biosciences, San Diego, USA). 
This determination was accomplished performing a specific surface labeling using 
the following specific monoclonal antibodies: mouse anti-rat CD11c (AbDserotec, 
Oxford, UK), which recognizes specifically rat alveolar macrophages and mouse anti-
rat RP-1 (BD Biosciences, San Diego, USA), which binds to rat peripheral blood 
neutrophils. Subsequently, cells were incubated under darkness conditions with a 
fluorescein (FITC)-conjugated goat anti mouse IgG secondary polyclonal antibody 
(AbDserotec, Oxford, UK). 
In order to avoid unspecific unions, cells were incubated with RPMI media 
supplemented with 10% bovine fetal serum (FBS) during 30 min previous to the 
incubation with specific antibodies. Among incubations, cells were washed with PBS 
and centrifuged at 1200 rpm during 5 min at 4ºC. Monoclonal antibody rat IgG2A 
(AbDserotec, Oxford, UK) was used as negative control in both cases. 
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After specific incubations, cells were washed and resuspended in 500µl of PBS. 
10.000 total events were counted and analyzed using BD CellQuest Pro™ Software 
(BD Biosciences, San Diego, USA) applying settings previously described to obtain 
specific forward (FSC)/ sideward (SSC) scatter plots of alveolar fluid cells from rodents 
(309, 310). 
 
6. Histological analysis. 
Samples preparation 
Pulmonary hilium zones from the left lung were collected and fixed with formol 
buffered 10% during 48h. Subsequently, samples were dehydrated performing an 
increment alcohols procedure (70º-96º-100º), fixated with xilol and submerged in 
paraffinduring 1h each process. Each paraffin block was cut in 7µm sections and stained 
by haematoxylin-eosin technique. Briefly, samples were dewaxed with xilol and 
rehydrated with decreasing graded alcohols procedure (100º-96º) during 10 min each, 
before washed them with distilled water. Subsequently, samples were submerged in 
eosin-phloxine during 5 min, dehydrated again by increment alcohols procedure and 
fixated with xilol to assemble them. Slides were stored at room temperature, and 
protected from light before use. 
Injury score quantification 
A modify injury score was used to quantify pulmonary damage (311, 312) 
examining10 random fields for each section by light microscopy (40x). A score of 0, 1, 
2or 3 was assigned if none, one, two or more than two membranes were found, 
respectively. The mean of all values of the examined fields was assigned as a measure 
of the degree of lung injury (305). 
 
7. Isolation of large and small aggregates of pulmonary surfactant. 
 BAL was centrifuged at 100,000g for 1h at 4ºC in an ultracentrifuge XL-90 
model (Beckman Coulter, Fullerton, USA) to separate the large surfactant aggregates 
(LA) constituted by multilamelar vesicles of phospholipids and PS specific 
apolipoproteins SP-A, SP-B and SP-C (313) from the small non-functional surfactant 
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aggregates (SA), which remain in the supernatant (314)(Figure 3). The resulting 
precipitate, LA fraction, was resuspended with 400 μl of saline 0.9%, reconstituted with 
a potter and aliquoted and stored at -80ºC. 2 ml of supernatant, SA fraction, were 
collected stored at -80ºC until it analysis. 
 
8. Total amount of phospholipids quantification. 
Lipid extraction was performed to determine the content of total phospholipids (PL) 
in LA and SA, by chloroform-methanol extraction (315) using 1 ml of SA and 50 µl of 
LA led to 1 ml by adding NaCl 0.9%. The organic phase of each sample was evaporated 
with a rotary evaporator R (Büchi, Flawil, Switzerland) and resuspended with 1 ml of 
chloroform/methanol (2/1, v/v). Total amount of PL from SA and LA was assessed 
from the organic extracts obtained by an analysis described by Rouser and col. (316) of 
phosphorous quantification.  
Briefly, samples (200µl of LA and 300 µl of SA) and standards (KH2PO4 0.05 
mg/ml) were dried in a sand bath before adding 450 µl of perchloric acid 70% (HClO4) 
and incubate covered during 30 min at 260ºC to accomplish the mineralization of the 
phosphorous. The quantification of mineralized phosphorous was achieved through a 
colorimetric reaction by adding ammonium molybdate (2.5%, w/v) which conform a 
complex with phosphorous. This complex was reduced by adding ascorbic acid (10%, 
w/v), which formed a colored compound after 8 min at 100 ºC of incubation stooped 
with ice. Absorbance was measured at 820 nm in a spectrophotometer model DU 800 
(Beckman Coulter, Fullerton, USA) and color absorbance values were directly related to 
phosphorous concentration by interpolation into a calibration curve built with known 
concentration standards. 
 
9. Lipid peroxidation assessment. 
 Lipid hydroperoxides (LPO) present in the organic extracts of LA were assessed by 
the FOX method (317). This process is based on the ability of LPO to oxidize Fe
2+
 to 
Fe
3+
. This oxidation is detected using thiocyanate ion as chromogen. To this purpose we 
used the Lipid Hydroperoxides Kit from Cayman (Cayman Chemical Company, Ann 
Arbor, USA). Samples (1.5 nmol PL/l) and standards (13-hydroperoxy acid-
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octadecadienoic acid [13-HpODE] 50M) were incubated covered during 5 min at room 
temperature (RT), with 4.5 mM ferrous sulfate reagent in 0.2 M hydrochloric acid and 
ammonium thiocyanate 3% methanol (v/v). Absorbance at 500 nm was measured in a 
spectrophotometer model DU 800 (Beckman Coulter, Fullerton, USA)and color 
absorbance values were directly related to LPO concentration by interpolation into a 
calibration curve built with known concentration standards (0 to 5 nmol/mlof 13-
HpODE). 
 
10. Cholesterol quantification. 
The presence of cholesterol (Ch) in LA and SA was determined by a colorimetric 
enzymatic assay using the CHOD-POD Enzymatic Colorimetric kit (Spinreact, 
SantEsteve de bas, Spain). The method is based on the cholesterol oxidase activity in a 
set of chained reactions ending in the formation of a colored compound. A first reaction 
is performed by cholesterol esterase, which breaks down Ch esters into Ch and fatty 
acids. Total free Ch in each sample is then oxidized by cholesterol oxidase into 4-
cholestenone and H2O2. The colorimetric reaction takes place between H2O2, phenol 
and 4-aminophenazone to produce quinonimine, a substance with a rosy color. Briefly, 
10 µl of Ch standard (200 mg/dl), LA and SA (1:10) samples were mixed with 1 ml of 
reactive mixture containing the enzymes above mentioned in a PIPES buffer pH= 6,9 
and phenol. This mixture was gently blended and incubated during 10 min at RT until 
its absorbance lecture at 505 nm in a spectrophotometer model DU 800 (Beckman 
Coulter, Fullerton, USA). 
 
11. Total protein determination. 
Total content of protein was determined in BAL, LA and SA samples by a 
colorimetric reaction based in Lowry method (318), modified by adding sodium 
dodecyl sulfate (SDS). This method is based on the denaturalization and exposition of 
protein tyrosine phenolic groups by copper ions under alkaline conditions. Therefore, 
samples and standards (albumin) were mixed with a solution composed by sodium 
tartrate 2% (w/v), cupric sulfate 1% (w/v), sodium carbonate 2% (w/v) and one pellet of 
sodium hydroxide (Merck, Darmstadt, Germany) and incubated for 15 min at RT. 
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Subsequently, they were incubated during 30 min with Folin-Ciocalteau reactive 
(Merck, Darmstadt, Germany), turning the yellow color of Folin-Ciocalteau reagent into 
blue due to Folin-Ciocalteau reduction by tyrosinresidues. The absorbance was read at 
700 nm with a spectrophotometer model DU 800 (Beckman Coulter, Fullerton, USA) 
and color absorbance values were directly related to protein concentration by 
interpolation into a calibration curve built with known concentration standards. 
 
12. Oxidized proteins quantification.  
  The presence of oxidized proteins in BAL was determined evaluating their carbonyl 
content by a spectrophotometric assay binding 2.4-dinitrophenylhydrazine (DNPH) 
(319). DNPH reacts with protein carbonyls, forming a Schiff base to produce the 
corresponding hydrazone, which can be analyzed spectrophotometrically. Therefore, 
100 µl of BAL samples per duplicate were incubated with DNPH 10mM in HCl 2.5 M 
during 1 h at RT in darkness and mixed every 15 min. Then, samples were precipitated 
with trichloroacetic acid (TCA) at 10% during 5 min in ice and subsequently they were 
centrifuged at 10.000g during 10 min at 4ºC and washed with ethanol/ethyl acetate (1:1, 
v/v). Finally, proteins were solubilized in 500 µl of guanidinium hydrochloride 6M 
(FlukaBiochemika, Buchs, Switzerland) and centrifuged at 10.000g for 10 min at 4°C to 
remove insoluble material traces. Carbonyls were measured spectrometrically at 370 nm 
in a spectrophotometer model DU 800 (Beckman Coulter, Fullerton, USA). The 
determination of carbonyls concentration was assessed by inserting the absorbance of 
each sample into the following equation: Protein Carbonyls (mol/ml) = 
[(Abs.)/0.022µM
-1
cm
-1*
] * [500µl (resuspension vol.)/ 100µl (sample vol.)]
* 
The actual 
extinction coefficient for DNPH at 370nm. 
 
13. Damage markers quantificationin BAL and plasma: 
TNF-α 
 TNF-α presence was evaluated in BAL and plasma samples in duplicated, using the 
same volume in both types of samples. This valuation was assessed with the BD 
Biosciences ELISA Colorimetric kit (San Diego, CA, USA) TNF-rat specific. A 
polystyrene plate (Maxisorp ®, Nunc, Rochester, USA) was incubated overnight (o/n) 
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at 4ºC with a monoclonal antibody anti-TNF-α. The next day, after a washing process 
with PBS/Tween-20 0.05% (v/v), the plate was blocked for 1 h at RT with PBS/FBS 
10% (v/v) to prevent non-specific binding. Then, the plate was incubated for 2h at RT 
with the samples and the calibration curve formed by the TNF-α standard between 2000 
to 31.25 pg/ml. After this period, a new washing step was performed to remove 
unbound protein followed by an incubation with a second anti-TNF-α biotinylated 
during 1h. Subsequently, another wash was done to remove unbound antibody and the 
plate was incubated 30 min with a streptavidin-peroxidase reagent, which binds to the 
biotinylated antibody, until it was washed for the last time, to remove unbound 
reagent.Finally, the plate was developed with tetramethylbenzidine (TMB) and once the 
reaction was stopped with 2N sulfuric acid and phosphoric acid 1M, the absorbance was 
read at 450nm in the plate reader DIGISCAN ELISA plates (AsysHitech GmbH, 
Eugendorf, Austria). 
IL-6 
 The amount of IL-6 was determined in BAL and plasma samples in duplicate, using 
the same volume of sample, being the plasma previously diluted ½. This quantification 
was assessed using a Quantikine ELISA kit Rat IL-6 Immunoassay (R&D Biosystems, 
Minneapolis, USA). First, it was mixed 50 ul of PBS/FBS 10% (v/v) with 50 ul of the 
samples and 50 ul of the IL-6 standard to perform a standard curve (2000 to 62.5 pg/ml 
IL-6 standard) in a polystyrene plate whose wells have bound a monoclonal antibody 
anti-rat IL-6. The plate was incubated for 2h at RT. Subsequently, after a wash with 
PBS/Tween-20 0.05% (v/v) to remove unbound protein, the plate was incubated another 
2h at RT with a second polyclonal anti-IL-6 coupled to peroxidase, which binds to the 
IL-6 antibodies previously attached to the plate. After this period, a new washing 
process was performed to remove unbound antibody and then, the plate was incubated 
half hour with a reagent mixture made 15 min prior to use, containing hydrogen 
peroxide and TMB. Finally, the reaction was stopped with dilute hydrochloric acid and 
the absorbance was read at 450nm in the plate reader DIGISCAN ELISA plates 
(AsysHitech GmbH, Eugendorf, Austria). 
MCP-1 
  The amount of MCP-1 was evaluated in BAL samples (dilution ½) and in plasma 
(¼ dilution) samples in duplicate, using the same sample volume. This quantification 
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was carried out using a Quantikine ELISA kit JE/MCP-1 Rat Immunoassay (R&D 
Biosystems, Minneapolis, USA). First, 50 ul of the samples and 50 ul of the standard 
curve (500 to 15.6 pg/ml MCP-1 standard) were mixed with 50 ul of PBS/FBS 10% 
(v/v) in a polystyrene plate whose wells having attached a monoclonal antibody to rat 
JE/MCP-1 and incubated for 2h at RT. Subsequently, after washing the plate with 
PBS/Tween-20 0.05% (v/v) to remove unbound protein, the plate was incubated for 2 h 
at RT with a second antibody polyclonal anti-rat JE/MCP-1 coupled to peroxidase, 
which joins the MCP-1 previously bound to the antibodies attached to the plate. After 
this period, a new washing process was performed to remove unbound antibody and 
then the plate was incubated during 30 min with a reagent done 15 minutes prior to use, 
containing hydrogen peroxide and TMB. The reaction was stopped with dilute 
hydrochloric acid and the absorbance was read at 450nm in the plate reader DIGISCAN 
ELISA plates (AsysHitech GmbH, Eugendorf, Austria).  
MIP-2 
 MIP-2 was determined in BAL and plasma samples in duplicate, using the same 
sample volume. This quantification was assessed using a Quantikine ELISA kit Rat 
CINC-3 Immunoassay (R&D Biosystems, Minneapolis, USA). Initially, 50 ul of the 
samples and 50 µl of the standard curve (1000 to 31.2 pg / ml CINC-3/MIP-2 standard) 
were added in a polystyrene plate and mixed with 50 ul of PBS/FBS 10% (v/v). The 
samples were incubated for 2 h at RT in this plate, whose wells are attached to the 
specific monoclonal rat antibody CINC-3/MIP-2. Then, after washing with PBS/Tween-
20 0.05% (v/v) to remove unbound protein, the plate was incubated for 2h at RT with a 
second polyclonal antibody anti-CINC-3/MIP-2 coupled to peroxidase that will stick 
with the MIP-2 antibodies previously attached to the plate. Subsequently, a new wash 
process was performed to remove unbound antibody and then, the plate was incubated 
30 min with a reagent containing a mixture of hydrogen peroxide and TMB made 15 
minutes before use. The reaction was quenched with dilute hydrochloric acid and the 
absorbance was read at 450nm in the plate reader DIGISCAN ELISA plates 
(AsysHitech GmbH, Eugendorf, Austria). 
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C-reactive protein 
  C-reactive protein (CRP) was measured in BAL samples in duplicate, using a 
specific rat ELISA kit of Chemicon (Millipore, Billerica, USA). To perform this assay 
the same volume was used in both types of samples being diluted at least 1:20 the BAL 
samples. First, samples and standards (133.3 to 4.9 mg/ml to perform a curve) were 
incubated for 30 min at RT in a polystyrene plate whose wells have attached a specific 
rat antibody anti-CRP. After a washing process with PBS/Tween-20 0.05% (v/v) to 
remove the unbound proteins, a second anti-CRP antibody coupled to peroxidase was 
incubated for 30 min at RT in order to bind the CRP previously bonded to the antibody 
attached to the plate. Finally, after another washing process, the plate was incubated 
with TMB developing reagent and the reaction was stopped with phosphoric acid for 
read the absorbance at 450nm in an ELISA plate reader DIGISCAN (AsysHitech 
GmbH, Eugendorf, Austria). 
 
14. Acid Sphingomyelinase activity determination. 
  Acid sphingomyelinase (ASMase) activity was determined in BAL and plasma 
samples performing an enzymatic assay. This assay is based on the ASMaseactivity, 
which catalyze the hydrolysis of radio labeled sphingomyelin (SM) to ceramide and 
radio labeled phophocholine. 
To this end, first it was dried by evaporation 10.15 nmoles of sphingomyelin (SM) 
composed by unlabeled SM (Sigma-Aldrich, St. Louis, USA) and [N-methyl-14C] SM 
(0.15 nmol ([N -methyl-14 C] sphingomyelin, 0.74 μCi/mol (GE Healthcare, 
Buckinghamshire, UK). Then, the SM was rehydrated in 90 µl of a buffer composed of 
0.2M sodium acetate pH 5, 0.5% Triton X-100 and 0.1 M zinc chloride, for 1 h at 45°C 
under continuous shaking. The rehydrated SM was gently mixed with 10μl of BAL or 
plasma samples before incubate them 2 h at 37ºC to carry out the enzymatic reaction. 
Subsequently, the enzymatic reaction was stopped performing an organic extraction 
(section 8) (320) and it was collected the upper aqueous phase containing 14C-
phosphocholine in a liquid scintillation vial (MP Biomedicals, Irvine, USA).Finally, the 
cpm of the samples were quantified in a liquid scintillation ISODATA gamma counter 
(Polymedco, Inc., Cortlandt Manor, USA) for 5 min/tube. 
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15. Determination of PS-associated proteins SP-A, SP-B and SP-C levels by 
Electrophoresis and Western blot analysis. 
To analyze the levels of specific surfactant proteins SP-A, SP-B and SP-C, first an 
electrophoretic analysis of LA samples was performed by one-dimensional sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis, using running gels of 12% for SP-A 
and SP-B, and 18% for SP-C. Reducing conditions (5% β-mercaptoethanol) were used 
for SP-A analysis and 1 μg of total protein was applied. In the case of SP-B and SP-C, 
the same amount of PL (5 nmol for SP-B and 3 nmol for SP-C) was applied. After 
electrophoresis, samples were transferred to a nitrocellulose membrane (SP-A and SP-
B) or a polyvinylidenedifluoride membrane (PVDF) (SP-C) using a Bio-Rad Transblot 
Cell (Bio-Rad, Hercules, USA). The transfer was performed at 300mA constant during 
1h, using 25 mMTris-HCl, pH 8.3, 192 mMglycine, and 20 % (v/v) methanol as transfer 
buffer.  
PS-associated proteins immunodetection was performed using the SNAP
TM
i.d. 
System (Millipore Corporation, Bedford, USA). For this purpose, blots were assembled 
in a hydrated holderand placed in the system chamber with the well side up. Rapidly, 
blots were blocked with a PBS containing 0.05% of low fat dry milk. Immediately, the 
vacuum was applied and, when the well was emptied, it was realized a washing step 
with PBS/Tween-20 0.1% (v/v) without turn off the vacuum. When the well was 
completely empty, the vacuum was turned off and the incubation of the primary 
antibody during 10 min was performed. To this, we used the following polyclonal 
antibodies developed in rabbit: anti-porcine-SP-A, anti-porcine-SP-B and anti-
recombinant-human-SP-C. Subsequently three washing steps were performed before 
incubate during 10 min with the vacuum off with the second antibody anti-rabbit-IgG 
coupled to peroxidase (Sigma-Aldrich, St. Louis, USA). Finally, another wash step was 
performed and the blots were removed from the holder system and incubated with the 
chemiluminescent detection reagent ECL (Western Immobilon, Millipore Corporartion, 
Bedford, USA) for 1 min. In all cases, proteins were visualized by superimposing a film 
on the blot to carry out its development in the developing machine (Curix 60, Agfa, 
Mortsel, Belgium).  
Quantification was achieved by densitometric evaluation using Quantity One 
software (Bio-Rad Laboratories, Hercules, USA). 
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16. Gene expression analysis by real time–PCR. 
  Total RNA was isolated from the lower lobe of the right lung using the RNeasy 
plus Mini Kit (Quiagen, Hilden, Germany) according to the protocol provided by the 
supplier. Lung tissue was weigh and freeze with N2 liquid to immediately pulverize it 
using a mortar and pestle underRNase-free and freezing conditions. Grind powder was 
homogenate using a lysisbuffer provided by the supplier containing β-Mercaptoethanol 
(1:100) and a sterile needle (25-gauche). The homogenate was centrifuged 3 min at 
16000g at RT and the supernatant was transfer to gDNA eliminator columns (used to 
eliminate DNA traces) provided by the supplier and centrifuged 30 sec at 8000g at RT. 
The fluid was collected, mixed with ethanol 70% and transferred toRNeasy 
spincolumns, which retain RNA in the membrane. Columns were centrifuged 30 sec at 
8000g at RT until all the fluid had passed and the eluate was discarded. Subsequently a 
wash process was performed and columns were treated with the RNase-free DNAse Set 
(Quiagen, Hilden, Germany) during 20 min to remove possible DNA contaminations. 
After several wash steps, columns were centrifuged 1min at 16000g to eliminate traces 
and finally the RNA was eluted with 40μl RNase-free water supplied. The amount of 
RNA extracted was measured at 260 nm in a spectrophotometer ND-1000 (NanoDrop 
Technologies, Wilmington, USA). 
 cDNA synthesis was performed with the Transcriptor High Fidelity cDNA 
Synthesis kit (Roche, Mannheim, Germany) using 1µg total RNA as input. The RNA 
was first incubated at 65ºC during 10 min (RNA denaturalization) in a Thermal-cycler 
C-1000(Bio-Rad, Hercules, USA) with the random hexamer primers supplied. Then, it 
was added a master mix containing: Transcriptor RT Reaction Buffer (5x), protector 
RNase inhibitor (40U/μl), deoxynucleotide mix (10mM) and transcriptor reverse 
transcriptase. All was gently mixed and tubes were incubated with the following 
thermo-cycling program: 25ºC during 20 min (primers annealing), 55ºC for 1 h (cDNA 
synthesis) and 85ºC during 5 min (enzyme inactivation). Then, the cDNA was stored at-
20ºC until the PCR design. 
  Real-time PCR (RT-PCR) was developed using the Universal Probe Library 
technique (Roche, Mannheim, Germany). This method is based on the identification 
ofimput sequences of the target genes using the ProbeFinder online software provided 
by Roche (www.universalprobelibrary.com). This software designs an optimal qPCR 
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assay combining the best probes and primers according to their organisms specificity, 
absence of cross-hybridations, intron-spanning amplicon, and a small amplicon size. 
The primers selected by this software were analyzed and re-design in some cases using 
PrimerSelect application (Lasergene Core Suite Software, DNASTAR, Madison, USA) 
and finally ordered to be synthesized (Sigma-Aldrich, St. Louis, USA) (Table.1).  
  RT-PCR was performed in triplicates using the appropriate probes and primers (20 
μM) for each target gene, mixed with FastStart Universal Probe Master (Rox, 2x) 
(Roche, Mannheim, Germany) to reach a final volume of 8μl. Allsample mixes (10l) 
were gently blended and transferred to a 384-well microplate (Applied Biosystems, Life 
Technologies, USA) which was incubated with the following thermo-cycling program: 
94ºC during 10 min (initial DNA molecule denaturalization), 94ºC for 10sec (DNA 
denaturalization) and 60ºC during 45 seg (primer annealing and DNA chains extension), 
being repeated 40 times the two last steps in The LightCycler® 480 Real-Time PCR 
System (Roche, Mannheim, Germany). 
  Results were analyzed using the ∆∆CT method (321), normalizing with the 
expression levels of β-actin. The final data were represented as the normalized fold 
change expression. 
 
Target gene Primer Forward Primer reverse Probe 
SP-A 5´-CAAGGGAGAGCCTGGAGAAAG-3´ 5´-CTGAGGACTCCCATTGTTTGC-3´ 50 
SP-B 5´-CTGATCAAGCGGGTCCAAGC-3´ 5´-GGCAGATGCCACCCACCAC-3  ´ 76 
SP-C 5´-GTAGCAAAGAGGTACTGATGG-3´ 5´-CACGATGAGAAGGCGTTTGAG-3´ 74 
ASM 5´-CAGCCTTATGGTCCTTTCAG-3´ 5´-CAGGATTGTTGGTCTCTTTTTC-3´ 62 
MMP-2 5´-CGTAACTCCACTACGCTTTTC-3´ 5´-CTTGCCGTCAAATGGGTATC-3´ 60 
TGF-β1 5´-CCTGGAAAGGGCTCAACAC-3´ 5´-CGTACACAGCAGTTCTTCTC-3´ 1 
β-ACTIN 5´-GGCCAACCGTGAAAAGATGAC-3´ 5´-GACCAGAGGCATACAGGGAC-3´ 64 
Table 1: Primers and probes design with the ProbeFinder software by Roche used to realize 
real-time-PCR assays. 
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17. Biophysical function of Pulmonary Surfactant.  
Interfacial Adsorption:  
The ability of LA to adsorb onto and spread at the air–water interface was tested at 
25ºC in a Wilhelmy-like high-sensitive surface microbalance, coupled to a King-
Clements Teflon dish (322, 323) (Figure 5). 450 nmol of LA phospholipids from each 
samplewas injected into the hypophase chamber of the Teflon dish containing 6 ml of 
buffer (pH 7.0) composed by 5 mM Hepes, 150 mM NaCl, and 5 mM CaCl2, altogether 
under continuous stirring to avoid diffusion from being the limiting step of adsorption. 
Interfacial adsorption was measured following the variation in surface pressure () as a 
function of time, using a platinum plate coupled to the microbalance (KSV 
Instruments). The surface pressure () is related to the surface tension () by the 
following expression: = 0-, where 0is the surface tension of the liquid in the air-
liquid interface without the surfactant presence, which its value is 72 mN/m. Therefore, 
when PS establish a monolayer in the air-liquid interface, the surface tension decreases 
up to the equilibrium  values between 22-25 mN/m and consequently, the  arise 
values between 47-50 mN/m.  
 
 
Figure 5: Schematic representation of a Wilhelmy microbalance for interfacial adsorption 
measurements. 
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Captive Bubble surfactometer 
Captive bubble surfactometer (CBS) is an experimental set up designed to evaluate 
the surface activity of surfactant when it is adsorbed onto the air-liquid interface of an 
air bubble enclosed in a controlled environment chamber. This system, not only 
emulates the air-liquid interface of alveoli and its movements during respiration, but 
also allows controlling several parameters such as temperature, humidity or pressure, 
essentials for the adequate surfactant functionality. 
CBS was designed, built and optimized in the late 80's by Dr. Samuel Schürch in 
order to study the behaviour of the native and synthetic surfactant films in physiological 
relevant conditions (324). 
Surface area (Ab), volume (Vb) and surface tension of the bubble(γb)are calculated 
in the CBS from the diameter and height of it, by monitoring, recording with a video-
camera (Model 765, Pulnix USA), and then digitizing with the computer software 
CBpost Ver1.5 © (325) 
Dr Samuel Schürch and Michael Schoel from the University of Calgary in Canada, 
built the CBS setup used in the experiments done in this thesis, for the Complutense 
University of Madrid.  
 
Components of the CBS system (Figure 6): 
The chamber is a glass cylinder fixed to a metal base with a 2 mm hole in diameter 
at the bottom, through which the air bubble is created (0.0035 to 0.040 cm
3
). The other 
side of the chamber is sealed with anagarose plug (1%, w/v) to create a hydrophilic 
environment that prevents the adhesion of the bubble. The agarose capis adjusted to a 
piston, which will start to compress and expand the space between the plug and the 
metal base, when initiating experimental process. 
This system is filled with approximately, 1.5 mL of a monolayer buffer (Tris 5 mM, 
NaCl 150 mM) containing sucrose 10% in order to increase the density of the aqueous 
subphase, leading the surfactant against the bubble and avoiding its dilution in the 
subphase. Besides, the chamber is placed in a metallic jacket used as a water bath 
thermostated by a heat external source strictly controlled by the computer. This jacket 
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also has a transparent side that allows observe the bubble and locate the IR video 
camera in front of it. This complex is positioned and adjusted by two screws in a holder 
to begin the procedure.  
 
 
 
 
 
Experimental protocol: 
Before starting the experimental protocol, a degasification procedure was essential 
to ensure that any other bubble alters the results. This step involves the expansion of the 
bubble in the sealed chamber for 10 min, to allow small bubbles formed in the aqueous 
subphase join the expanded one.  
To accomplish CBS experiments we used LA samples with a concentration of 20.0 
 2.5 mg/ml of PL. This value was determined as a critical concentration to observe 
differences between groups. 
The CBS allows determining if the surfactant measured fulfills its dynamic 
properties, which are:  
 Very rapid interfacial adsorption (Initial adsorption) 
 Low surface tension upon compression (less than 2mN/m)  (Dynamic cycles) 
 Efficient re-extension upon expansion. (Post-expansion adsorption) 
 
Figure 6: Schematic representation of the CBS device (A) and a detailed view of the bubble 
chamber (B).   
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As a result, the protocol used simulates each feature respectively accomplishing the 
following steps: 
(I) Initial adsorption (IA) kinetics: registers the ability of the surfactant to reach the 
interface and form a film able to reduce the surface tension to the equilibrium. PS 
(150 nL) is applied with a syringe connected to a transparent capillary close to 
the bubble without contact, transferring the material onto the interface. This event 
can be visualized through the changes in the bubble shape during 5 min after the 
aplication of the material. The more flattens the bubble, the more surface tension 
is reduced. Therefore, the equilibrium surface tension reached with surfactant 
presence of 22-23 mN/m in less than 5 sec, from the inicial surface tension of the 
aqueous subphase of 70 mN/m (Figure 7). 
 
 
(II) Post-expansion adsorption (PEA) kinetics: allows analyzing the reorganization 
and spreading of surfactant in an enlarged interface. To that purpose, after the 
initial adsorption experiment, the chamber is carefully sealed and, the bubble 
volume is re-determined before expanding the bubble to a maximum size of 0.15 
cm
3 
controlled by the software. After the bubble expansion, the changes in 
surface tension were registered during 5 min, visualized by the changes in the 
bubble shape described previously in IA (Figure 8). 
Figure 7: Initial Adsorption: 
changes in the surface tension 
detected by the alteration of 
the bubble shape. 
Figure 8: Post-expansion 
adsorption:changes in bubble 
shape due to decrease of 
thesurface tension in function 
of time during the subsequent 
adsorption to expansion. 
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(III) Quasi-static compression and expansion cycles: the air bubble is subjected after 
the adsorption of the surfactant, to four discrete step-wise compression-expansion 
consecutive cycles to permit the relaxation and reorganization of the material 
after each area change. This step, permits to analyze in detail the behaviour of 
surfactant, as consequence of using cycling speeds much slower than those 
associated with breathing, which allows the detection of structural features such 
as phase changes, three-dimensional restructuration and progressive purification 
of interfacial films.  
 To this purpose, first the initial bubble volume was established as the maximum 
bubble volume during PEA. Then, the bubble was compress up to the volume required 
to achieve the minimum surface tension without reaching the interfacial film collapse 
(Figure 9). This event can be detected because the bubble area decreases without 
reducing the surface tension. Therefore, the cycles were performed with 1 sec delay 
between de compression steps and reducing 20% its previous volume.  
 Usually, the first quasi-static cycle is different from the other three, because 
presents a higher hysteresis loops. This means that the energy provided by the 
compression is used to reorganize the material at the interface and purifies the material 
instead of reducing the surface tension. In addition, thanks to this event, subsequent 
cycles will show progressively lower hysteresis and less compression will be needed 
to reduce the surface tension to minimum. 
 
 
 
 
 
 
 
 
 
Figure 9: Quasi-static 
compression and expansion 
cycles: changes in the bubble 
shape related with the surface 
tension/ area isotherms obtained 
during the quasi-static cycling 
process. 
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(IV) Compression and expansion dynamic cycles: reproduces the compression-
expansion of continuous cycles, simulating the physiological human respiratory 
rates (20 cycles/min) in order to observe the real stability and functionality of the 
surfactant in the interface (Figure 10). In the present study, 20 cycles/min were 
performed according to previous CBS studies in high-stretched rats (326) and the 
cycles 1, 10 and 20 were represented. This step was carried out after ending the 
quasi-static cycles, using the maximum and minimum volumes of the quasi-static 
cycles.  
 A functional surfactant decreases the surface tension to the maximum recurrently 
with the minimal compression and exhibiting reduced hysteresis, despite the speediness 
of the cycles that avoids the possibility of relaxation or reorganization. 
 
 
 
18. Statistical analysis 
Data are represented as mean  standard error of mean (SEM) of individual 
measurements. Means were normally distributed (Shapiro-Wilk test). Differences 
between means of each group were analyzed using a one-way analysis of variance 
(ANOVA) followed by a Bonferroni pos hoc analysis. A two-tailed unpaired Student´s 
T test was performed when required. A confidence level of 95% or greater (p< 0.05) 
was considered significant. The statistical analysis was performed using Sigma Plot 
11.0 statistical software. 
 
 
  
Figure 10: Dynamic compression 
and expansion cycles: changes in 
the bubble shape associated with 
the surface tension/ area isotherms 
achieved during the 
dynamiccycling process. 
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1. ABSTRACT 
 The aim of this study was to characterize changes produced in the alveolar 
compartment due to injurious high-stretch ventilation.  
 Sprague-Dawley rats were randomly assigned to control conditions [no 
mechanical ventilation (n=15)], low-stretch [VT = 9 ml/kg, positive-end expiratory 
pressure (PEEP) = 5 cm H2O (n=24)] or high-stretch [VT = 25 ml/kg, PEEP = 0 cm 
H2O (n=24)] ventilation strategies and monitored for 150 min. Subsequently, lung 
tissue, plasma, bronchoalveolar fluid (BAL), BAL cells, and isolated surfactant were 
analyzed. 
 The high-stretch ventilation group, presented several factors implicated in acute 
lung injury, such as leakage of proteins into the alveoli, release of inflammatory 
mediators, oxidative stress in the alveolar compartment, decrease of alveolar fluid 
cells and hyaline membranes deposition, together with factors involved in the 
alteration of pulmonary surfactant system such as protein contamination, surfactant 
oxidation and decrease of surfactant-associated proteins, as depicts alteration of 
surfactant metabolism and its biophysical function impairment. All this alterations in 
the alveolar space are coupled with impaired gas exchange and decrease in dynamic 
compliance, rendering the lung susceptible to atelectasis. Furthermore, we detected 
slightly alterations in the low-stretched group like decrease of alveolar fluid cells and 
increase of some damage markers in the alveolar space. 
 This study indicates that injurious high-stretch ventilation produces direct 
damage to the lung, promoting inflammation, oxidative stress, edema and release of 
factors that together inactivate pulmonary surfactant. Lung surfactant impairment 
leads to atelectasis as depicted by impaired gas exchange and decrease in dynamic 
compliance. 
 
2. INTRODUCTION 
 The acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) are 
common respiratory syndromes in critically care units associated with elevated 
mortality rates (47). However, their only effective treatment to date is mechanical 
ventilation (MV) (173). Thus, many studies have been undertaken in order to improve 
the ventilator strategies and therefore achieve a decrease in their currently mortality 
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rates of 43% (47, 168, 173). However, these researches also discovered that ventilate 
with certain strategies characterized by high tidal volumes (VT) or lack of positive 
end-expiratory pressure (PEEP) administration lead to aggravate and even develop 
lung damage per se, outcome denominated ventilator-induced lung injury (VILI) and 
widely used as animal model of ALI characterization (7). Since then, a wide range of 
VILI models has been conducted in order to elucidate the main factors attributable to 
this alteration.  
As a result, a large number of studies concluded that tissue injury, characterized 
by thickening of the alveolar wall or alveolar type I cells necrosis, is a main feature of 
VILI, which is tightly linked to alterations in alveolar-capillary barrier permeability 
(235). In particular, the alteration of the alveolar–capillary barrier is an important 
mechanism responsible of alveolar edema presence, which is characteristic of VILI 
(236, 327). Also, many other studies highlighted some physiological data, such as 
hypoxemia, as a key feature of VILI (328). 
On the other hand ,the role of the innate immune response and inflammation in 
VILI has been broadly studied, being demonstrated that most of alveolar cells are 
capable to release inflammatory mediators, including IL-1β, IL-6, IL-8, IL-10 and 
TNF-α (238). However this field remains controversial, as some studies observed an 
increase of cytokines release in lungs ventilated without PEEP (250) whereas other 
studies reported no association between VILI and productionof proinflammatory 
cytokines in the same animal model (257). 
As well, different studies were focused on elucidate the role and outcome of 
pulmonary surfactant (PS) in VILI. PS is a surface-active lipoprotein complex 
secreted as its active fraction, called large aggregates (LA), by alveolar type II cells 
(ATII), which accomplish its main function: to stabilize the alveoli by the reduction 
of surface tension at the air-liquid interface, preventing the alveolar collapse during 
end-exhalation (329). Several in vivo and ex vivo investigations concluded that PS 
biophysical function is impaired in VILI (295-298, 330). Ex vivo studies, determined 
together with PS dysfunction some alterations in PS metabolism and composition, 
such as cholesterol increase in LA or hydrophobic PS-associated proteins RNA levels 
decrease (295, 297, 330). Conversely, fewer studies have been conducted in vivo, 
detecting similar alterations (296, 298). Therefore, further investigation must be done 
in order to elucidate the mechanisms and factors that lead PS alterations in VILI. 
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 Therefore, the aim of the present study was to characterize the impact of high-
stretch ventilation in the alveolar space and in particular its effects on the 
composition, structure, and functional activity of lung surfactant assessing the causes 
of surfactant alterations. 
 To accomplish this objective, we characterize physiological, histological, 
inflammatory and PS changes in an in vivo model using injurious (VT = 25mL/kg, no 
PEEP) ventilator strategies or conventional strategies (VT = 9 mL/kg, PEEP = 5 
cmH2O) resembling clinical situations (10). 
 
 
3. EXPERIMENTAL DESIGN 
We established three experimental groups:  
1) Control group: animals subjected to identical anesthetic and surgical procedures 
without being mechanical ventilated (n=15). 
2) Low VT ventilated group: VT = 9 mL/kg, PEEP = 5 cm H2O (n=24). 
3) High VT ventilated group: VT = 25 mL/kg, zero PEEP (n=24).  
Figure 1: Experimental design. Representation of all groups established subdivided 
according to mechanical ventilation strategies. 
Experimental design
t: 0 min t: 150 min
HV 
n=24
VT = 25 ml/kg, 0 PEEP
Settling time
30 min
Settling time
30 min
t: 0 min t: 150 min
LV 
n=24
VT=9 ml/kg, 5 cmH2O PEEP
C: non-ventilated rats.
n=15.
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In both MV groups, respiratory rate was 70 bpm, inspiratory time 0.3 seconds, 
expiratory time 0.56 seconds and FiO2 0.35. 
Animals were ventilated for an equilibration period of 30 min using the low VT 
ventilation parameters. Then, they were assigned randomly to one of the groups. 
Dead-space ventilation was increased in animals ventilated with high VT (by 
increasing the length of the ventilatory circuit) to attain comparable values of PaCO2 
during the ventilation period. The assigned VT was administered starting at t=0 min 
up to 150 min.  
At t=0 min and t=150 min, mean arterial pressure (MAP), peak airway pressure 
[PAW], and dynamic respiratory system compliance [CRS]) were registered. Blood 
samples were drawn at t=150 min to assess biochemical and gases analysis. 
Animals were sacrificed by exsanguination after 150 min and subsequently we 
proceeded to sampling. We obtained lung tissue and bronchoalveolar lavage that it 
was separated from the alveolar fluid cells by centrifugation. The remaining 
bronchoalveolar lavage free of cells (BAL) was processed to obtain PS. 
 
 
4. RESULTS 
 
4.1. Physiology 
 Lung functionality was determined by hemodynamic and ventilatory 
measurements in both groups of study.  
 Ventilator parameters (PAW, CRS) and MAP were measured at the start and end of 
the ventilation period. As depicted in Table 1, rats ventilated with high VT showed a 
significant increase in PAW over time, as well as a significant decrease in CRS and 
MAP.  
Arterial blood gases, pH and lactate concentration were measured in blood at the 
end of MV. Rats exposed to high VT MV presented systemic acidosis, hypoxemia and 
hyperlactatemia in contrast with rats ventilated with low VT (Table 1). Specifically, 
PaO2/FiO2 ratio was below 300 mmHg in high-stretched rats (data not shown), criteria 
defined by the ARDSnet (2). 
All these data suggest the existence of atelectasis in the animals ventilated with 
high VT. 
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Table1:  Changes in mechanical ventilatory parameters (PAW, CRS), mean 
arterial pressure (MAP), blood gases and lactate concentration in rats exposed to 
Low (VT= 9 mL/kg) or High (VT=25 mL/kg) mechanical ventilation strategies. 
  Low VT High VT 
PAW (cmH2O) 
t=0 
t=150 
17.36±0.38 
17.36±0.31 
28.86±0.72 
36.50±1.96 * 
CRS (mL/cmH2O) 
t=0 
t=150 
0.32±0.01 
0.32±0.01 
0.44±0.02 
0.34±0.03 * 
MAP (mmHg) 
t=0 
t=150 
114.16±4.23 
114.04±4.49 
115.59±4.49 
71.15±6.32 * 
PaO2 (mmHg) t=150 146.75±3.37 88.00±12.32 # 
PaCO2 (mmHg) t=150 30.35±1.17 39.13±1.14 
pH t=150 7.42±0.01 7.29±0.02 # 
Lactate (mmol/L) t=150 1.53±0.11 2.63±0.44 # 
 
Definition of abbreviation: PAW: peak airway pressure; CRS: respiratory system 
compliance; MAP: mean arterial pressure; PaO2: partial pressure of arterial oxygen; 
PaCO2: partial pressure of arterial carbon dioxide. 
PAW, CRS and MAP were measured at baseline (t=0) and after 150 minutes of 
mechanical ventilation. PaO2, PaCO2, pH and lactate concentration were measured at 
t=150 min. Data are mean ± S.E.M. * p<0.05, t=0 vs. t=150 min; #p<0.05 Low VT vs. 
High VT. 
 
4.2. Alveolar injury 
Several parameters were evaluated in order to characterize the injury induced by 
high VT ventilation.  
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4.2.1. Cellular and histological analysis 
Total cell counts in the alveolar fluid were significantly decreased in MV groups 
(p<0.001), having significant differences between them (p<0.05 HV vs. LV) as 
depicts Figure 2 (n=14 in all groups).  
 
As well, histopathological studies revealed alterations in the high-stretched 
animals. Figure 3 displays representative micrographs of n = 15 lungs examined in 
both MV groups. Left micrograph corresponds to LV rats, which had no evidence of 
morphological lung injury. In contrast, capillary congestion, alveolar type I cells 
necrosis, and hyaline membrane formation covering the denuded epithelial surface 
were presented in HV animals (Figure 3 [right]). 
 
 
Figure 2: BAL cell counts in all experimental groups (all groups n=14).  
 The number of cells recovered in BAL was determined by cell viability with trypan 
blue dye exclusion. Data are mean ± S.E.M. ** p< 0.001 vs. C; # p<0.05 vs. LV.  
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4.2.2. Total protein and carbonylated proteins in BAL 
Total amount of proteins in the alveolar fluid as well as their oxidized state were 
evaluated in BAL of n=8 and n=5 rats per group, respectively (Figure 4). 
 There was a significant increase in total protein presence in BAL in HV in 
contrast with all groups (p<0.001). This result reflects an increase of protein in BAL 
probably due to an increase of protein release in the alveolar space and alterations in 
the alveolar-capillary barrier allowing leakage of plasma proteins into the alveolar 
space. 
As well, we observed in these rats an increase of carbonylated proteins in BAL of 
the rats injuriously MV in contrast with Control group (p<0.01). 
Figure 3: Histological micrographs of rats ventilated with Low or High tidal volumes 
during 150 min (all groups n=15).  
Representative light micrographs obtained from isolated left lungs of LVgroup (left) and 
HV group (right) stained withhematoxylin-eosin. 
 
LV HV
Lung tissue micrographs from MV groups
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4.2.3. Damage markers 
We studied the presence of two damage markers in the alveolar space using n=5 
animals per group: TNF-α and Acid Sphingomyelinase (ASMase) activity (Figure 5).  
TNF-α is a pleiotropic cytokine with multiple functions in the inflammatory 
response(331). This cytokine increased significantly in BAL of HV group (p<0.001), 
while it was undetectable in plasma of both groups (Figure 5a). 
On the other hand, ASMase catalyze the hydrolysis of sphingomyelin (SM) to 
ceramide and coline phosphate, being ASMase-derived ceramide a promoter of 
several pathways leading to ALI (332). We observed a significant increase of 
ASMase activity in BAL of MV groups, being significantly higher in HV group 
(Figure 5b). Interestingly, its levels in plasma did not vary between groups (data not 
shown). 
Figure 4: Total protein levels and its oxidized state in broncholalveolarlavage of 
Control and ventilated rats with Low/High tidal volumes during 150 min. 
Total amount of proteins (a, n=8) and protein oxidation content (b, n=5) were 
assessed in BAL in all groups of study.  
Data are mean ± S.E.M. **p< 0.01vs. Control and ***p< 0.001 vs. all groups. 
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4.3. Surfactant analysis 
 
4.3.1. Composition analysis 
PS is comprised of 90% lipids, predominantly phospholipids (PL), and 10% of 
proteins, mainly the PS-associated proteins: SP-A, SP-B, SP-C and SP-D. PS is 
secreted as its functional fraction (LA) by ATII to the alveolar space. In a normal 
lung, compression and expansion during respiration leads the conversion of LA to a 
non-functional fraction (SA), are either degraded or recycled by alveolar macrophages 
or ATII (314). Conversely, under pathological situations, there is an alteration of the 
conversion of LA to SA, being the increase of the SA/LA ratio a damage marker of 
VILI.  
Figure 5: TNF-α and Acid Sphingomyelinase activity levelsin 
broncholalveolarlavage of control and ventilated rats with Low/High tidal volumes 
during 150 min.  
a) TNF-αwas measured in BAL and plasma of all groups using a colorimetric rat 
ELISA kit (n=5 per group). There were significant differences between HV and all 
groups in BAL. Plasma levels were undetectable. 
b) ASMase activity was measured in BAL and plasma of both ventilated groups 
performing an enzymatic assay (n=5 per group).There were significant differences 
between MV groups and Control group in BAL while there were no differences in 
plasma among groups (data not shown). 
Data are mean ± S.E.M. ** p<0.01vs. Control and *** p< 0.001 vs. all groups. 
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Therefore, we evaluate possible alterations in LA to SA conversion and their total 
PL amounts in n=11 rats per group (Figure 6). Moreover, we studied PS-associated 
protein levels in LA and its RNA expression in lung tissue of n=5 rats in all groups 
(Figures 7, 8 and 9). 
The content of total PL in PS significantly increased in High VT group (p<0.001). 
This increase was primary due to a significant increase of PL in SA fraction (p<0.001) 
while in LA did not differ among groups. Accordingly, SA/LA ratio was significantly 
altered in those rats exposed to high VTMV (p<0.001). These data suggest that 
injurious MV increases PS secretion but also alters its metabolism. 
 
 
 
 
Figures 7, 8 and 9 represent RNA and protein levels of PS-associated proteins 
analyzed in n=5 animals of all groups of study.  
Figure 7 represents SP-A data. Immunoblotting reveals a significant decrease of 
SP-A in HV groups in contrast with rest of groups (p<0.01). Additionally, we also 
detected a significant decrease of SP-A RNA levels in HV group vs. Control 
(p<0.05).  
 
 
Figure 6: Total amount of phospholipids (PL) in pulmonary surfactant (PS) and PS 
fractions of rats ventilated with Low/High tidal volumes during 150 min. 
Total PL content in PS and the active (LA) and inactive (SA) fractions of PS were 
measured in n=8 animals of both groups of study.As well, it was determined the ratio of 
PL content between SA and LA in both groups. We observed significant differences in 
HV group. Data represent mean ± S.E.M. ***p< 0.001 vs. all groups. 
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On the other hand, Figure 8 depicts SP-B results. Interestingly, we detected a 
significant decrease in HV group of both protein and RNA levels vs. Control whereas 
we observed and increasing trend of SP-B protein levels in LV group together with a 
significant increaseof its RNA levels in this group (p<0.01).  
SP-C results showed in Figure 9, depicts a significant increase of protein levels in 
LV group in contrast with the significant decrease observed in HV group. As well, 
RT-PCR revealed a significant fold decrease of SP-C in HV group (p<0.001 vs. all 
groups). 
 
 
Figure 7: Presence of the collectin SP-A in large aggregates (left) and its RNA 
expression in lung tissue (right) of n=5 rats ventilated with Low/High tidal volumes 
during 150 min or non-ventilated (C).  
Protein levels of SP-A were detected in LA by Western blot (WB) after 12% reducing 
SDS/PAGE loading 1 µg of total protein and quantified by densitometric evaluation.  
RNA expression of SP-A in lung tissue was assessed using total RNA isolated from the 
lower lobe of the right lung. cDNA synthesis was performed using 1µg total RNA as input 
and it was amplified by RT-PCR using specific primers.  
Data represent mean ± S.E.M. * p<0.01 vs. C and ** p<0.01 vs. all groups. 
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Figure 8: Presence of the hydrophobic peptide SP-B in large aggregates (LA) and 
their RNA expression in lung tissue of n=5 rats ventilated with Low/High tidal 
volumes during 150 min or non-ventilated (C). 
Protein levels of SP-B were detected by WB after 12% SDS/PAGE under non-reducing 
conditions applying 5 nmol of total PL of LA (left) and quantified by densitometric 
evaluation (center). RNA expression of SP-B was assessed by RT-PCR using specific 
primers previous isolation of RNA from the lower lobe of the right lung. Results were 
analyzed using ΔΔCT method and expressed as normalized fold expression (right).  
Data represent mean ± S.E.M. * p<0.05 vs. Control and ** p<0.01 vs. all groups. 
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Figure 9: Presence of the hydrophobic peptide SP-C in large aggregates (LA) and 
their RNA expression in lung tissue of n=5 rats ventilated with Low/High tidal 
volumes during 150 min or non-ventilated (C). 
Protein levels of SP-C were detected by WB after 18% SDS/PAGE under non-reducing 
conditions applying 3 nmol of total PL of LA (left) and quantified by densitometric 
evaluation (center).RNA expression of SP-C was detected using total RNA isolated from 
the lower lobe of the right lung. cDNA synthesis was performed using 1µg total RNA as 
input and it was amplified by RT-PCR using specific primers. Results were analyzed 
using ΔΔCT method and expressed as normalized fold expression (right).  
Data represent mean ± S.E.M. * p<0.05 vs. Control and *** p<0.001 vs. all groups. 
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4.3.2. Pulmonary surfactant functionality 
PS biophysical function was determined measuring the ability of LA to adsorb 
onto and spread at the air–water interface, by following the variation in surface 
pressure as a function of time (322). 
Figure 10 depicts PS interfacial adsorption of all groups of study (n=5 per group). 
While Control and LV groups were near to the equilibrium pressure at 30 minutes, 
HV group pressure was significantly lower at the same time, suggesting functional 
impairment (p<0.001). 
 
 
 
 
 
 
Figure 10: Pulmonary surfactant functionality of n=5 rats from all groups. 
Surfactant function was determined measuring its ability to adsorb onto and spread 
at an air-water interface. Surfactant interfacial adsorption in HV groups decreased 
significantly compared with rest of groups (*** p< 0.001). Data are mean ± S.E.M. 
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4.3.3. Presence of pulmonary surfactant inhibitors. 
We studied several inhibitors of surfactant function previously described in other 
animal models and in vitro studies (6, 322, 333). For example, protein leakage into 
the alveolar space contributes to PS impairment due to the possible competition 
between LA and surface-active plasmatic proteins for reaching the air-liquid interface 
(6). According to this, we detected a significant contamination of proteins in the 
active fraction of PS in the HV group (p<0.001), depicted as protein to PL ratio in LA 
(Figure 11a, n=6 in both groups). Furthermore, we observed a significant increased in 
HV group of C-reactive protein (CRP) levels (p<0.001), determined in 4 rats per 
group as the percentage of CRP to PL in PS (Figure 11b). Previous studies in our 
laboratory determined that CRP is an acute-phase protein that inhibits PS 
functionality by binding to it when reaches the alveolar space (333). Therefore, this 
data indicates that CRP is implicated in PS impairment in this model.  
On the other hand, it is widely accepted that mechanical stress stimulates reactive 
oxygen species (ROS) production (292) and some studies also demonstrated in vitro 
that PS oxidation is intimately related with PS impairment (334). Hence, we observed 
a significant increase of LA lipid peroxidation in HV group (p<0.05) as depicts Figure 
11c (n=4 in both groups). 
Figure 11: Presence of pulmonary surfactant inhibitors in all groups.  
a) Total protein to PL ratio in LA was assessed in n=6 animals of all groups of study. 
This ratio significantly increased in HV group. 
b) CRP was measured using a rat CRP ELISA kit. CRP to total PL in PS ratio 
significantly increased in HV group (n=4 per group). 
c) Lipid hydroperoxides were quantified in lipid extracts of LA of n=4 samples by 
FOX method. Lipid hydroperoxides significantly increased in LA of HV group. 
Data represent mean ± S.E.M. *p<0.05 vs. Control and ***p<0.001 vs. all groups. 
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5. DISCUSSION 
The present study allows linking the alterations detected in the alveolar space due 
to VILI as well as highlights novel factors directly involved in PS alterations. This 
model depicts that injurious MV disturbs simultaneously three levels in the alveolar 
space: alveolar epithelium, alveolar fluid cells and PS. 
Light micrographs from the injurious ventilated group showed alterations in the 
alveolar space concerning epithelial disturbances such as alveolar type I cells necrosis 
or thickening of the alveolar wall by hyaline membranes deposition. Also, we 
observed a decrease of alveolar fluid cells in this group. As hyaline membranes are 
composed by cellular debris and fibrin, our data suggest that the overinflation 
produced by high VT and PEEP absence may induce alveolar cells necrosis 
comprising part of hyaline membranes. However, we also observed a significant 
decrease of alveolar fluid cells in LV group. As other groups have previously 
suggested that MV may induce alveolar cells adhesion to the epithelium (273, 309), 
we dare to speculate that MV may push alveolar cells to alveolar epithelium and 
depending on the overinflation produced,might lead to cell death. Therefore, it is 
reasonable to suggest that MV itself directly affects to alveolar cells by several 
mechanisms depending on the strategy applied.  
Interestingly, tissue injury is usually linked with alterations in the alveolar 
capillary barrier (235). Accordingly, our data suggest similar alterations as we 
observed an increase of total protein in BAL. However, an increase of damage 
markers release in the alveolar space may contribute to this result.  
In fact, we detected a significant increase of two damage markers in the alveolar 
space of HV group.  
Sphingomyelinases are enzymes that catalyze the hydrolysis of sphingomyelin to 
ceramide and coline phosphate (335). Specifically, ASMase plays a key role in the 
SM/ceramide-signaling pathway, important for its implication in the pathogenesis of 
ALI (332). Several in vivo studies reported an increase of ASMase activity in lungs 
and serum (336, 337), and the lack of its presence showed an attenuation of 
inflammation (337) and edema (336) in ALI. Here we observed an increase of 
ASMase activity in BAL of MV groups, being its presence higher in high-ventilated 
animals. These data suggest that MV may induce the increment of ASMase activity in 
the alveolar space considering edema as a possible source in the case of HV group. 
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Additionally, we observed an increase of TNF-α exclusively in the alveolar 
compartment. Even though several models of VILI reported no changes in TNF-α 
levels in BAL (257, 294), many other VILI models including ours found an increment 
of this acute-phase cytokine in the alveolar space (250, 296). 
However, an interesting role of this early acute inducible cytokine is its 
involvement in the production of reactive oxygen species (ROS) by various cell types 
(331, 338). It is known that patients with ARDS are subjected to an increase 
generation of ROS and reactive nitrogen species (RNS) produced by alveolar cells 
after proinflammatory stimulation, altering the endothelial barrier function and thus 
increasing its permeability (339, 340). Furthermore, stimulation of ROS production in 
response to elevated mechanical stretch has been mainly detected in endothelial cells, 
but also in epithelial cells, macrophages or fibroblasts, being widely accepted that 
they may contribute to the onset of VILI (290-292). However, sources and pathways 
leading to this production are still under discussion (290). Besides, we observed an 
increase in carbonyl proteins in BAL fluid together with lipid peroxidation increment 
in LA of high-stretched rats, suggesting that alveolar space is under oxidative stress. 
It has been previously reported increments of carbonyl proteins in lung tissue 
(341) and malondialdehyde contents in the epithelial lining fluid (342) under MV as 
well as several studies confirm a relationship between PS biophysical activity 
impairment and its oxidation by different mechanisms (334). However, detection of 
LA peroxidation in a VILI in vivo model is a novelty and directly contributes to the 
PS impairment observed. 
Conversely, we observed a significant increase of PS release in the alveolar space 
in those rats highly stretched. Interestingly, we only detected a significant increase of 
SA meanwhile LA remained stable, together with an increment of the SA/LA ratio. 
These findings are consistent with similar results previously obtained applying high 
VT and no PEEP during 1h (294, 296, 297), being suggested that the increment of the 
SA/LA ratio due to the alteration of the LA to SA conversion is a damage marker in 
VILI (298). These data suggest that injurious MV induced PS release into the alveolar 
space but fresh PS may be rapidly altered by several damage markers in the alveolar 
space as depicts the increment of LA to SA conversion.  
Together with LA peroxidation, we observed a significant increase of protein 
contamination in this fraction that may contribute to both functional impairment and 
alteration in LA to SA conversion. In fact, it is widely accepted that vascular leakage 
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of proteins into the alveolar space contributes to PS biophysical activity dysfunction 
(329). The increment of total protein to PL ratio in LA suggests a possible 
competition between LA and some surface-active plasmatic proteins such as albumin 
or fibrinogen, which has been shown to compete for reaching the air-liquid interface 
(6).  
However, we studied CRP, an acute-phase protein that directly binds to PS 
inhibiting its biophysical function (322, 333). CRP is produced in humans and other 
animal species primarily by hepatocytes after inflammation or infection and secreted 
to the serum (343, 344). Besides, alveolar ATII and macrophages stimulated by pro-
inflammatory mediators are also able to produce it (345-347). Previous studies in our 
laboratory detected elevated levels of CRP in BAL and plasma in patients with 
ischemia-reperfusion injury and studied the effect of CRP in PS functionality in vivo 
and in vitro (322, 333). In this study, we detected a significant increase of the 
percentage of CRP to total PL of PS ratio in injurious MV rats. Consequently, this 
study demonstrates for the first time the implication of CRP in the pathogenesis of 
VILI. In addition, previous studies in our group observed an increase in CRP 
associated with a decrease in SP-A under lung injury. This SP-A deficiency is critical 
because our laboratory demonstrated previously in vitro that SP-A binds to CRP, 
inhibiting its adverse effect (322, 333). 
Accordingly, we observed a significant decrease of protein and RNA levels of 
SP-A in rats injuriously ventilated. The hydrophilic collectin SP-A is involved in 
several functions in the alveolar space such as lung defense or PS homeostasis. 
Specifically, SP-A contributes to LA maintenance, protects PS against inactivation by 
binding blockade and enhances PS adsorption (55). Hence, these data suggest that SP-
A deficiency is also critical in VILI, as it cannot accomplish its protective and 
homeostatic role appropriately. 
Moreover, we observed a decrement of protein and RNA levels of the 
hydrophobic peptides SP-B and SP-C, being both essential in PS adsorption and 
surface tension reduction (55). Interestingly, these protein decrease has been observed 
in several clinical studies of ARDS patients (5, 61, 348) as well as some VILI models 
revealed a decrease of SP-B and SP-C RNA levels (295) and SP-B protein levels 
(296).  
However, it is the first time, as far as we know, that is detected a decrease of 
both, RNA and protein levels, of SP-A, SP-B and SP-C in VILI. Hence, these data 
  
126 Chapter 1  
suggest that high-stretch MV altersPS-associated proteins production by ATII, being 
their lack a direct contributor of PS functionality impairment. A plausible explanation 
for the altered pattern of PS-associated proteins expression could be an increase of 
modulator factors in the alveolar space, such as proinflammatory mediators, leading 
to ATII alterations. For example, previous studies indicate a relation between 
increased TNF-α concentrations and a decreased of RNA levels of SP-B and SP-C 
(295). Nevertheless, degradation of these proteins in the alveolar space might be 
another contributor of their lack. 
To summarize, injurious MV instigates the release of inflammatory factors by 
alveolar epithelial and fluid cells as well as promote protein contamination due to the 
alteration of the alveolar-capillary barrier. These features are involved in signaling 
pathways that exacerbate the existing damage, being an important target PS.  
As a result, the presence of damage markers in the alveolar space directly affects 
PS functionality by oxidizing its functional fraction or due to protein binding that 
directly inhibits its function. As well, PS composition is altered, probably caused by 
ATII alterations, directly affecting its functionality due to decrease of PS-associated 
proteins. Moreover, ATII and alveolar cells alterations are involved in LA to SA 
conversion and reuptake. Consequently alteration of PS metabolism and functionality, 
in turn triggers an increase of alveolar infiltrations by altering the equilibrium 
pressures between the alveoli and the capillaries, generating a damaging feedback 
leading to atelectasis and impairment of gas exchange. 
Therefore, this study allows interrelating many of the factors directly involved in 
acute lung injury that also contributes to pulmonary surfactant impairment.  
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1. ABSTRACT 
 Ventilator-induced lung injury is a pulmonary damage caused by injurious 
mechanical ventilation that besides having a wide range of known alveolar alterations 
it also has a heterogeneous outcome.  
The aim of the present study was to elucidate the possible different responses to 
the application of the same injurious high-stretch ventilation, trying to identify factors 
involved in the resistance to ventilator-induced lung injury. 
  Sprague-Dawley rats were randomly distributed in the following groups: Control 
(n=5), low-stretch ventilation (LV) (VT = 9 ml/kg, PEEP = 5 cm H2O) (n=5) or high-
stretch ventilation (HV) (VT = 25 ml/kg, PEEP = 0cm H2O) (n=17). HV group was 
subdivided in two groups: 1) animals greatly susceptible to HV (sHV), showing a 
substantial PaO2/FiO2 reduction at 60 min of ventilation; and 2) animals resistant to 
HV (rHV), with insignificant changes inPaO2/FiO2 at 60 min. Lung tissue, plasma, 
bronchoalveolar fluid (BAL), BAL cells and lung surfactant were analyzed in all 
groups. 
Injurious high-stretch ventilation induced a vulnerable and a resistant response. 
The vulnerable group was characterized by hyaline membranes formation, 
pronounced decrease of alveolar macrophages, intra-alveolar edema, inflammatory 
markers in BAL (TNF-α, MIP-2, MCP-1 and acid sphingomyelinase activity) and 
alterations in the composition and biophysical activity of lung surfactant, which 
contained significant levels of peroxides. In contrast, the resistant group was 
distinguished by an attenuate lung inflammatory response (characterized by IL-6 
increase), high amounts of fully active surfactant, absence of edema and normal 
physiological parameters after 150 min of HV. 
These findings suggest that an attenuate inflammatory response together with 
increased release of active surfactant into the alveolar space prevent edema and a 
worsened response to high-stretch ventilation. 
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2. INTRODUCTION 
 Acute lung injury (ALI) and its severe form, acute respiratory distress 
syndrome (ARDS), are the major acute respiratory failures with an elevated incidence 
in critical care units (175). However, the determination of their incidence has been 
complicated to assess due to their etiologic variability. These syndromes are closely 
related with insults that directly or indirectly affects to the lungs (e.g. pneumonia, 
sepsis, respectively.), contributing to their heterogeneity outcome (173). Furthermore, 
some studies suggest age and race as other factors involved in mortality risk (173, 
175). Despite this, mortality rates have decreased significantly in the last decade (47, 
173).  
The main factor involved in this mortality reduction is the improvement of 
protective ventilation strategies, the only effective treatment to date (173). However, 
these studies also highlighted ventilator strategies that worsening the existing damage 
or even initiate it. Therefore, knowing the alterations attributable to mechanical 
ventilation (MV) has an essential clinical relevance that led to develop several clinical 
trials and establish numerous animal models to characterize it. 
Clinical studies concluded that even applying the same stress to the lungs of 
different patients, forces that reach to their cells and the corresponding response are 
quite heterogeneous and variable (299), presuming that personalizing ventilator 
strategies according to the particular patient injury status will improve their outcome 
(349). 
On the other hand, several experimental models have been performed in order to 
elucidate the main features attributable to MV. As a result, many groups studied 
inflammatory responses under different stretching stimuli (238, 293). Also some 
studies were aimed at discovering mechanisms leading to vascular permeability (236, 
327, 336), detecting physiological variables alterations (328) or examining pulmonary 
surfactant alterations due to MV (294-298, 330). However, few studies addressed a 
global study in a single model in vivo (Chapter 1). Consequently, the experimental 
design variability and the variation of factors influencing this injury, lead to a wide 
range of biologic outcomes that limited a consensus on the importance of the factors 
determined and their link to systemic dysfunction (256, 350). 
Nonetheless, some studies attribute these heterogeneity outcomes to different 
degrees of susceptibility to mechanical stress, arguing that a failure in the activation 
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of protective mechanisms or their inhibition may lead to a damaging imbalance (299, 
351, 352). 
On the basis of the above information, we formulate the following questions: 
 Experimental animals facing the same injurious mechanical stress may develop 
different responses according to their susceptibility?  
If they do so, which are the main factors contributing to these different responses 
to damage? Some of these factors could be useful to develop therapeutic strategies? 
To address these questions we established a model of injurious MV which was 
subdivided in two groups according to variations in mean arterial pressure (MAP) at 
60 min. Subsequently, we investigate the possible different responses to injurious MV 
at different levels: physiological, histological, cellular, molecular and biochemical, 
focusing especially on pulmonary surfactant. 
 
 
3. EXPERIMENTAL DESIGN 
 Male Sprague-Dawley rats were anesthetized and a surgical tracheotomy was 
performed to ventilate them. Subsequently, animals were randomly distributed in the 
following groups: 
 Control group (C) (n=5): animals undergoing identical anesthetic and surgical 
procedures than the other groups but without applying MV.  
 Low-stretch ventilation group (LV) (n=5): rats were ventilated applying this 
protective parameters: Tidal volume (VT) = 9 ml/kg, positive end-expiratory 
pressure (PEEP) = 5 cmH2O, during 150 min. 
  High-stretch ventilation group (HV) (n=17): animals were ventilated under 
damaging conditions: VT = 25 ml/kg, PEEP = 0 cm H2O, during 150 min. 
In both ventilated groups, respiratory rate was 70 bpm, inspiratory time 0.35 
sec., expiratory time 0.56 sec. and FiO2 0.35. Animals were ventilated for an 
equilibration period of 30 min using the low VT ventilation parameters. Then, the 
assigned VT was administered starting at t=0 min up to 150 min.  
Ventilatory and hemodynamic parameters of ventilated groups were registered 
and controlled during the ventilatory process. HV group was subdivided according to 
the variations in MAP at one hour: 
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 Animals resistant to HV (rHV) (n=6): animals with no changes in MAP at 60 
min, sacrificed at 150 min.  
 Animals susceptible to HV (sHV) (n=11): animals with a significant MAP 
reduction at 60 min and sacrificed at this point (MAP≤50 mmHg).  
Hemodynamic and ventilatory parameters were registered at t=0 min, t=60 min 
and t=150 min. Blood samples were drawn before and after the ventilatory procedure 
for blood gases determination and its biochemical analysis. 
At the end of the ventilatory period, the animals were sacrificed by 
exsanguination and subsequently we proceeded to obtain bronchoalveolar lavage free 
of cells (BAL), alveolar fluid cells and lung tissue. 
 
 
 
 
 
 
 
Experimental design
Control (C): non-ventilated rats; n=5.
Settling time
30 min
t: 0 min t: 150 min
LV
n=5
t: 0 min t: 60 min
HV
n=17 Settling time
30 min
VT=9 ml/kg, 5 cmH2O PEEP
VT = 25 ml/kg, 0 PEEP
Check
point
sHV:       MAP ≤ 50 mmHg
n= 11 sacrificed at 60 min 
t: 150 min
rHV:     no changes in MAP 
n= 6   sacrificed at 150 min
Figure 1: Experimental design. Representation of all groups established subdivided 
according to the mechanical ventilation strategies. 
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4. RESULTS 
4.1. Physiology 
We measured hemodinamic and ventilatory parameters in five rats per ventilated 
group. Peak inspiratory pressure (PIP) and mean arterial pressure (MAP) were 
analyzed at t=0 min, t=60 min and t=150 min of the ventilation period. As a result, 
significant changes in MAP resulted in the subdivision of HV group according to this 
criterion: MAP≤50 mmHg (Figure 2a). Interestingly, PIP already increased 
significantly at the beginning of HV in sHV group (p<0.01 vs. rHV) and kept growing 
during the following hour (p<0.001 vs. rHV), suggesting that PIP may be a good early 
damage marker in the prediction of VILI (Figure 3). We also detected a severe 
hypoxemia at the end of the ventilator period of sHV in contrast with rHV (p<0.01) as 
depicted PaO2/FiO2 ratio in Figure 2b. 
 
 
 
Figure 2: Changes during the mechanical ventilation (MV) period in hemodynamic 
variables in n=5 rats from ventilated groups with Low or High tidal volumes.  
a) Mean arterial pressure (MAP) was measured at baseline, start and after 1 and 2.5 hours of 
MV. b) Arterial partial pressure of oxygen (PaO2)-to-fractional inspired oxygen (FiO2) ratio 
values were assessed before and after MV. 
 Data represent mean ± S.E.M of n=5 rats per group. *p<0.001 vs. rHV.  
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We also measured pH and lactate concentration in arterial blood at the end of 
MV. Rats from sHV group presented systemic acidosis and hyperlactatemia in 
contrast with both LV and rHV in the same time frame (Table 1). Furthermore, we 
determined the levels of glucose, creatinine, lactate aminotrasferase (LDH) and 
creatinine kinase (CK) enzymes in blood harvested at the end of MV. There was a 
significant increase of glucose and LDH in sHV group vs. LV and rHV groups. Also 
CK significantly increased vs. LV group (Table 1). Our data suggest an increase of 
anaerobic metabolism in sHV group. 
PIP
Basal
c
m
 H
2
O
0
10
20
30
40 LV 
rHV
sHV
0 h 1 h 2.5 h
Mechanical ventilation time
**
*
Figure 3: Changes during the mechanical ventilation (MV) period in peak inspiratory 
pressure (PIP) in n=5 rats from ventilated groups with Low or High tidal volumes.  
PIP was measured at baseline, start and after 1 and 2.5 hours of MV. Data represent mean ± 
S.E.M of n=5 rats per group. *p<0.01 and **p<0.001 vs. rHV.  
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4.2. Alveolar injury 
Changes in the alveolar space due to MV were characterized by the evaluation of 
histological score, alveolar fluid cells alterations and damage markers presence.  
4.2.1. Alterations in the alveolar space 
Histological score was evaluated in 5 animals per group and revealed alterations 
in high-stretched animals, being significant in sHV group (p<0.05) (Figure 4a). 
Interestingly, edema presence, represented as total amount of proteins in BAL 
determined in 5 animals per group, only appeared in sHV group (p<0.001) (Figure 
4b). 
 
 
Parameter LV rHV sHV
pH 7.27±0.01 7.28±0.02 7.18±0.02* ###
Lactate (mmol/L) 0.73±0.13 0.87±0.08 2.85±0.39*** ###
Glucose  (mg/dL) 121.8±6.73 147.85±10.47 253.5±20.64*** ###
Creatinine (mg/dL) 0.76±0.08 0.57±0.04 0.75±0.06
LDH (IU/L) 366.4±101.8 502.83±61.64 876.83±119.38* #
CK (IU/L) 317.2±33.78 756.3±176.3 1423.67±386.72*
Table 1: Changes in pH, blood enzymes and blood metabolites in rats subjected to Low (LV) or 
High mechanical ventilation strategies during 60 (sHV) or 150 min (rHV).
Definition of abbreviation: LDH: lactate aminotrasferase; CK: creatinine kinase.
All factors were measured at the end of the ventilator period. Data are mean ± S.E.M. *p<0.05, 
**p<0.01, ***p<0.001, vs. LV; #p<0.05, ##p<0.01, ###p<0.001, vs. rHV.
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4.2.2. Alveolar fluid cells 
Total cell counts in BAL were assessed in five animals of all groups. 
Interestingly, alveolar cell counts decreased when MV was applied. In particular, cell 
counts significantly decreased in the rHV (p<0.05) and sHV (p<0.001) groups (Figure 
5a, left panel). Also, macrophages proportion significantly decreased in rHV (p<0.05) 
and sHV (p<0.001) groups (Figure 4a, right panel). Hence, MV may change alveolar 
fluid cells profile as depict the representative flow cytometric side scatter (SSC, 
relative complexity)/forward scatter (FSC, relative size) dot plots from all 
experimental groups (Figure 5b). 
Figure 4:  Alveolar injury in the different experimental groups. 
Histological score was assessed by hematoxylin-eosin staining of the isolated and fixated left 
lungs of n=5 animals of all groups. Edema presence was measured as total protein content of 
bronchoalveolar fluid in n=5 animal per group. 
Data represent mean ± S.E.M. *p<0.05, ***p<0.001 vs. Control. 
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Figure 5: Alveolar cells profile in all experimental groups (n=5).  
a) Left panel represent total cell counts recovered in BALdetermined by assessing cell 
viability with trypan blue dye exclusion. Right panel depicted the proportion of alveolar 
macrophages in BAL fluid determined by fluorescence flow cytometry using a specific 
monoclonal antibodies anti-CD11c for alveolar. n=5 animal per group were analyzed. 
Data represent mean ± S.E.M. *p<0.05, ***p<0.001 vs. Control; 
###
p<0.001 vs. rHV. 
b) Representative side scatter (SSC)/forward scatter (FSC) dot plots of the flow cytometric 
profile of total alveolar fluid cells from all groups of study.  
. 
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4.2.3. Damage markers 
The presence of cytokines (n=4) and chemokines (n=5) was determined in BAL 
(Figure 6a and 6b) and plasma (Table 2) as well as the presence of acid 
sphingomyelinase (ASMase) activity in these fluids (n=3) (Figure 6c and table 2). 
IL-6 is a pleiotropic cytokine with multiple functions in the inflammatory 
response (353). This cytokine only increased significantly in rHV group (p<0.05) 
while its levels in plasma did not change among groups. Another pleiotropic cytokine 
involved in acute inflammatory responses, TNF-α (331), also increased its levels in 
the HV groups, being significant in sHV vs. Control (p<0.001), while it was 
undetectable in plasma of all groups of study. 
We also studied the presence of chemokines MCP-1 and MIP-2. MCP-1 is a 
chemokine involved in proinflammatory responses, recruitment of monocytes and 
memory T cells as well as a contributor of macrophages activation (354, 355). 
Interestingly, MCP-1 significantly increased in BAL sHV (p<0.001 vs. Control and 
p<0.05 vs. rHV). On the other hand, MIP-2 is a well-known neutrophil 
chemoattractant involved in the elicitation of pulmonary neutrophilia (356), which 
was significantly increased in rHV (p<0.05) and sHV (p<0.001 vs. Control and 
p<0.05 vs. rHV) groups in BAL and also was significantly increased in plasma of 
sHV (p<0.05).  
In order to assess the possible modulatory role of IL-6, we determined a ratio 
between each cytokine evaluated in BAL (TNF-α, MCP-1 and MIP-2) and IL-6. As a 
result, we observe in Table 2 a significant increase of these ratios in sHV group in 
contrast with control group values. 
These data suggest that there are different inflammatory responses between HV 
groups being exacerbated in sHV group.  
ASMase catalyze the hydrolysis of sphingomyelin (SM) to ceramide and coline 
phosphate, being ASMase-derived ceramide a promoter of several pathways leading 
to ALI (332). ASMase activity significantly increases in BAL of sHV group (p<0.05) 
compared with all groups whereas its levels in plasma did not vary among groups 
(Table 2).  
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Figure 6: Damage markers detected in BAL of all groups. 
a) Inflammatory cytokines IL-6 and TNF-were measured in BAL of  n=4 rats per group by 
colorimetric rat ELISA kits. TNF-α levels increase in High VT groups and significantly in 
sHV while IL-6 levels augment in High VT groups and significantly in rHV. 
 b) Inflammatory chemokines MCP-1 and MIP-2 were both detected by ELISA kits in BAL 
on five rats per group. MCP-1 levels significantly increases in BAL of sHV group and MIP-2 
significantly increases in both high-ventilated groups. 
c) ASMase activity in BAL was measured by performing an enzymatic assay (n=3). ASMase 
activity values in BAL increase in sHV vs. all groups. 
Data represent mean ± S.E.M. *p<0.05, **p<0.01, ***p<0.001 vs. Control; 
#
p<0.05 vs. rHV. 
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4.3. Surfactant analysis 
4.3.1. Pulmonary surfactant composition analysis 
Pulmonary surfactant is a surface-active lipoprotein complex mainly composed 
by 90% lipids, most of them PL but also a small proportion of neutral lipids and 
cholesterol, and 10% of proteins being four the PS-associated proteins: SP-A, SP-B, 
SP-C and SP-D. PS is secreted by ATII as large aggregates (LA), which accomplish 
its main function. In a normal lung, compression and expansion during respiration 
leads the conversion of LA to a non-functional fraction, the small aggregates (SA), 
which are either degraded or recycled by alveolar macrophages or ATII (314). 
Conversely, under pathological situations, there is an alteration of the conversion of 
LA to SA, being the increase of the SA/LA ratio a damage marker of VILI.  
Therefore, we evaluate possible alterations in total PL amounts in PS and its 
fractions (Figure 7). Also we assess PS-associated protein levels and its RNA 
expression in lung tissue (Figure 8).  
The content of PL in PS is significantly increased in both high MV groups. 
However, rHV group had LA significantly increased compared with all groups 
(p<0.001) whereas sHV had significantly increased SA (p<0.001) as well as its 
SA/LA ratio (p<0.001) in contrast with all groups. Therefore, high MV may induce 
PS release into the alveolar space but in sHV is rapidly conversed to non-functional 
aggregates. 
Table 2:  Relative content of cytokines referred to IL-6 levels in BAL and damage markers in plasma 
of Control (C) and rats subjected to Low (LV) or High mechanical ventilation strategies during 60 
(sHV) or 150 min (rHV). 
Groups 
BAL Plasma  
TNF-α/IL-6 MIP-2/IL-6 MCP-1/IL-6 
IL-6 
(pg/ml) 
MIP-2 
(pg/ml) 
ASMase activity 
(nmol/ml/h) 
C 7.1e
-3
±4.9e
-3
 0.3±0.11 0.55±0.17 29.12±6 10.04±1.58 170.9±11.9 
LV 0.03±0.017 0.8±0.2 0.49±0.1 40.5±2.3 8.1±2.1 178.3±13.5 
rHV 0.066±0.03 1.1±0.3 0.95±0.15 42.3±1.5 13.65±1.82 161.7±15.3 
sHV 0.16±0.04
**
 2.9±0.45
***
 2.25±0.35
***
 48.4±7.25 35.2±14.7
*
 152.6±15.3 
Definition of abbreviation: TNF-α: Tumor necrosis factor alpha; IL-6: Interleukin 6; MIP-2: macrophage 
inflammatory protein 2; MCP-1: monocyte chemotactic protein 1; ASMase: Acid sphingomyelinase.  
All factors were measured at the end of the ventilator period. Data are mean ± S.E.M.* p<0.05 and 
**p<0.01 vs. Control; *** p<0.001 vs. all groups. 
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Figure 8 shows protein and RNA levels of the specific surfactant proteins SP-A, 
SP-B and SP-C of all MV groups.  
Immunoblotting reveals a significant decrease of SP-A (p<0.05 vs. rHV) and SP-
B (p<0.001 vs. rHV and p<0.01 vs. LV) levels in sHV group analyzing four animals 
per ventilator group. SP-C protein levels were analyzed in two animals per ventilator 
group. The results depicted significant decrease of SP-C levels in HV groups 
(p<0.001 vs. LV), obtaining significant differences between them (p<0.05).  
As well, RNA levels were evaluated in four animals per HV group and two 
animals in LV group. As a result, we detected a significant fold decrease of the RNA 
levels of the three PS-associated proteins evaluated in both HV groups in contrast 
with LV.   
 
 
 
Figure 7: Total amount of phospholipids (PL) in pulmonary surfactant (PS)and its 
fractions of all experimental groups (n=5). 
Total PL content in PS and its active (LA) and inactive (SA) fractions were measured in all 
groups of study. As well, it was determined the ratio of PL content between SA and LA. 
There was a significant increase of PS in high-stretched groups. Interestingly, there was a 
significant increase of the LA amounts in rHV whereas sHV had a significant increase in 
SA and SA/LA ratio.  
Data represent mean ± S.E.M. ** p<0.01 and ***p<0.001 vs. Control; 
###
p<0.001 vs. rHV. 
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Figure 8: Presence of specific surfactant proteins SP-A, SP-B and SP-C in large 
aggregates (LA) and its RNA expression in lung tissue of all ventilated groups. 
Protein levels were detected in LA samples by Western blot. Proteins quantification was 
achieved by densitometric evaluation (n=4 per group in SP-A and SP-B; n=2 per group in 
SPC). 
RNA expression of SP-A, SP-B and SP-C was detected using total RNA isolated from the 
lower lobe of the right lung. cDNA synthesis was performed using 1µg total RNA as input 
and it was amplified by RT-PCR using specific primers. Results were analyzed using ΔΔCT 
method and expressed as normalized fold expression. (n=4 per HV group and n=2 in LV 
group). 
Data represent mean ± S.E.M. **p<0.01 and***p<0.001 vs. LV; 
#
p<0.05 and 
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4.3.2. Pulmonary surfactant functionality 
 Pulmonary surfactant biophysical function was determined using to techniques: 
Interfacial adsorption assay and Captive Bubble Surfactometry. 
4.3.2.1. Interfacial adsorption  
The ability of LA to adsorb onto and spread at the air–water interface was 
measuredin four rats per experimental group using a Wilhelmy-like high-sensitive 
surface microbalance, coupled to a teflon dish of very small size by following the 
variation in surface pressure as a function of time, as previously described (322). This 
ability has been significantly impaired in sHVgroup at 30 min in contrast with all 
groups (p<0.001), as shows Figure 9. 
 
Figure 9: Interfacial adsorption of the active fraction of pulmonary surfactant of all 
experimental groups (n=4). 
Surfactant interfacial adsorption was determined in a Wilhelmy-like high-sensitive surface 
microbalance. Surfactant interfacial adsorption of sHV is significantly altered. 
Data represent mean ± S.E.M. ***p<0.001 vs. all groups, by one-way ANOVA using a 
Bonferroni pos hoc test when appropriate. 
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4.3.2.2. Captive Bubble Surfactometry 
This is the best technique to simulate the compression-expansion cycling that 
happens at the breathing interface in order to evaluate the three main characteristic 
dynamic properties of PS: very rapid interfacial adsorption (~23 mN/m), low surface 
tension upon compression (less than 2mN/m) and efficient re-extension upon 
expansion (325, 357, 358). Figure 10 compares interfacial adsorption kinetics of 20 
mg/ml of LA of three rats from HV groups and Control group assessed after 
deposition at the interface of the captive air bubble in the captive bubble 
surfactometer. Control group adsorbs to form a stable surface film with a minimum 
equilibrium surface tension of ~23 mN/m within the first seconds after deposition. 
rHV also reached this surface tension but it takes more time. However, sHV LA was 
far from reaching the equilibrium tension (41.6 ± 0.7 mN/m; p<0.001 vs. all groups) 
(Table 3). Also, re-adsorption of excess material upon expansion of the bubble (see 
the lower panel in figure 10) had the same pattern in all groups than in initial 
adsorption measurements, being significantly increased the equilibrium tension of 
sHV LA (p<0.001 vs. all groups) (Table 3). 
Cycling isotherms acquired from LA of three rats from Control and rHV rats did 
not represent any compression/expansion hysteresis along dynamic cycles (Figure 
11). Only the first dynamic cycle of rHV group exhibited hysteresis presence, which 
was lost in the subsequent cycles. All isotherms reached surface tensions ~4mN/m 
with <15% compression. In contrast, isotherms of sHV LA (n=3) depicted a marginal 
hysteresis as well as maximal and minimal surface tensions significantly higher than 
the other groups associated with 30% compression (Figure 11 and Table 4).  
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Figure 10: Initial and post-expansion adsorption of the active fraction (LA) of 
pulmonary surfactant from n=3 animals of Control and high-ventilated groups 
evaluated in captive bubble surfactometer.  
Upper panels are representative samples of initial adsorption (top) immediately after the 
application of 20 mg/ml of LA into the bubble‟s air-liquid interface and post-expansion 
adsorption (below) of all samples. As well, media values of the minimum surface tension (γi) 
reached at 5 min after sample application and media values of the minimum surface tension 
(γpost) reached at 5 min after interface expansion are represented (lower panels).  
Data represent mean ± S.E.M. ***p<0.001 vs. all groups. 
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Table 3:  Initial adsorption and post-expansion adsorption of 
pulmonary surfactant from control rats and rats injuriously ventilated 
during 60 (sHV) or 150 min (rHV) assessed in a captive bubble 
surfactometer.  
Groups Interfacial adsorption 
γmin (mN/m) t=5 min 
Post-expansion adsorption 
γmin (mN/m) t=5 min 
C 22.7±1.4 22.4±0.4 
rHV 23.6±0.8 23.8±0.4 
sHV 41.6±0.7
*** 
45.1±1.2
***
 
Definition of abbreviation: γmin: minimum surface tension. 
Data are mean ± S.E.M. 
***
p<0.001 vs. all groups. 
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Figure 11: Dynamic compression-expansion isotherms of the active fraction (LA) of 
pulmonary surfactant fromn=3 animals of Control and high-stretched groups evaluated 
in captive bubble surfactometer.  
Upper panels are representative surface tension/relative area isotherms obtained from 1º, 10º 
and 20º cycles during the dynamic cycling process of 20 cycles/min. Lower panels depict 
media values of minimum (γmin) and maximum (γmax) surface tensions as well as compressed 
area values at γmin (ACγmin) registered during the first and last cycle from dynamic processes.  
Data represent mean ± S.E.M. **p<0.01, ***p<0.001 vs. Control; 
###
p<0.001 vs. rHV. 
 
Table 4:  Effect of injurious mechanical ventilation during 60 (sHV) or 150 min (rHV) 
on the active fraction of pulmonary surfactant surface activity assessed in a captive 
bubble surfactometer under dynamic conditions.  
Definition of abbreviation: γmin: minimum surface tension; ACγmin: relative area of 
compression at minimum surface tension; γmax: maximum surface tension.  
Data are mean ± S.E.M. 
**
p<0.01 and 
***
p<0.001 vs. Control; 
###
p<0.001 vs. rHV. 
Groups 
Dynamic Cycles 
Cycle 1 Cycle 20 
γmin (mN/m) ACγmin (%) γmax (mN/m) γmin (mN/m) ACγmin (%) γmax (mN/m) 
C 4±1.2 16.1±3.8 24.1±0.5 2.9±0.2 12.3±1.6 29.5±1.6 
rHV 8±2 26±4 24.3±0.6 3.5±0.1 13±0.6 30.7±0.6 
sHV 21.2±0.2
***### 34.3±1.7** 48.6±1.4***### 21.2±0.2***### 34.6±1.5***### 56.2±0.8***### 
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4.3.3. Presence of pulmonary surfactant functionality inhibitors. 
Previous studies in our laboratory demonstrate that C-Reactive Protein (CRP) and 
lipid peroxidation are main causes of surfactant impairment in VILI (Chapter 1).  
CRP is an acute-phase protein that inhibits pulmonary surfactant by binding to it 
when reaches the alveolar space (333). As we can see in Figure 12b, CRP to PL ratio 
significantly increased in sHV group compared with Control (p<0.01) (n=3 per 
group). 
On the other hand, is widely accepted that mechanical stress stimulates ROS 
production (292). As a result, this oxidative environment directly affects PS by lipid 
peroxidation of LA. We observed a significant increase of LA lipid peroxidation in 
sHV group in contrast with rHV (p<0.05) in Figure 12d (n=4 per group). 
Finally, we also assessed total protein and Ch content in LA in five and four 
animal per group respectively, as they are considered potential inhibitors of PS 
functionality (296). Accordingly, we observed a significant increase of both, protein 
to PL ratio in LA (p<0.001 vs. all groups) and the molar percentage of Ch to PL ratio 
in LA of sHV group (p<0.05 vs. Control and rHV) (Figure 12a and 12c). These data 
suggest alterations in LA composition as well as plasma protein contamination, which 
may lead to surfactant biophysical activity impairment. 
Therefore, the presence of all these factors contributes to PS functionality 
dysfunction. 
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Figure 12: Presence of pulmonary surfactant inactivators in all groups of study. 
a) Total protein to PL ratio in LA was assessed in five animals of all groups of study. This 
ratio significantly increases in sHV group as a result of plasma-derived proteins 
contamination.  
b) CRP was measured using a rat CRP ELISA kit. CRP to PL in pulmonary surfactant ratio 
significantly increased in sHV (n=3 per group). 
c) Analysis of Ch was performed using an enzymatic colorimetric kit (n=4 per group). 
Molar percentage of Ch to PL ratio in LA of sHV significantly increases vs. Control and 
rHV groups.  
d) Lipid hydroperoxides were quantified in lipid extracts of LA from n=4 animals per group 
by FOX method. Lipid hydroperoxides significantly increase in LA of sHV group vs. rHV 
group.  
Data represent mean ± S.E.M. *p<0.05 and **p<0.01 vs. Control; ***p<0.001 vs. all 
groups; 
#
p<0.05 vs. rHV. 
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5. DISCUSSION 
 This study demonstrated that under the same injurious MV stress, 
experimental animals had two different outcomes: a susceptible response (sHV) or a 
resistant outcome to injurious MV (rHV). These two phenotypes almost differed in all 
levels studied involving several factors.  
Previous studies in our laboratory observed a relationship between MV and a 
reduction of total number of fluid cells (Chapter 1), being remarkable under injurious 
MV. In this research we also observed this pattern together with a decrement of 
alveolar macrophages in HV groups, being stronger in sHV group. Furthermore, this 
decrease was accompanied by an injury score increase in HV groups, characterized by 
presence of capillary congestion, type I pneumocyte necrosis and hyaline membrane 
formation covering the denuded epithelial surface, being noteworthy in sHV. As 
hyaline membranes are composed by cellular debris and fibrin, our data suggest that 
alveolar macrophages from sHV group are more susceptible to overinflation produced 
by high VT and PEEP absence and therefore to necrosis, comprising part of hyaline 
membranes. Conversely, alveolar macrophages from rHV group may be more 
resistant to overinflation as proof their higher rates. Therefore, it is reasonable to 
suggest that MV itself directly affects to alveolar cells by several mechanisms 
depending on their susceptibility. Interestingly, this susceptibility may also explain 
the different inflammatory responses observed in HV groups. 
IL-6 is a typical early inducible cytokine synthesized by many cell types 
participating in initiation and regulation of inflammation (213, 359). Interestingly, 
while there is no doubt about the proinflammatory role of other early inducible 
cytokines such as TNF-α and MIP-2 after applying an insult to the lung, IL-6 seems to 
be more than a merely acute phase reaction-inducing cytokine (353), it should be 
defined as a resolution factor that balances pro- and anti-inflammatory outcomes to 
further the immunological response (213). In fact, some studies of acute inflammation 
demonstrated that the lack of IL-6 was related with higher levels of MIP-2 and TNF-
α, which in high doses is considered a pathological inflammatory mediator causing 
cells activation and affecting permeability in combination with other cytokines (353, 
359). Our results indicate a possible modulator role of proinflammatory cytokine sby 
IL-6 as we observed a contradictory pattern in HV groups: while in the alveolar fluid 
of rHVgroup IL-6 levels significantly increased, TNF-α, MCP-1 and MIP-2 levels 
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were slightly increased, whereas in BAL of sHV group TNF-α, MCP-1 and MIP-2 
significantly increased while IL-6 remained at basal levels. Furthermore, TNF-α/IL-6 
ratio, as well as MIP-2/IL-6 ratio and MCP-1/IL-6 ratio significantly increased in 
sHV group while remained similar in rest of groups. These data suggest a regulation 
role of IL-6 in rHV that is altered in sHV group leading to an exacerbated 
proinflammatory status. It is important to note that the only significant difference 
observe in plasma of ventilated groups was in sHV where MIP-2 levels significantly 
increased, suggesting a loss of compartmentalization.  
All these data suggest that alveolar cells from HV groups had different responses 
to MV with high VT and absence of PEEP, which may entail an attenuated or 
exacerbated inflammatory response in the alveolar space leading to different 
outcomes.  
Also, as previously detected in our laboratory (Chapter 1), we observed an 
increase of ASMase activity in BAL of sHV group without changes in plasma levels 
among groups. Interestingly, ASMase activity-derived ceramide increase is involved 
in permeability alterations and promotes edema formation in models of ALI (336). 
Here, we observed a significant increase of total protein in the alveolar space 
only in sHV group, suggesting edema presence probably due to alterations in the 
alveolar-capillary barrier while considering the increase of cytokines release as a 
contributor of this protein increment. Interestingly, an activated proinflammatory 
status in the alveolar space is considered a main contributor of alterations in alveolar-
capillary barrier and tissue injury (173), which are usually linked (235), as we also 
detected in sHV group. Therefore, these data support the hypothesis that the same 
stress may induce different activation pathways that leads to an attenuated or 
exacerbated outcome depending on their susceptibility to injurious MV. 
Indeed, we detected other factors that are known to be contributors of alveolar-
capillary alterations in VILI. Many studies reported that ventilation with elevated PIP 
promotes edema (235) as well as few studies reported an increase of PIP values 
among time under injurious MVstrategies (296, 360). Here we observed a significant 
increase of PIP in sHV group in contrast with rHV group just at the beginning of 
high-stretch strategy setup that is aggravated at 1h of injurious MV. This result led us 
to speculate that PIP under VT fixated strategies might be an early marker of MV 
susceptibility. 
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As well, another contributor to alter alveolar-capillary barrier leading to edema 
formation is PS impairment (298). An alteration in PS functionality by increasing 
surface tension at the air-liquid interface in the alveoli not only alters the gradient 
pressures across the barrier but also leads to decrease pulmonary compliance, 
atelectasis and hypoxemia associated with anaerobic metabolism (9, 298). 
Interestingly, we have detected these physiological alterations related with surfactant 
impairment and PIP increased values in sHV group while rHV had a proper 
functionality. We observed alterations in interfacial adsorption of sHV using two 
different techniques. As well, we further evaluated the other dynamic properties of PS 
detecting a surface tension decrease upon compression that did not reach appropriate 
values as well as an inefficient re-extension upon expansion of sHV group. Besides 
PS impairment in sHV, there was also a change in endogenous PS system and its 
composition.  
Several studies reported the conversion of the active fraction of PS (LA) to the 
inactive fraction (SA) as a primary mechanism of PS impairment, being considered an 
increase in SA/LA ratio as a damage marker of VILI (298, 361). Here, we observed 
an alteration of SA/LA conversion in sHV together with a decrease in RNA levels and 
protein levels of PS-associated proteins, an increase of Ch values relative to PL 
amount in LA and presence of lipid peroxidation in LA. These findings are consistent 
with similar results previously obtained in our laboratory (Chapter 1) and other 
studies using ex vivo models (294, 297). However, PS from rHV group had an 
opposite outcome. We observed adequate biophysical dynamic properties and 
optimum levels of PS-associated proteins, Ch and absence of peroxidation in this 
group.  
Interestingly, both injuriously MV groups had in common an increase of total PS 
release into the alveolar space. Previous studies, including ours, have demonstrated 
that high VT ventilation increased PS secretion (Chapter 1) (296). However, while 
rHV group had significantly increased the LA pool without changes in SA, sHV 
group has the opposite pattern. Therefore injurious MV induced PS release into the 
alveolar space but depending on animal susceptibility may be rapidly altered probably 
due to the exacerbated inflammatory status in the alveolar space or may remain stable 
probably helping to ensure the attenuated response to injurious MV. As a result, a 
proper maintenance of PS against VILI may contribute to attenuate immune 
responses, as some studies reported immuno-modulator properties of PS PL (88, 148) 
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as well as maintain the alveolar barrier integrity. 
In fact, it is worth highlighting that PS alterations contributing to edema presence 
provokes a vicious circle of surfactant inactivation as several plasma-derived proteins 
are able to even compete with PS for reaching the air-liquid interface (6) or directly 
binding to it. In this research we have detected protein contamination in LA in sHV 
group as well as a significant increase of CRP, an acute-phase protein that inhibits PS 
functionality by binding to it (Chapter 1) (333).  
To summarize, we demonstrated that injurious MV could develop two different 
outcomes according to the animal susceptibility. The main factor that seems to 
contribute to protect the lung against injurious MV is an attenuated inflammatory 
response where IL-6 seems to play a key role. As a result, lack of edema, tissue injury 
or PS alterations are the main characteristic factors of this resistant outcome against 
VILI. Interestingly, our data indicated that VILI occurred only in animal models when 
surfactant is inactivated. Therefore, these results show that there is a direct link 
between pronounced proinflammatory response and surfactant inactivation. 
Consequently, we suggest that the best approach for early intervention, prior to 
exposition to mechanical ventilation, would be the administration of antiinflammatory 
agents. Given the beneficial effects of high surfactant secretion in survival animals 
exposed to high VT, surfactant-like nanoliposomes could be useful as carriers for 
delivering antiinflammatory agents to the alveolar spaces. Surfactant-like vesicles 
used as a vehicle could ensure drug contact with the alveolar spaces and could 
increase the potency of anti-inflammatory agents on alveolar epithelial cells and 
macrophages, facilitating their entrance into the cells. At the same time, exogenous 
surfactant administration could contribute to improve pulmonary function. 
To conclude, these results depicts that an attenuated inflammatory response 
together with increasing endogenous, fully active, lung surfactant into the alveolar 
space prevents edema and a worsened outcome to high-stretch ventilation. 
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1. ABSTRACT 
 The aim of the present study was to elucidate the effect of prolonged 
conventional low-stretch ventilation, with or without previous exposition to injurious 
high-stretch ventilation. 
Sprague-Dawley rats were randomly assigned to control conditions (no MV), low-
stretch ventilation during 8.5 h (LV) [Tidal volume (VT) = 9 ml/kg, positive-end 
expiratory pressure (PEEP) = 5 cm H2O] or injurious ventilation [VT = 25 ml/kg, PEEP 
= 0cm H2O] during 2.5 h followed by 6 h of low stretch-ventilation (HV+LV). 
Subsequently, lung tissue, plasma, bronchoalveolar fluid (BAL), BAL cells, and 
isolated surfactant were analyzed. 
Animals subjected to prolonged low-stretch MV after high-stretch ventilation had 
two different outcomes according to their susceptibility. Susceptible animals s(HV+LV) 
had a characteristic ventilator-induced lung injury (VILI) outcome distinguish by 
surfactant alterations, proinflammatory cytokines increase in BAL, edema and 
hypoxemia (PaO2/FiO2<200 mmHg). Resistant animals r(HV+LV) were characterized 
by alterations in the alveolar capillary-barrier, an increase of neutrophils in BAL, 
increased levels of MIP-2 and ASMase activity in plasma and slight alterations in gas 
exchange. Animals exclusively subjected to low-stretch ventilation strategies developed 
inflammatory changes without histological or physiological alterations. 
To conclude conventional low-stretch ventilation length is directly related with the 
development of lung inflammation regardless of whether animals were or not previously 
exposed to high-stretch ventilation. In this context, lung surfactant alterations do not 
precede the onset of acute lung injury induced by prolonged low-stretch ventilation after 
high-stretch ventilation but its proper functioning is essential for survival.  
 
 
2. INTRODUCTION 
Numerous direct and indirect pulmonary clinical factors contribute to develop acute 
lung injury (ALI) hampering the assessment of its remarkable incidence (173). Despite 
of the etiological variability of this syndrome, its mortality rates has successfully 
decreased over the last two decades (173). The main factor contributing to this 
decrement is the improvement of mechanical ventilation strategies (MV). In fact, MV is 
an integral part of ALI therapy, but an inappropriate application can lead to side effects, 
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called ventilator-induced lung injury (VILI) (299). To date, limiting VILI through lower 
tidal volumes (VT) is the only intervention demonstrated to reduce ALI mortality rates 
(362). However, some clinical trials have been developed to determine the possible 
effects of low VT MV parameters (363). 
Conversely, other clinical studies concluded that even applying the same MV stress 
to different patients, forces reaching to alveolar cells and their corresponding response 
are quite heterogeneous and variable (299), presuming that a personalization of the 
ventilator strategies according to the patient‟s condition will improve the outcome 
(349). 
As clinical studies provide descriptive data about the onset and evolution of ALI 
leading to hypothesize about its mechanisms of injury, animal models yield 
straightforward methods to study in depth those assumptions. 
The most frequent animal model of ALI is the application of MV (232) due to its 
clinical relevance (173).As a result, several harmful protocols characterized by the 
application of high VT, high peak-pressures and/or the lack of positive end-expiratory 
pressure (PEEP) have been performed to characterized VILI (7). Generally, VILI 
models are no longer ventilated than 8 h depending on ventilatory settings and support 
(206), being usual to not exceed 4 h of high VT or peak-pressures in rodents due to 
survival (206, 305, 364). These high-stretched models result in alveolar hemorrhage, 
hyaline membranes formation, neutrophilic infiltration, decreased compliance and gas-
exchange abnormalities (232). Interestingly, a previous study in our laboratory 
described two different outcomes to the same injurious MV strategy, highlighting the 
existence of variability in stress susceptibility to MV in animal models (Chapter 2). 
Conversely, some experimental models recently studied the possible adverse effects of 
low VT ventilation (286). Indeed, even there are many studies concerning the 
application of protective MV combined with other insults (365), little research has been 
performed related to the possible effects of protective MV after the induction of lung 
injury, specifically VILI (206). 
Therefore, the aim of the present study was to characterize the effect of prolonged 
low VT MV and specifically in animals resistant to previous application of injurious 
MV. To accomplish this objective, we established a rodent model of low or high VT MV 
during 2.5 h followed by 6 more hours of low VT MV to characterize the physiological, 
inflammatory and pulmonary surfactant changes in the lung. 
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3. EXPERIMENTAL PROTOCOL  
Male Sprague-Dawley rats were randomly distributed in the following groups: 
 Control group (n=5): animals undergoing identical anesthetic and surgical 
procedures than the other groups but without applying MV.  
 Low-stretched group during 8.5 h. (LV) (n=7): animals subjected to protective 
MV parameters during 2.5 h followed by 6 more hours under this ventilation 
protocol until their sacrifice.  
 High-stretched group during 8.5 h. (HV+LV) (n=10): animals subjected to 
injurious MV parameters during 2.5 h followed by 6 more hours applying 
protective MV until their sacrifice. Interestingly, some of the animals subjected 
to this MV protocol did not survive to the 6 h of protective MV. As a result, we 
obtained two groups: animals that finished the experimental protocol 
[r(HV+LV), n=7] and animals that did not reached the 8.5 h of MV [s(HV+LV), 
n=3]. 
 
 
Figure 1: Experimental design. Representation of all groups established for the study 
subdivided according to the mechanical ventilation strategies. 
Experimental design
Control (C): non-ventilated rats; n=5.
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t: 0 h
HV + LV
n=10 Settling time
30 min
VT=25 ml/kg  
0 PEEP
Dead
s(HV + LV) 
n=3
r(HV + LV)
n=7
VT=9 ml/kg, 5 cmH2O PEEP
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 In all ventilated groups, respiratory rate was 70 bpm, inspiratory time 0.35 sec., 
expiratory time 0.56 sec. and FiO2 0.35. Animals were ventilated for an equilibration 
period of 30 min using the low VT ventilation parameters. Then, the assigned VT was 
administered starting at t=0 min.  
Hemodynamic and ventilatory parameters were registered at t=0 min, t=2.5 h and 
t=8.5 h. Blood samples were collected at the beginning and end of the ventilatory 
procedure to gases analysis. 
Animals were sacrificed by exsanguination after the established ventilatory period 
and subsequently we proceeded to sampling. We obtained lung tissue and 
bronchoalveola rlavage that it was separated from the alveolar fluid cells by 
centrifugation. The remaining bronchoalveolar lavage free of cells (BAL) was 
processed to obtain pulmonary surfactant (PS). 
 
 
4. RESULTS 
4.1. Alterations under long exposure to MV 
4.1.1. Physiology 
Lung function [peak inspiratory pressure (PIP) and respiratory system compliance 
(CRS)] were significantly altered in s(HV+LV) group in contrast with r(HV+LV) group 
just starting injurious MV as depicts Figure 2.  
Figure 2: Changes during the ventilator period in peak inspiratory pressure (PIP) and 
respiratory system compliance (CRS) in rats ventilated with Low or High tidal 
volumes.  
PIP and CRS were measured at baseline, start and after 2.5 and 8.5 hours of mechanical 
ventilation according to the experimental protocol requirements.  
Data represent mean ± S.E.M. *p<0.05 and **p<0.01 vs. r(HV+LV) group. 
 
PIP
Basal
c
m
 H
2
O
0
10
20
30
40 LV 
r(HV+LV) 
s(HV+LV) 
0 h 2.5 h 8.5 h
MV time
*
*
*
Compliance
Basal
m
L
/c
m
 H
2
O
0,0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
LV 
r(HV+LV) 
s (HV+LV)
0 h 2.5 h 8.5 h
MV time
*
**
*
  
Chapter 3  159 
 
As well, mean arterial pressure (MAP) and arterial partial pressure of oxygen 
(PaO2)-to-fractional inspired oxygen (FiO2) ratio were significantly decreased at 8.5 h in 
s(HV+LV) group together with a significant increased of arterial partial pressure of  
carbon dioxide (PaCO2) in this group (Figure 3). Interestingly, PaO2/FiO2 ratio was also 
slightly decreased in r(HV+LV) group, without reaching the damaging values fixed by 
the ARDSnet (2). 
These data suggest alterations in gas exchange and atelectasis in s(HV+LV). 
 
 
 
Figure 3: Changes during the mechanical ventilation (MV) period in hemodynamic 
variables in rats ventilated groups with Low or High tidal volumes.  
a) Mean arterial pressure (MAP) was measured at baseline, start and after 2.5 and 8.5 hours of 
MV. b) Arterial partial pressure of oxygen (PaO2)-to-fractional inspired oxygen (FiO2) ratio 
values were assessed before and after 2.5 and 8.5 hours of MV. c) Arterial partial pressure of 
carbon dioxide (PaCO2) was evaluated before and after 2.5 and 8.5 hours of MV. 
Data represent mean ± S.E.M. *p<0.05 vs. Control and*** p<0.001 vs. all groups. 
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4.1.2. Alveolar injury 
Changes in the alveolar space due to long exposure to MV were characterized 
evaluating presence of edema and alveolar fluid cells alterations as well as assessing the 
histological score and damage markers levels.  
4.1.2.1. Intra-alveolar edema and histological injury score 
Histological score revealed significant alterations in s(HV+LV) group whereas 
edema presence, represented as total amount of proteins in BAL, had an increasing 
trend in both HV groups, being significant in s(HV+LV) group (Figure 4). 
 
4.1.2.2. Alveolar fluid cells  
Total cell counts in BAL presented a decreasing trend when prolonged MV is 
applied. In particular, cell counts significantly decreased in s(HV+LV) group (Figure 
5a, left panel). In addition, the proportion of alveolar macrophages significantly 
decreased in all HV groups. Interestingly, only neutrophils proportion was significantly 
raised in r(HV+LV) group though there was an increasing trend in all prolonged MV 
groups (Figure 5b, right panel), suggesting that prolonged protective MV may promote 
Figure 4:  Alveolar injury in the different experimental groups.  
a) Edema presence was measured as total protein content in bronchoalveolar fluid.           
b) Histological score was assessed by hematoxylin-eosin staining of isolated and fixated 
left lungs of all groups.  
 Data represent mean ± S.E.M. *p<0.05 vs. Control and ***p<0.001 vs. all groups. 
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neutrophils infiltration in the alveolar space together with alveolar macrophages 
decrement.  
Hence, MV may change alveolar fluid cells profile as depict the representative 
flow cytometric side scatter (SSC, relative complexity)/forward scatter (FSC, relative 
size) dot plots from all experimental groups (Figure 5b). 
Figure 5: Alveolar fluid cells profile in all experimental groups.  
a) Left panel represents total cell counts recovered in BALdetermined by assessing cell 
viability with trypan blue dye exclusion. Data represent mean ± S.E.M. *p<0.05 vs. Control. 
Right panel depicts the proportion of alveolar macrophages and neutrophils in BAL fluid 
determined by fluorescence flow cytometry assays using specific monoclonal antibodies 
(anti-CD11c for alveolar macrophages and anti-RP-1 for blood neutrophils). Data represent 
mean ± S.E.M. *p<0.05 vs. Control of neutrophils. 
#
p<0.05 and 
##
p<0.01 vs. Control of 
alveolar macrophages. 
b) Representative side scatter (SSC)/forward scatter (FSC) dot plots of the flow cytometric 
profile of total alveolar fluid cells from all groups of study.  
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4.1.2.3. Damage markers 
We determined the presence of the inflammatory cytokines TNF-α, IL-6, MIP-2 
and MCP-1 in BAL (Figure 6a) and plasma (Figure 6b). In addition, we studied the acid 
sphingomyelinase (ASMase) activity in these fluids as well as its RNA levels in lung 
tissue (Figure 7).  
Cytokines results indicated an exacerbated increase of all the cytokines studied in 
BAL in s(HV+LV) group. Furthermore, we observed a significant increase of IL-6 and 
MIP-2 levels in plasma in this group while TNF-α was undetectable in all groups and 
MCP-1 plasma levels did not change among groups (data not shown). It is worth noting 
that we observed a significant increase of MIP-2 levels in BAL and plasma of 
r(HV+LV) group, chemokine tightly related with neutrophils recruitment. Interestingly, 
we also observed changes in the low-stretched group. Specifically, we detected a 
significant increase of MIP-2 and IL-6 levels in BAL. Moreover, we observed an 
increase of IL-6 levels in plasma in LV group and also in r(HV+LV) group. 
These data suggest an activation of inflammatory processes under prolonged MV 
even under protective strategies.  
According to the results related to ASMase activity, we did not observe changes 
among groups in BAL, whose values were lower than those obtained in plasma. 
Conversely, we detected a significant increase of this enzymatic activity in plasma 
together with a significant increase of its RNA expression in lung tissue in r(HV+LV) 
group. These data let us to speculate that prolonged conventional MV after high-stretch 
MV up-regulates ASMase production and release to the bloodstream and therefore 
activating ASMase-derived ceramide pathway a promoter of several routes leading to 
ALI (332).  
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Figure 6: Inflammatory cytokines detected in all the experimental groups. 
All cytokines were measured in BAL and plasma by colorimetric rat ELISA kits following 
the instructions provided by the supplier. TNF-α levels in plasma were undetectable and 
MCP-1 levels in plasma did not changed among groups (data not shown). 
Data represent mean ± S.E.M. *p<0.05 and **p<0.01 vs. Control; ***p<0.001 vs. all 
groups. 
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4.1.3. Pulmonary surfactant analysis 
 Pulmonary surfactant (PS) is comprised of 90% lipids, predominantly 
phospholipids (PL), and 10% of proteins, mainly the PS-associated proteins: SP-A, SP-
B, SP-C and SP-D. PS is secreted into the alveolar space by alveolar type II cells (ATII) 
as high-organized lipoprotein structures capable of establishing a surface film that 
stabilize the alveoli by the reduction of the surface tension at the air-liquid interface. 
This function is accomplished by PS large aggregates (LA), which may be transformed 
to a non-functional fraction, called small aggregates (SA), due to compression and 
expansion movements during respiration (314). Under pathological situations, LA to SA 
conversion is altered, being the SA/LA ratio increase a damage marker of VILI.  
Therefore, we assessed PS biophysical function as well as presence of protein 
contamination in LA which is considered a potential inhibitor of PS functionality (296). 
Also, we evaluated possible alterations in LA to SA conversion and determined PS-
associated protein levels in LA (Figure 8).  
Pulmonary surfactant biophysical function was determined performing an 
interfacial adsorption assay. The ability of LA to adsorb onto and spread at the air–
water interface was measured using a Wilhelmy-like high-sensitive surface 
microbalance, coupled to a teflon dish of very small size by following the variation in 
Figure 7: Acid sphingomyelinase activity in BAL and plasma and its RNA expression 
in lung tissue of all experimental groups. 
a) RNA expression of ASMase was detected using total RNA isolated from the lower lobe 
of the right lung. cDNA synthesis was performed using 1µg total RNA as input and it was 
amplified by RT-PCR using specific primers. Results were analyzed using ΔΔCT method 
and expressed as normalized fold expression. b and c) ASMase activity in BAL and 
plasma measured performing an enzymatic assay. ASMase activity values in BAL were 
similar between groups and smaller than the values observed in plasma. 
Data represent mean ± S.E.M.*p<0.05 and ** p<0.01 vs. Control. 
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surface pressure as a function of time, as previously described (322). This ability is 
significantly impaired in s(HV+LV) group at 30 min as represents figure 8a. 
Accordingly, we observed a significant increase of SA/LA ratio in s(HV+LV) 
group, indicating alterations in PS conversion probably due to the alterations detected in 
the alveolar space (Figure 8b). Specifically, we observed protein contamination in the 
active fraction of s(HV+LV) group (Figure d) which may alter PS function. Also, the 
variation on PS-associated proteins levels might be considered as another marker of 
alveolar alterations due to injurious MV that directly affects PS (Chapter 1 and 2). As a 
result, we observed no difference among groups of SP-A protein levels in LA (data not 
shown). Conversely, we observed a significant decrease of SP-B and SP-C levels in 
s(HV+LV) group. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Pulmonary surfactant alterations due to prolonged mechanical ventilation. 
a) Surfactant interfacial adsorption was determined in all groups of study in a Wilhelmy-
like high-sensitive surface microbalance by following the variation in surface pressure as a 
function of time. Interfacial adsorption was impaired in s(HV+LV) group. b) LA to SA 
conversion as the ratio of PL content between SA and LA of all experimental groups. This 
ratio significantly increased in s(HV+LV) group. c) Pulmonary surfactant-associated 
proteinswere detected by Western blot analysis (WB) in LA samples. Proteins 
quantification was achieved by densitometric evaluation of the bands obtained in WB. SP-
B and SP-C levels significantly decreased in s(HV+LV) group.  d) Total protein to PL 
ratio in LA was assessed in all groups of study. This ratio significantly increased in 
s(HV+LV) group.  
Data represent mean ± S.E.M. * p<0.05, **p<0.01 and ***p<0.001 vs. Control. 
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4.2. Comparison between short and long exposure to MV under the same 
ventilation strategy. 
In order to discern possible factors attributable to longer exposure to MV under 
conventional parameters we compared these data with the results obtained from the 
resistant groups to high-stretch MV studied in Chapter 2 (Table 1). As well, we assessed 
neutrophils proportion in BAL of n=5 rats per group under short strategies used in 
Chapter 2 to compare neutrophil infiltration values between short and long exposures to 
MV (Table 1). Furthermore, we also studied gene expression in lung tissue of factors 
usually observed in a later-stage of ALI such transforming growth beta (TGF-β) and 
matrix metalloproteinase-2 (MMP-2) in short and long-ventilated rats under both MV 
strategies (Figure 9). 
Interestingly, in Table 1 we observed differences between HV groups but also 
among LV groups, suggesting that prolonged MV even under conventional strategies 
lead changes in the alveolar space. Specifically, we observed a significant increase of 
neutrophils percentage in the alveolar fluid along with a significant increase of 
chemokines (MCP-1 and MIP-2) and IL-6 in BAL in prolonged conventional 
mechanical ventilated animals in contrast with the short low-stretched group. Also we 
observed a significant increase of IL-6 in plasma in the prolonged low-stretched group. 
However, SP-A protein levels significantly decreased in the prolonged low-stretched 
group in contrast with the short LV group. 
On the other hand, rHV and r(HV+LV) differed in almost all variables represented 
in Table 1. In particular, r(HV+LV) group was characterized by an increase of edema 
presence, neutrophils percentage and MIP-2 and IL-6 levels in plasma in contrast with 
rHV group. Conversely, the levels of the early inducible pleiotropic cytokines involved 
in acute inflammatory responses TNF-α and IL-6 (331, 353) were significantly decrease 
in BAL of r(HV+LV) group in contrast with rHV. However, MCP-1 and MIP-2 levels, 
chemokines involved in the attraction of leukocytes like monocytes, lymphocytes or 
neutrophils (355, 366, 367) were similar among rHV and r(HV+LV) groups and higher 
than in control group. Interestingly, rHV had a significant increase in PS secretion 
levels and SP-A protein levels. 
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We also analyze TGF-β and MMP-2 gene expression in lung tissue from all the 
experimental groups of this Chapter and Chapter 2.  
TGF-β1 RNA expression levels revealed a significant increase of its expression in 
r(HV+LV) group. On the other hand, Matrix metalloproteinase 2 (MMP-2) is a zinc-
dependent endopeptidase that degrades several components of the extracellular matrix 
Table 1:  Differences between resistant animals subjected to short (2.5h) or long 
exposure (2.5h + 6h) to mechanical ventilation (MV) under conventional (Low tidal 
volume [VT]) or injurious (High VT) MV strategies. 
 
Definition of abbreviation: BAL: bronchoalveolar lavage; TNF-α: Tumor necrosis factor alpha; 
IL-6: Interleukin 6; MIP-2: macrophage inflammatory protein 2; MCP-1: monocyte chemotactic 
protein 1. PS: pulmonary surfactant; SP-A: pulmonary surfactant-associated protein A; WB: 
western blot.  
All factors were measured at the end of the ventilator period. Data are mean ± S.E.M; A two-
tailed unpaired Student T-test was performed between groups of the same mechanical 
ventilation strategy. * p<0.05, **p<0.01 and p<0.001 vs. LV; 
#
p<0.05 and 
##
p<0.01 vs. HV. 
Variables 
 Groups 
Control 
Low VT MV Resistant to High VT MV 
2.5h 2.5h + 6h 2.5h 
2.5h + 6h 
(Low VT) 
Edema 
(BAL 
protein) 
11.91±1.57 9.2±0.83 10.19±1.04 11.65±1.51 36.6±9.8
#
 
% 
Neutrophils 
in BAL 
2.65± 0.43 3.24±0.87 7.53±1.3* 3.65±0.73 9.74±2.39
#
 
TNF-α 
(BAL) 
0.7±0.46 1.15±0.75 1.58±0.92 9.3±2.4
#
 2.65±1.17 
IL-6 (BAL) 93.1±11.88 40.64± 4.04 136.9±6.4*** 130.7±5.7
##
 89.58±8.75 
MIP-2 
(BAL) 
22.28±4.05 32.5±6.5 137.55±26.58** 147.55±36.69 147.55±32.82 
MCP-1 
(BAL) 
68.38±12.49 18.35±3.24 148.37±34.39* 126.99±24.28 92.75±28.71 
IL-6 
(Plasma) 
29.12±5.98 40.5±2.3 59.975±7.575* 43.73±0.48 56.3±4.75
#
 
MIP-2 
(Plasma) 
10.04±1.58 8.1±2.1 8.78±1.33 13.66±1.82 25.27±3.09
#
 
PS 
secretion 
4.03±0.04 2.66±0.44 2.9±0.6 7.34±0.66
#
 4.58±0.73 
SP-A (WB 
band 
intensity) 
100% 174.07±9.83*** 79.74±3.56 185.73±26.95
#
 86.58±9.01 
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(ECM), including type IV collagen and laminin (368). Our data indicated that MMP-2 
RNA expression overcame a significant decrease in all HV groups and long-exposure 
animals to conventional MV. 
 
 
5. DISCUSSION 
This study highlights that prolonged low-stretch MV usually applied in clinic, has 
effects not as harmless as could be expected. Thus, animals ventilated under the same 
low-stretch MV strategy during all the experimentdeveloped an inflammatory status in 
the alveolar space. However, animals subjected to previous high-stretch MV having a 
resistant outcome before prolonged low-stretch MV developed two different responses 
according to their resistance. 
In line with the results previously obtained in our laboratory (Chapter 1 & 2), we 
observed that MV decreased total alveolar cells counts, being significantly decreased in 
s(HV+LV) group. Suitably, alveolar macrophages proportion had also a decreasing 
trend in all MV groups being significant in HV+LV groups. Interestingly, we also 
detected an increasing trend in neutrophils percentage in MV groups, being significant 
Figure 7: RNA expression of TGF-β and MMP-2 in lung tissue of animals exposed to 
short or long exposure to MV under conventional or injurious strategies.  
RNA expression of TGF-β and MMP-2 was detected using total RNA isolated from the 
lower lobe of the right lung. cDNA synthesis was performed using 1µg total RNA as input 
and it was amplified by qPCR using specific primers. Results were analyzed using ΔΔCT 
method and expressed as normalized fold expression. Data represent mean ± S.E.M. * 
p<0.05 and **p<0.001 vs. Control. 
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in r(HV+LV) group. These data suggest that prolonged MV lead changes in the alveolar 
fluid cells profile, due to neutrophils infiltration and macrophages decrease, as depicts 
the side scatter/ forward scatter dot plot profile obtained by flow cytometry 
measurements of alveolar fluid cells from all experimental groups. It is noteworthy that 
the animals subjected to low or high MV strategies during 2.5 h had significantly lower 
levels of neutrophils than prolonged MV groups suggesting that prolonged MV may 
promote neutrophils infiltration in the alveolar space. 
Furthermore, we studied the presence of MIP-2, also named CXCL-2, which is the 
most relevant chemokine for neutrophil recruitment into the lung of rodents (369) and 
its elevated expression exclusively in the alveolar compartment paralleled neutrophil 
sequestration in VILI (367). Accordingly, we observed a significant increase of MIP-2 
levels in BAL of all prolonged MV groups. Interestingly, this MIP-2 levels were similar 
to those observed in the group resistant to 2.5 h of injurious MV studied in Chapter 2 
[r(HV)]. Therefore, these data support the hypothesis that prolonged MV may induce 
neutrophil recruitment into the alveolar space, being an important factor the over-
expression of MIP-2 in the alveolar compartment that may begin at early stages under 
injurious MV. In fact, some studies suggested that short ventilator strategies applied in 
small animals did not allow a massive recruitment (235). Nevertheless, our prolonged 
MV model permits to assess the evolution of neutrophils recruitment to the alveolar 
space.  
Interestingly we also assessed a significant increase of MIP-2 levels in plasma only 
in HV+LV groups, suggesting that this rising values might be considered as possible 
damage biomarkers. Probably this increase might be related with the alveolar-capillary 
barrier alterations observed in these groups without rejecting the possibility of MIP-2 
release by other cells susceptible to the mechanical stress generated by this MV 
strategy. 
Alveolar-capillary barrier alterations were assessed measuring total protein content 
in BAL of all groups, detecting a significant increase in both HV+LV groups.  
Moreover, we observed presence of histological injury in both HV+LV groups being 
significant in s(HV+LV) group. Conversely, we did not find a trail of histological 
alterations or edema in LV group. Furthermore, the histological score values of 
r(HV+LV) were similar to the values obtained in rHV group but total protein levels 
differed due to a significant increase in r(HV+LV) group. Consequently, these data let 
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us to speculate that prolonged MV after high-stretch MV promotes alterations in the 
alveolar-capillary barrier. 
As previous studies related neutrophils increment with hyaline membranes 
deposition (264), basement membrane destruction and increased permeability of the 
alveolar–capillary barrier (173, 206), we suspect that one of the main contributors to 
these alterations in our HV+LV groups is neutrophils infiltration, being the increased 
MIP-2 levels in plasma a good biomarker to realize it. 
However, many other factors modulating inflammatory responses contribute to 
explain their different outcomes.  
Specifically, we observed an exacerbated proinflammatory status in the alveolar 
space of s(HV+LV) group characterized by a significant increase of all cytokines 
measured in BAL. However, r(HV+LV) group had only increased MIP-2 as previously 
described. Furthermore, we observed that rHV had significantly increased TNF-and 
IL-6 values in BAL in contrast with r(HV+LV) group explained by the fact that there 
are considered early inducible proinflammatory cytokines involved in acute 
inflammatory responses (331, 353). Conversely, we observed a significant increase of 
IL-6 in LV group together with a significant increase of this pleiotropic cytokine in 
plasma of all prolonged MV groups. 
IL-6 is defined as a resolution factor that balances pro- and anti-inflammatory 
outcomes to further the immunological response (213), suggesting a complex role for 
IL-6 in lung injury (370). However, many studies reported a protective role of IL-6 by 
the attenuation of lung inflammation or pulmonary edema (353, 370). Specifically, IL-6 
limits alveolar barrier disruption and therefore edema, by reducing neutrophil contact 
with the endothelium in VILI (370). These data support our findings, suggesting that an 
increase of IL-6 in BAL may protect the alveolar space against alterations in the 
alveolar-capillary barrier by limiting neutrophil contact with the endothelial cells in LV 
group. Conversely, the basal levels of IL-6 observed in BAL of r(HV+LV) group may 
not be enough to protect the alveolar-capillary barrier against neutrophils. Interestingly, 
we observed a significant increase of IL-6 levels in plasma of all prolonged MV groups. 
A wide range of cells besides cells from the alveolar compartment, including 
fibroblasts, vascular endothelial and smooth muscle cells (SMC) secretes IL-6 (371). 
Moreover, some studies suggest that alveolar SMC secreted IL-6 under certain 
proinflammatory stimuli (372) and others detected that vascular endothelial and SMC 
cells induced IL-6 expression under mechanical stress (373, 374). Therefore, we dare to 
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speculate that prolonged MV might promote IL-6 release to the bloodstream by cells 
closely related to the alveolar space suffering the mechanical stress. 
Nevertheless, we have also reported other factors that may contribute to the 
alteration of the alveolar-capillary barrier in r(HV+LV) group. Specifically, we detected 
a significant increase of RNA expression of ASMase in lung tissue along with a 
significant increase of its activity in plasma of r(HV+LV) group. ASMase is mainly 
released by alveolar endothelial cells and has two subtypes, lysosomal and secretory 
ASMase both derived from the same gene (SMPD1) (332).  As we observed that 
prolonged MV tend to stimulate ASMase RNA expression, only r(HV+LV) group had a 
significant detection of its action exclusively in plasma while there is an absence of 
ASMase activity increase either in BAL or plasma of the rest of groups. These results 
suggest a secretory ASMase translation in r(HV+LV) group to the bloodstream. 
Interestingly, secretory ASMase activity-derived ceramide is involved in alter vascular 
permeability and promote edema formation when this enzyme is increased in plasma in 
models of ALI (336). These data suggest that an increase of ASMase activity in plasma 
may contribute to alter the alveolar-capillary barrier in r(HV+LV) group and might be 
considered as possible damage biomarker of VILI. 
On the other hand, it has been reported that an increase of TGF-ß1 gene expression 
levels contributes to develop alveolar flooding in a model of bleomycin-induced lung 
injury as well as is intimately related with an increase of ECM deposition in VILI (309, 
375, 376). However, TGF-ß1 has a complex and critical role at late phases of ALI 
leading to antagonistic outcomes due to the activation of different effector pathways 
according to the presence of other stimuli in the alveolar space and the state of the target 
cells (377). Thus, some studies reported that TGF-ß1 has an important antiinflammatory 
and fibrotic effect inducing wound repair though other investigations concluded that 
TGF-ß1 has a proinflammatory effect, promoting fibrogenesis and consequently 
underlying the progression of tissue injury and fibrosis (376-378). Therefore, TGF-ß1 
transcriptional responses seem to be involved in both inflammatory and proliferative 
phases of ALI (378). Interestingly, we observed a significant increase of TGF-ß1 RNA 
expression in lung tissue of r(HV+LV) group. This result suggests a possible 
implication of TGF-ß1 in alveolar-capillary barrier alterations as well as a possible role 
in the absence of hyaline membranes resolution, indicating a possible fibroproliferative 
stage at the proliferative phase. Thus, future studies with prolonged MV periods may 
elucidate this possibility. 
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Many studies related the increase of the active presence of MMP-2 with acute 
inflammation and fibrosis development in ALI and pulmonary fibrosis (379, 380). 
Conversely, others described that MMP-2 active presence is a key factor of injury repair 
and its inhibition seems to impair repair processes (206, 381). In this study we observed 
a strong decrease of MMP-2 RNA levels in lung tissue observed in HV groups. As 
some previous studies using models of mechanical stretch observed a significant 
increase of MMP-2 levels in vitro (382) and in vivo (308, 379), a recent two-hit model 
in vivo, detected a MMP-2 gene expression decrement after 8 h of MV (383). These 
data suggest that MMP-2 RNA strong inhibition due to high MV contributes to 
alterations in the alveolar space. However, though structural cells including fibroblasts, 
endothelial and alveolar epithelial cells mainly secrete MMP-2, we cannot reject the 
possibility of its release by leukocytes or even the release of other MMPs. Importantly, 
an in vitro study observed that MMP-2 up-regulation by TGF-ß1 resulted in injury 
repair (381). As we observed TGF-ß1 gene expression increment in r(HV+LV) group 
we could speculate about possible up-regulation of MMP-2 in later phases. Therefore, 
further investigation must be done in order to elucidate the pathway that leads to MMP-
2 inhibition as well as its contribution over time. 
Previous studies in our laboratory observed that HV induced a significant secretion 
of PS to the alveolar space (Chapters 1 and 2). Interestingly, rHV groups observed in 
Chapter 2 had increased the active fraction of PS together with a significant increase of 
SP-A protein levels in contrast with r(HV+LV) group which reached basal levels. SP-A 
prevents the inhibition of PS by binding proteins (384), is involved in control PS 
secretion and reuptake by alveolar cells and also contributes to maintain LA forms 
during surface-area cycling by stabilizing tubular myelin and multilamellar structures, 
avoiding LA to SA conversion (314, 385, 386). Therefore, SP-A may play a critical role 
in PS homeostasis in resistant HV groups at short times that it is loss during prolonged 
MV. Despite we did not found any trail of PS alterations in r(HV+LV) group, we 
reported that s(HV+LV) had impaired PS functionality together with alterations in LA 
to SA conversion (SA/LA ratio), total protein contamination in LA and significant 
decrease of the hydrophobic peptides SP-B and SP-C. As previous studies in our 
laboratory observed that animals susceptible to HV had associated PS alterations 
(Chapters 1 & 2), we hypothesize that PS alterations are closely linked with an 
exacerbated inflammatory status in the alveolar space of animals developing VILI. 
Therefore, these data suggest that PS impairment is a damage marker of VILI.  
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In fact, PS functional alteration by increasing surface tension at the air-liquid 
interface in the alveoli is associated with alterations in the gradient pressures across 
alveolar-capillary barrier, pulmonary compliance decrease, atelectasis and hypoxemia 
(9, 298), as we also observed in s(HV+LV) group. 
Furthermore, previous studies in our laboratory observed a relation between PIP 
increment values and susceptibility to injurious MV, suggesting PIP as an early marker 
of VILI (Chapter 2). Our results are consistent with these previous observations as 
s(HV+LV) group significantly increased PIP values in contrast with r(HV+LV) group at 
the beginning and during the high-stretch strategy setup. Furthermore after the 
settlement of LV strategy, PIP values remained significantly higher in s(HV+LV) 
groups while r(HV+LV) PIP values reached LV group values. Accordingly to these 
results and taking into account that many studies reported that ventilation with elevated 
PIP promotes edema (235), we hypothesize that PIP values under high VT strategies 
might be an early marker of susceptibility to develop VILI. 
To summarize prolonged low-stretch MV led changes in the alveolar space that 
differed accordingly to the ventilation strategy applied. An exclusively prolonged low-
stretch ventilation strategy develops inflammatory changes that do not impact on 
histological or physiological parameters. However, if prolonged low-stretch MV is 
applied after high-stretch ventilation, we observed two different outcomes according to 
their susceptibility. As a result, susceptible animals develop VILI characterized by PS 
alterations, inflammatory exacerbation, edema and hypoxemia. Conversely, resistant 
animals reveal alterations in the alveolar-capillary barrier together with neutrophils 
infiltration, increased levels of MIP-2 and ASMase activity in plasma and slight 
alterations in gas exchange.  
Consequently, these data suggest that long exposure to low-stretch MV is directly 
related with the development of inflammatory responses in animals previously 
subjected to high-stretch mechanical ventilation or not. Furthermore, these results allow 
us to conclude that adequate pulmonary surfactant functioning is essential for survival 
of rats exposed to injurious and/or prolonged non-injurious mechanical ventilation and 
its impairment does not precede the onset of acute lung injury in this model. 
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The main objective of this thesis was to address the impact of mechanical 
ventilation in the alveolar space and in particular the effects on the pulmonary surfactant 
system. The thesis employed a translational animal model that permits investigation of 
mechanical ventilation effects using different biochemical, biophysical, immunological, 
cellular, and physiological techniques. As a result, we obtained significant data that 
support the suggestion that proper functioning of pulmonary surfactant is essential for 
the survival of animals exposed to high-stretch ventilation.  
As is currently known, the development of ALI is due to multiple closely linked 
factors, which hinders prognosis and diagnosis (173). This difficulty is transferred to 
animal models where the variety of damage-inducing factors combines with the 
assortment of animal and experimental designs to increase complexity (256, 350). Thus, 
in 2010 an ATS Official Committee established the main features that characterize ALI 
animal models (4). These features include histological evidence of tissue injury, 
alteration of the alveolar-capillary barrier, presence of inflammatory responses, and 
evidence of physiological dysfunction. 
This thesis employed an animal model of VILI (10) due to its clinical relevance, as 
MV is currently the only effective treatment for ALI (173). Accordingly, a model of 
VILI using high tidal volumes (VT=25 ml/kg) and absence of positive end-expiratory 
pressure application was established, as our aim was to provoke alveolar alterations. 
Moreover, we also used a ventilator strategy characterized by the application of 
moderated tidal volume and positive end-expiratory pressure (VT=9 ml/kg, PEEP=5 cm 
H2O) because this is a conventional strategy widely applied in critical care units. 
The first chapter of this thesis reported that our VILI model fulfilled all the 
requirements established by the ATS Official Committee (4). In particular we observed 
a significant decrease of arterial oxygen tension/inspiratory oxygen fraction ratio 
(PaO2/FiO2< 300 mmHg), histological evidences of tissue injury, an increase of 
inflammatory markers such as TNF- and acidic sphingomyelinase activity together 
with increased levels of protein carbonyls in BAL and leakage of plasma proteins into 
the alveoli. Besides, we also determined alterations in the composition and functionality 
of pulmonary surfactant. In particular, we observed a marked decrease in levels of 
surfactant apolipoproteins (SP-A, SP-B, and SP-C) and reduced expression of these 
proteins by lung tissue. Furthermore, we observed that even though high-stretch 
ventilation stimulated surfactant secretion by type II cells, surfactant was rapidly 
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inactivated. This inactivation can emerge due to presence of lipid peroxidation of 
surfactant membranes, low content of surfactant apolipoproteins, and increased levels of 
surfactant inhibitors such as C reactive protein (CRP) that insert into surfactant 
membranes and critically affect surfactant physical properties (1). 
Consequently, these results showed that injurious high-stretch ventilation produces 
direct damage to the lung, promoting inflammation, oxidative stress, leakage of plasma 
proteins into the alveolar space, and release of factors that altogether contributes to 
inactivate lung surfactant.  
However, during the previous study we realized that a small number of animals 
subjected to high-stretch ventilation did not show evidence of physiological lung 
dysfunction. Interestingly, prior to this study, Nin and co-workers also observed rats 
resistant to injurious high-stretch ventilation (305). In light of all this information we 
hypothesized that experimental animals facing the same stress may have heterogeneous 
outcomes, as clinical patients have been observed to have different responses to the 
same mechanical ventilation strategy (299, 349).  
Hence, the aim of the next chapter was to identify factors involved in the resistance 
outcome to ventilator-induced lung injury. To this end, we designed an experimental 
model applying an endpoint criterion defined by the sacrifice of those animals with 
mean arterial pressure values below 50 mmHg at 60 min, as these values are 
incompatible with life in the short term. This criterion permitted us to establish two 
different groups differentiated not only by hemodynamic and ventilatory values but also 
by different alveolar alteration profiles. 
As a result, in the second chapter, we observed that high-stretch ventilation 
induced a susceptible and a resistant response. The susceptible response corresponded 
to the damage profile observed in chapter 1. In particular, we observed that injurious 
high-stretch ventilation induced exacerbated inflammatory response together with 
alterations in the alveolar epithelial cells. On the other hand, even though the secretion 
of pulmonary surfactant increased by high-stretch ventilation, the exacerbated 
inflammatory response provokes surfactant inactivation, hindering the possibility of 
fresh-active pulmonary surfactant replacement in the air-liquid interface. Consequently, 
surface tension at the air-liquid interface increases, resulting in edema, hypoxemia, and 
death. 
  
General Discussion  179 
On the other hand, the animals resistant to injurious high-stretch ventilation 
increased the secretion of fresh pulmonary surfactant. However, pulmonary surfactant 
from these resistant rats had normal protein and lipid composition, absence of lipid 
peroxides and accomplished its biophysical, functions appropriately. As well, we 
observed an attenuated proinflammatory response, indicated by increased levels of IL-6 
but reduced levels of TNF-α, MCP-1, and MIP-2 and absence of acidic 
sphingomyelinase activity in BAL. All together may contribute to the absence of edema 
or gas exchange alterations. Therefore, these data suggest that injurious MV could 
develop two different outcomes according to animal vulnerability. The key to their 
survival resides in their weakened inflammatory response and the good functioning of 
pulmonary surfactant, which seems to be a good damage maker as its impairment is 
intimately related to worse outcomes. 
Thus, these results suggest that there is a direct link between pronounced 
proinflammatory response and surfactant inactivation in high-stretched rats. Also, they 
reinforced our statement that correct functioning of pulmonary surfactant is essential for 
survival in high-stretch ventilated rats.  
This conclusion was further supported by the studies conducted in the third 
chapter. Given the demonstration of heterogeneous outcomes, we speculated on 
possible outcomes of the resistant group under low-stretch mechanical ventilation over 
time. This study would attempt to simulate clinical situations in which stable patients 
with pulmonary alterations would be subjected to conventional low-stretch mechanical 
ventilation.  
Unexpectedly, we observed that the maintenance of conventional low-stretch 
mechanical ventilation worsened the animal's condition. In particular, we observed that 
the animals ventilated under conventional low-stretch ventilation during prolonged 
periods of time developed an inflammatory status characterized by neutrophils 
infiltration and an increase in the concentration of pr-inflammatory cytokines in BAL 
(IL-6 and MIP-2, but not TNF-α) and plasma (IL-6).  However, the inflammatory status 
was not damaging enough to alter the epithelial cells and the pulmonary surfactant 
system.  
In addition, we discovered that animals subjected to prolonged low-stretch 
ventilation after exposition to high-stretch ventilation showed edema together with 
neutrophils infiltration and slight alterations in gas exchange, whereas before the 
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application of prolonged low-stretch ventilation there was an attenuated inflammatory 
status and absence of edema. Moreover, few animals did not survive the whole 
ventilation process and were characterized by an exacerbated inflammatory response, 
edema, alterations in pulmonary surfactant system and hypoxemia. These results were 
consistent with the damage profile defined in the other chapters. 
Therefore, the application of prolonged conventional low-stretch ventilation 
triggers mechanotransduction processes that activate different pathways according to 
the strategy applied and the vulnerability of the experimental animals to it. However, 
only the vulnerable animals had altered pulmonary surfactant system and its function. 
Consequently, these results suggested that the maintenance of conventional low-stretch 
ventilation promotes alterations in the alveolar space, corroborated the existence of 
different outcomes depending on vulnerability to mechanical ventilation, and 
strengthened the hypothesis that proper functioning of pulmonary surfactant is essential 
for survival in high-stretched rats. Furthermore, these results indicated that changes in 
surfactant composition and function do not precede the onset of acute lung injury 
induced by mechanical ventilation. 
To conclude, the studies conducted in this thesis suggest that mechanical 
ventilation developed two different outcomes according to animal vulnerability. This 
vulnerability is mainly due to the outbreak of an exacerbated inflammatory response 
that may promote alterations in the alveolar-capillary barrier and pulmonary surfactant. 
Thus, we can conclude that impairment of pulmonary surfactant is an unequivocal VILI 
characteristic tightly linked with the exacerbation of the inflammatory response.  
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The research presented in this thesis highlights alterations in the lungs after 
exposition to mechanical ventilation. This research emphasizes the important role of 
pulmonary surfactant. The results obtained using a translational animal model of 
acute lung injury induced by mechanical ventilation allow us to conclude that:  
 
 Injurious high-stretch ventilation produces direct damage to the lung, 
promoting pronounced inflammation, oxidative stress, leakage of plasma 
proteins into the alveolar space, and release of factors that together contribute 
to pulmonary surfactant impairment. Our results indicated that changes in lung 
surfactant composition and function do not precede the onset of acute lung 
injury induced by mechanical ventilation. 
 
 Experimental animals treated with the same mechanical ventilation strategy 
have different outcomes according to their vulnerability to mechanical 
ventilation, which are mainly differentiated by their inflammatory response. 
 
 VILI occurred in animal models only when surfactant was inactivated. There is 
a direct link between pronounced proinflammatory response and surfactant 
inactivation. In addition, we conclude that an attenuated inflammatory response 
together with increasing endogenous, fully active surfactant pools protect 
against the hypoxia and protein leakage that usually occur when ventilating 
animals with injurious high-stretch ventilation. 
 
 With respect to the effect of non-injurious low-stretch ventilation, our results 
indicate that inflammation in the lung was directly related to the duration of 
conventional low-stretch ventilation and that proper functioning of pulmonary 
surfactant is essential for survival of rats exposed to injurious and/or prolonged 
non-injurious mechanical ventilation. 
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